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CHAPTER 1: INTRODUCTION 
POST-TRANSLATIONAL MODIFICATION OF PROTEINS BY KINASE-
CATALYZED PHOSPHORYLATION 
 
The size of the human proteome is more than two fold larger than the size of the coding 
genome. One of the main reasons accounting for a larger proteome than genome is the post-
translational modifications (PTM) of proteins. PTMs occur through two main mechanisms. One 
is by the cleavage of a translated pre-protein by proteases or acids to produce the truncated active 
form of a protein. The other mechanism is the transfer of a chemical group to proteins through 
enzymatic reactions, such as phosphorylation, ribosylation and palmiotylation.
4
 The addition of 
different chemical groups to proteins, changes the structure and the function of proteins, 
allowing PTMs to diversify cellular proteome and coordinate the same proteins in numerous 
signaling pathways. Out of several PTMs, phosphorylation plays an essential role in physiology 
by dynamically influencing numerous aspects of cellular functions, such as metabolism, cell 
division, and apoptosis.
5
 Phosphorylation is the focus of this thesis work and is discussed in 
detail in the following sections. 
1.1 Phosphorylation 
Phosphorylation is catalyzed by kinases, which transfer phosphoryl groups to proteins, 
sugars or lipid molecules
6
 The backward reaction of reversible phosphorylation is catalyzed by 
equivalent phosphatases, which removes the added phosphate groups (Figure 1.1). From all 
kinases, protein kinases represent a very large and unique group, consisting of more than 500 
members. 
2 
 
 
 
 
1.2 Kinases 
Protein kinases represent a very large gene family, contributing 2% of the human 
genome.
7
 Based on amino acid preferences for the substrate protein or sequence similarities in 
kinase active sites, the ~500 protein kinases can be classified in two ways.
8
 In the first 
classification, protein kinases are divided into two groups, serine/threonine protein kinases 
(SPK) and tyrosine protein kinases (TPK), based on the preferred amino acid residue of the 
substrate being phosphorylated.
8-9
 About 80% of protein kinases are serine/threonine protein 
Figure 1.1: Protein phosphorylation. Ser/Thr and Tyr kinases catalyze the transfer of a 
phosphoryl onto serine, threonine, or tyrosine residues of a protein, respectively, while Ser/Thr 
and Tyr phosphatases remove the respective phosphate group.  
3 
 
 
 
kinases (SPK), while majority of the rest (~19%) are tyrosine protein kinases (TPK).
10
 The 
remaining small percentage represents serine/threonine kinases that do not adhere to the 
specificity rule and are capable of phosphorylating both serine/threonine and tyrosine amino 
acids on proteins.
10
 
The structural analysis of the catalytic clefts in the catalytic domains of SPKs and TPKs 
displayed a huge similarity. However, a significant difference can be observed when analyzing 
the depth of the catalytic cleft.
10
 The catalytic cleft of TPKs is relatively longer and deeper than 
the catalytic cleft of SPKs. Thus the long and bulky tyrosine group can reach into the catalytic 
cleft to position the side chain for catalysis,
11
 while the relatively short serine and threonine 
groups cannot reach the catalytic site of TPKs.
10, 12
 Similar structural features are responsible for 
the specificity of tyrosine phosphatases and serine/threonine phosphatases to the respective 
phosphorylated site on the protein.
13
 
TPKs can further be subdivided and classified into two more subgroups: receptor tyrosine 
kinases (RTK) and non-receptor tyrosine kinases. RTKs are mostly transmembrane proteins and 
contribute initiating signaling pathways (section 1.5) by binding to extra cellular lignads,
14
 while 
non-RTKs mostly constitute the inner membrane, cytoplasm, or nucleus and contribute to signal 
transmission.
15
 Since tyrosine phosphorylation plays a pivotal role in regulation of signaling, it is 
tightly regulated to be present at lower levels compared to serine/threonine phosphorylation.
16
 
The second classification of kinases is based on the sequence similarity and differences in 
the catalytic domains of kinase active site.
17
 All members of serine/threonine and tyrosine 
kinases are categorized into seven families; TK, TKL, STE, CK1, CAMK, CMGC and AGC 
based on the similarities and differences in the active site of protein kinases (Figure 1.2).
17
 Even 
4 
 
 
 
though protein kinases are classified into various groups for clarity in organization and for 
effective communication, all kinases have more or less a similar structure and mechanism.
18-19
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Protein kinase structure and mechanism 
A typical kinase is comprised of two main domains made from a carboxy-terminal (C-
terminal) α-helical region and a (amine-terminal) N-terminal β-sheet region connected together 
through a linker region (Figure 1.3a).
19-20
 Adenosine 5’-triphosphate (ATP) usually binds to the 
linker region, while protein substrate binds to the active site α-helical domain.9, 21 Binding of 
Figure 1.2: Classification of protein kinases into main groups. All human protein 
kinases are mainly categorized into seven main groups, including; TK: Tyrosine kinase, 
TKL: Tyrosine kinase-like; STE: Homologs of yeast strerile kinases; CK1: Casein 
kinase; CAMK: Calcium/calmodulin-dependent protein kinase; CMGC: Containing 
CDK, MAPK, GSK3, CLK families; AGC: Containing PKA, PKG, PKC families; other: 
rest of other protein kinases  
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ATP to the linker region brings both α-helical and β-sheet regions together22 to create a close 
proximity between the protein substrate and bound ATP. The hydroxyl of the substrate will 
attack ATP and transfer the gamma-phosphoryl group from ATP to serine, threonine, or tyrosine 
residues of a protein substrate (Figure 1.3b).
23-25
 
To understand the catalytic mechanism of kinases, cAMP-dependent protein kinase A 
(PKA) was selected as a model kinase. In the PKA active site, there are nine conserved 
residues
26
 to facilitate the catalytic mechanism (G52, K72, Q91, D166, N171, D184, G186, 
Q208, and R280).
27
 From these nine, six residues are involved in triphosphate binding (Figure 
1.3b), while the other three bind with the adenine ring of ATP. During phosphoryl transfer, ATP 
is further stabilized by chelation through metal ions, Mg
2+
or Mn
2+ 
(Figure 1.3b).
27
 In the active 
site, a nucleophilic attack will take place on the gamma-phosphate of ATP by the hydroxyl group 
of the protein substrate, leading to bond formation between oxygen on the protein and the 
phosphoryl of ATP (Figure 1.3b) and allowing the transfer of a charged phosphoryl to the protein 
substrate.
9
 The charged phosphoryl group added to the protein can change the activity and the 
function of the protein inside a cell. Thus, kinase-catalyzed phosphorylation is specific, selective 
and tightly regulated to avoid aberrant activities of substrate proteins.
11
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The crystal Structure and the active site residues of PKA. a: Crystal 
structure of PKA (cartoon) with a bound ATP (ball and stick structure). The solvent 
exposed ATP is pointed by the arrow (GenBank ID 6755076, PDB 1ATP). b: Active 
site residues of PKA with a bound ATP and Mg
2+
 ions. 
 
 
a) 
b) 
7 
 
 
 
1.4 Kinase consensus sites  
 
In cells, a particular protein kinase must specifically recognize the phosphosite of its 
substrate out of a pool of ~700,000 potential phosphosites.
10
 Kinases use several mechanisms to 
perform this task selectively and efficiently. The primary mechanism of phosphorylation is the 
use of specific interactions between the amino acid residues of protein kinase active site and the 
protein substrate phosphorylation site.
28
 In addition, structural features of the kinase active site, 
such as the depth and the length of the active site cleft (Chapter 1, section 1.2) and the presence 
or the absence of regulatory subunits and scaffolding proteins, play an important role in 
selectively.
28
  
During phosphorylation, kinases search for amino acids that resides immediately 
upstream (N-terminal) and downstream (C-terminal) to the phosphosite (p-site) of the protein 
substrate to achieve selectivity.
29
 The particular sequence of amino acids surrounding the P-site 
is known as the kinase consensus site.
30-31
 Different kinases require different amino acids near 
the p-site, such as acidic, basic or stericaly bulky residues to achieve efficient interactions at the 
kinase active site. Thus, consensus sites can be grouped into categories based on the type of 
required amino acids near the p-site. Some of the known consensus sites and motif categories of 
kinases are listed in Table 1.1. Even though the specific consensus sites are important to give rise 
to selective substrate profiles, all kinases exhibit a small flexibility towards the amino acids in 
the consensus site. For an example, PKA consensus site is R-R-X-S/T-Z.
32
 However, PKA can 
phosphorylate sites such as R/L-R/L-X-S/T-Z, R/L-X-X-S/T-Z or X-R/L-X-S/T-Z, (X: any 
amino acid, Z: hydrophobic amino acid) due to the presence of basic amino acids
33
, and still 
achieve substrate selectivity, which is important for cell signaling.
34
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Kinase Consensus site/Motif Motif group 
PKA R-R-X-S/T Basic 
CDK S/T-P-X-K/R Proline, Basic 
ERK2 P-X-S/T-P Proline 
CK1 Ps-X-X-S/T Basic 
CK2 S/T-D/E-X-D/E Acidic 
CAMK2 I/V/L-Y-X-X-P/F Hydrophobic 
ABL I/V/L-Y-X-X-P/F Hydrophobic 
EGFR E-E-E-Y-F Acidic 
Src E-E-I-Y-E/G-X-F Acidic 
Aurora R/K/N-R-X-S/T-B Basic 
PKB/AKT R-X-R-X-X-S/T Basic 
 
X: any amino acid residue, Ps: phosphorylated serine residue, Red/bold amino acids represents 
the sites of phosphorylation. B: any hydrophobic residue except Proline. 
1.5 Kinase-mediated cell signaling 
Addition of a charged phosphate to proteins by kinases can change the structure and the 
function of a protein.
35
 Thus, protein phosphorylation regulates a myriad of cellular activities, 
such as proliferation, adhesion and differentiation, through phosphoprotein-dependent signaling 
cascades.
36
 Out of many signaling cascades, cAMP-dependent protein kinase (PKA) and EGFR 
signaling is the most widely explored cell signaling pathways in humans, possibly due to the 
widespread involvement of PKA and EGFR signaling in cellular events and the association of 
kinase dependent diseases.
37-42
 Here, PKA pathway will be discussed given the emphasis in 
Table 1.1: The consensus sites and motif groups of selected protein kinases. 
9 
 
 
 
Figure 1.4: PKA influences diverse signaling events in cells. PKA signaling initiates through 
GPCRs (G-protein coupled receptors) on the surface of cells to activate adenylate cyclase (AC) 
to produce cAMP. More details on the mechanism can be found in text. R: regulatory subunits 
of PKA, C; Catalytic subunits of PKA. 
 
 
 
 
 
Chapter 3 on PKA (section 1.5.1). The EGFR pathway will be introduced in Chapter 4 (section 
4.1). 
 1.5.1 PKA signaling  
 
PKA is one of the simplest members of the human kinome with well-characterized 
kinetic properties and a well-defined crystal structure.
19-20, 43-45
 PKA phosphorylates hundreds of 
substrates and is responsible for a plethora of cellular activities, such as metabolism, ion channel 
transport and gene expression (Figure 1.4). Generally, PKA signaling begins through the 
10 
 
 
 
activated G-protein coupled receptor-mediated adenylase cyclase (AC) enzyme (Figure 1.4). 
Upon activation, AC will produce the secondary messengers, 3',5’-cyclic adenosine 
monophosphates (cAMPs). PKA-dependent specific phosphorylation events are primarily 
regulated by the concentration of cAMP in cells. These intracellular cAMP ligands bind to the 
regulatory subunits of PKA (R) to release catalytic subunit (C) for specific protein 
phosphorylation (Figure 1.4).
46
 One specific example of PKA signaling is the phosphorylation of 
cAMP responsive element binding (CREB) protein serine 133 site by the catalytic subunit of 
PKA. Phosphorylated CREB acts as a transcription factor and binds to CREB binding sequences 
in DNA to regulate gene expression, especially in neuronal cells.
47
  
In addition, specific PKA dependent phosphorylation events are also regulated by another 
protein family known as A kinase anchoring proteins (AKAPS).
46
 AKAPS acts as scaffolding 
proteins by binding to regulatory subunits of PKA to bring the catalytic PKA close to substrates 
to achieve substrate selectivity during cell signaling (Figure 1.5).
48
 A few methods using 
fluorescent probes are available to monitor cAMP and AKAP-regulated PKA signaling dynamics 
in normal and disease states.
49
 These studies provide valuable imaging information about how 
AKAPs facilitate compartmentalization of the catalytic subunit of PKA during 
phosphorylation.
50
 However, to the best of my knowledge, no methods are available to identify 
PKA substrates in live cells during dynamic cell signaling. Thus, despite the concern with the 
loss of cellular compartmentalization, identifying kinase substrates in cellular lysates under 
normal and pathological conditions is proven to be the gold standard for kinase substrate 
detection. Deregulation of PKA activity by mutations is implicated in diseases such as sporadic 
tumors especially in adrenal and thyroid glands48 highlighting the importance of exploiting 
signaling cascades to aid therapeutic efforts. 
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1.6 Kinase-mediated pathological conditions 
Involvement of kinase-mediated signaling events in pathological conditions such as 
cancer, inflammation, and diabetes, highlights the importance of protein kinases as therapeutic 
targets. The most common reason for the pathological involvement of protein kinases is the 
frequent hyperactivity of kinases due to mutations, over expressions, gene amplifications or 
chromosomal rearrangements.
51
  One example of a kinase-mediated pathological condition is the 
altered cAMP/PKA signaling leading to tumor formation. PKA signaling in cells is tightly 
regulated by the concentration of cAMP level in cells, as discussed in section 1.5.1. Since 
regulatory subunits of PKA binds to cAMP, the expression level of regulatory subunits similarly 
play a huge role in PKA mediated pathological conditions. Over expression of regulatory 
subunits RI of PKA in thyroid and adrenal tumors have been reported.
52
 In addition, the 
expression of inactive RI subunits has proven to be the main reason for over-active PKA-
mediated nodular adrenocortical disease, neoplasia syndrome, and other sporadic tumors in 
endocrine.
52
 Further studies have shown that pharmacological inhibition of PKA activity using 
cAMP analogs or PKA regulatory subunit expression by antisense oligonucleotides have reduced 
tumor proliferation.
52
 A second example of a kinase-mediated pathological condition is Abelson 
(Abl)-kinase mediated chronic myeloid leukemia (CML). The disease is caused by a hyper-
active break-point cluster (BCR)-Abl kinase created due to a fusion-mediated chromosomal 
rearrangement between the Abl gene in chromosome 9 and BCR gene in chromosome 22.
53
 
Since the BCR-Abl mutant kinase is constitutively active, it phosphorylates various downstream 
signaling proteins, regardless of cellular requirements or homeostasis. Thus, abnormal BCR-Abl 
signaling leads to alterations in apoptosis, cell adhesion and migration of myeloid cells to give 
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rise CML in patients. Patients with CML are currently being treated with the FDA approved, 
BCR-Abl kinase inhibitor Gleevec.
53
 
1.7 Kinase inhibitors for therapeutics 
Over the past decade more than a hundred of protein kinase inhibitors have been tested in 
clinical trials as potential drugs to treat diseases. Many inhibitors have entered commercial 
markets.
51
 There are three main approaches taken for therapeutic intervention of kinase activity 
by an inhibitor.
2, 51
  
1.7.1 Monoclonal antibodies and vaccines as kinase inhibitors 
The first approach for kinase inhibition is use of monoclonal antibodies and vaccines.
2
 
Both vaccines and antibodies have been successfully developed to inhibit aberrant receptor 
tyrosine kinase-mediated signaling cascades.
54
 During inhibition, typically monoclonal 
antibodies either bind to the growth factor or the receptor to prevent receptor kinase activation 
and downstream signaling.
55
 One example is the monoclonal antibody Erbitux from ImClone, 
which binds to the EGF receptor and blocks EGF binding and activation. A second example is 
the antibody Avastin from Genentech/ Roche, which binds to VEGF growth factor and prevents 
signal initiation.
54
 Further, there are ongoing research and clinical trials on immunological 
vaccines to inhibit RTK signaling. One such example is the peptide-derived HER2 vaccine for 
breast cancer treatment.
56
 In addition to the above mentioned examples, there are numerous other 
antibodies and vaccines that have been developed to inhibit aberrant receptor tyrosine kinase 
activity to prevent angiogenesis and tumor generation. 
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1.7.2 Small molecule kinase inhibitors 
The second approach to inhibit kinase activity is the use of small molecule inhibitors.
2
 
Small molecule inhibitors are generally designed based on the structures of a few natural product 
compounds. Most natural product inhibitors are not selective to a particular kinase, but rather 
offer broad inhibition. One such example is the natural product staurosporine, which is a potent 
general inhibitor of many kinases.
57
 Staurosporine-derived kinase inhibitor, N-benzoyl-
staurosporine by Novartis, is a synthesized small molecule inhibitor currently under clinical trials 
for cancer treatment.
58
 
1.7.3 Structure based drug design 
Elucidation of the crystal structure of protein kinases has tremendously aided the third 
approach to inhibitor development which is structure based drug design.
12, 19
 One reason for the 
relative ease in the structural development of kinase inhibitors is the presence of flexible ATP-
binding and substrate binding sites on protein kinases.
12
 However, there is a drawback; kinase 
inhibitors designed to target the ATP-binding site offer less selectivity due to the conserved 
nature of ATP-binding site between kinases. Nevertheless, there are many of FDA approved 
kinase inhibitors on the market that target the ATP-binding site yet still offer selectivity towards 
a particular kinase (Figure 1.5). These inhibitors include Gleevec, which inhibits Abl kinase, and 
Iressa, which inhibits EGFR, which are shown in Figure 1.5. Many drugs in clinical trials have 
also been developed using the structural and conformational information of the kinase active site 
with bound ATP analog and a peptide.
59
 Structural features and different binding interactions 
specific to each kinase are used to develop and modify the structure of inhibitors to achieve 
selectivity towards a particular kinase.
59   
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Figure 1.5: Some of the FDA-approved kinase inhibitors currently in the market. Redrawn.
2
 
 
 
 
 
 
Small molecule kinase inhibitors can further be subdivided into two major categories; 
reversible and irreversible. Irreversible inhibitors react with a catalytic lysine or a cysteine 
residue close to the ATP binding region of protein kinases to sterically block the active site. The 
loss of the free catalytic lysine will prevent phosphoryl transfer to substrates. In contrast, 
irreversible inhibitors bind non-covalently to the ATP binding site, the allosteric site, or both 
sites simultaneously to lead to inhibition.  
Even though the above methods offer multiple approaches for kinase inhibition, the 
presence of a vast number of cellular kinases and the similarities of their active sites have 
challenged the development of selective kinase inhibitors. When attempting to find a new 
therapeutic target for kinase inhibitor development, it is important to gain a thorough knowledge 
15 
 
 
 
of kinase biology, substrate profile, and cell signaling outcomes. Once a target kinase or a kinase 
group is narrowed down, an exceptional knowledge of the structural features of the targeted 
kinase is required. Finally, a thorough understanding of the biological background is important to 
rationalize and identify possible targets and off targets of the inhibitor. Thus, kinase substrate 
profiling and mapping signaling pathways are extremely important for kinase inhibitor design. 
1.8 Kinase substrate profiling and mapping signaling pathway 
 Not only to aid future drug discovery, but also to have an elaborate understanding of 
kinase biology, it is important to identify kinase substrates and map signaling pathways. 
Currently, there are many methods available to identify kinase substrates. Some of the most 
widely used methods are highlighted in Chapter 3, section 3.1. However, each method offers 
advantages and disadvantages. As an alternative, a convenient and selective approach to detect 
kinase substrates is to label substrates with a tag using a kinase-catalyzed mechanism, as 
described in the following sections. The finding of kinase cosubstrate promiscuity has opened a 
new path to perform kinase-assisted labeling of substrates efficiently and selectively. 
1.9 Kinase cosubstrate promiscuity with gamma-phosphate modified ATP analogs 
Many enzymes catalyzing PTMs exhibit promiscuity towards their cosubstrates.
60-69
 Prior 
studies from Pflum lab and other researchers have discovered that kinases promiscuously accept 
gamma-phosphate modified ATP analogs as cosubstrates.
70-72
 Specifically, when the gamma 
phosphate of ATP is modified with a tag, such as a thiol, biotin or azide, that tag can be 
transferred to the phosphosite of the substrate due to kinase activity (Figure 1.7).
72-73
 The 
rationale behind cosubstrate promiscuity is the presence of a solvent exposed region at the 
gamma phosphate when ATP is bound to kinase active site (Figure 1.4a).
12, 20, 45
 Our hypothesis 
16 
 
 
 
was that the solvent exposed region of the kinase would accommodate modifications at gamma 
phosphate position of ATP without significantly affecting the binding or catalytic activity of the 
kinase. Evidence for the efficiency and utility of kinase-catalyzed labeling is discussed in the 
followings sections. 
1.9.1 ATP-γS 
 Adenosine 5’-[γ-thio]-triphosphate (ATP-γS), is the first modified ATP analog reported 
as a cosubstrate of protein kinases.
74-75
 In ATP-γS, the oxygen at the gamma-phosphate position 
is replaced with sulfur. Therefore, a thiophoshoryl group will be transferred to protein substrates 
during kinase-catalyzed phosphorylation (Figure 1.6).  
The ability to transfer a thiophosphoryl group onto proteins has been exploited to develop tools 
to purify and identify kinase substrates. When the kinetic efficiencies of thiophosphorylation was 
compared to ATP-dependent phosphorylation, a much lower catalytic efficiency was detected 
with ATP-γS.76 Moreover, studies have shown the phosphatase insensitivity of 
thiophosphorylation, relative to phosphorylation.
75
 Thus, regardless of the reduced kinetic 
efficiencies, ATP-γS is commonly used in the field of proteomics due to the possibility of 
detecting low abundance phosphoproteins.
77
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Figure 1.6: Kinase-catalyzed thio-phosphorylation with ATP- γS. Protein kinases use ATP- γS as 
a cosubstrate and label serine/threonine or tyrosine residues on protein substrates. 
Figure 1.7: Kinase-catalyzed dansylation with ATP-dansyl. Protein kinases use ATP-dansyl 
as a cosubstrate to label serine/threnonine or tyrosine residues on protein substrates. 
 
 
1.9.2 ATP-dansyl 
 
ATP-dansyl is another gamma-modified ATP analog that has been tested by previous 
Pflum lab members for kinase cosubstrate promiscuity. The special feature of ATP-dansyl 
compared to other gamma-modified ATP analogs is the presence of fluorescent group at the 
gamma phosphate that will get transferred to substrates (Figure 1.7).
78
 Thus, kinase substrates 
will be labeled with a fluorescent tag, which allows monitoring phosphorylation though 
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absorbance. Previously, quantitative MS and kinetic analysis was performed on ATP-dansyl 
using PKA, CK2 and Abl kinases to compare phosphorylation with ATP. When Km values for 
ATP-dansyl were compared to that of ATP, a similar value was observed, suggesting ATP-
dansyl binds to the active site of the kinase in a similar manner as ATP. However, the kcat 
displayed approximate 9-fold reduction compare to ATP, suggesting a slow rate of phosphoryl 
transfer with ATP-dansyl compared to ATP.
78
 These results confirmed that, in addition to ATP-
γS, other gamma-modified ATP analogs also act as cosubstrates( Figure 1.9). 
1.9.3 ATP-aryl azide  
To broaden the applications of modified ATP analogs as cosubstrates of kinases, another 
gamma-modified ATP analog, ATP-aryl azide, was synthesized for cross-linking applications 
(Figure 1.8).
79-80
 Here, the gamma phosphate of ATP is attached to a photocrosslinking (azide) 
group, which crosslink with the kinase and protein substrate during phosphorylation in the 
presence of UV light (Figure 1.8). This crosslinking strategy allows the identification of an 
unknown kinase that phosphorylate a known protein substrate. 
1.9.4 ATP-BODIPY and ATP-ferrocene 
In addition to γ-phosphate modified ATP analogs developed in Pflum lab, a couple of 
other analogs were also reported. Two examples include, ATP-BODIPY developed by Carlson 
lab
81
 and ATP-ferrocene by Kratz lab (Figure 1.9)
82
. ATP-BODIPY is a modified ATP analog 
with a fluorescent BODIPY group attached at the gamma position of ATP, primarily used as a 
probe to measure histidine kinase activity.
81
 ATP-ferrocene developed by Kratz lab is also a γ-
phosphate modified ATP analog. Kinase-catalyzed phosphorylation with ATP-ferrocene will 
transfer ferrocene-phosphoryl groups on to protein substrates, which can be monitored using 
antibodies against ferrocene groups.
82
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Figure 1.8: Kinase-catalyzed cross-linking with ATP-aryl azide. Protein substrates will be 
cross-linked to protein kinase during phosphorylation in the presence of UV. 
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Figure 1.9: Some of the available γ-phosphate modified ATP analogs developed by Pflum 
and other labs. 
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Figure 1.10: Kinase-catalyzed phosphorylation with ATP-biotin. Kinase-catalyzed 
phosphorylation of protein substrates using ATP or ATP-biotin as cosubstrates. 
1.9.5 ATP-biotin 
ATP-biotin is the most characterized gamma-modified ATP analog in Pflum lab, to date. 
Here, the gamma phosphate of ATP is attached to a biotin group, which allows the transfer of a 
phosphobiotinyl group to protein substrates during kinase-catalyzed phosphorylation (Figure 
1.10).
72-73, 83
 The ability of ATP-biotin to biotinylate kinase substrates was initially tested with 
PKA, CK2 and Abl kinases by quantitative MS analysis.
83
 Each protein kinase was separately 
incubated with ATP-biotin and peptide substrates containing the corresponding phosphosite. 
Peptides were also incubated with each kinase and ATP as control reactions. After kinase 
reaction, isotopically labeled peptide products for each ATP-biotin and ATP reaction was 
analyzed by matrix-assisted laser desorption-ionization-time-of-flight mass spectrometry 
(MALDI-TOF MS) to calculate the efficiency in conversion to phosphopeptides with ATP-biotin 
compared to ATP (Table 1.2). These experiments gave the first evidence for efficient kinase-
catalyzed biotinylation. Next, full length casein protein was incubated with ATP-biotin and CK2 
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Table 1.2 Percent conversion data for kinase reaction with ATP-biotin and PKA, CK2 and 
Abl, compared to ATP reaction.  
kinase to observe biotinylation of the substrate. After kinase reaction, protein products were 
analyzed by gel methods and biotin containing proteins were visualized by streptavidin-
horseradish peroxidase (SA-HRP) conjugate. Results confirmed the ability of CK2 to use ATP-
biotin as a cosubstrate and label full length proteins with a biotin tag. The robust biotin-
streptavidin interaction can be used for pull-down and purification of biotin-labeled protein 
substrates,
83
 and the highly sensitive LC-MS/MS can be used for substrate identification from 
cellular lysates. With these future goals in mind, previous members in Pflum lab, further 
characterized kinase-catalyzed biotinylation reaction.  
 
Kinase Peptide Conversion 
PKA LRRASLG 79% 
CK2 RRREEETEEE 56% 
Abl EAIYAAPFAKKK 80% 
 
Initial experiments performed with ATP-biotin and cellular lysates confirmed the 
compatibly of kinase-catalyzed biotinylation in cellular lysates. To understand how phosphatase 
activity would impact kinase-catalyzed labeling, a previous member of Pflum lab characterized 
phosphoryl biotin degradation by phosphatases.
84
 When biotinylated products was compared 
before and after phosphatase treatment, it was revealed that 70-80% of the modification 
remained intact, indicating that the phosphobiotin modification is less sensitive to 
phosphatases.
84
 With these results it was hypothesized that kinase-catalyzed biotinylation can be 
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used as a robust labeling technique to detect, enrich, and identify low abundance and dynamic 
kinase substrates from a complex cellular mixture of proteins following highly sensitive LC-
MS/MS. Based on previous findings, kinase-catalyzed biotinylation was further explored in this 
thesis as described in Chapter 2, and to expand the use of ATP-biotin as a kinase-substrate 
labeling probe as described in Chapter 3 and 4. 
1.10 Thesis Projects 
 Due to the importance of kinase-catalyzed phosphorylation in cell physiology, additional 
methods are needed to discover kinase substrates and explore biology. Since each method will 
have advantages and limitations, it is essential to develop alternative techniques to aid kinase 
substrate discovery approaches. This thesis comprises methods developed using kinase-catalyzed 
biotinylation to discover novel phosphoproteins and to explore cell signaling cascades.  
The Chapter 2 focuses on the characterization of the generality of kinase-catalyzed 
biotinylation using recombinant protein kinases and substrates, which was performed as a 
collaborative project with a previous lab member, Dr. Chamara Senevirathne. In this 
collaborative project, we tested the ability of ATP-biotin to biotinylate substrates with a variety 
of kinases. Experimental results concluded that all tested protein kinases were capable of 
transferring a biotin tag to protein substrates, confirming the generality of kinase-catalyzed 
biotinylation.
85
  
Chapter 3 describes an application of kinase-catalyzed biotinylation to develop a 
substrate-discovery method, entitled, K-BILDS (Kinase-catalyzed biotinylation with inactivated 
lysates for discovery of substrates) to identify substrates of an interested kinase.  Here, kinase 
inactivated cell lysates were used as the pool of cellular proteins to identify substrates of one 
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particular kinase. As a proof-of-concept, K-BILDS was initially applied to PKA, which resulted 
in successful identification of PKA substrates and validation of the method.  
Kinase-catalyzed biotinylation was finally applied in Chapter 4 to map a cell signaling 
network. Here, a screen entitled, K-BMAPS (kinase-catalyzed biotinylation to map signaling) 
was developed by initially applying to EGF-treated cell lysates to map EGFR pathway-related 
phosphoproteins. K-BMAPS with EGF-treated lysates successfully discovered many EGFR 
pathway-related phosphoproteins, confirming the ability of K-BMAPS to map a cell signaling 
network. Thorough analysis established that K-BMAPS detected late and continuous effects of a 
signaling network, validating the screen to monitor kinase signaling cascades. 
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CHAPTER 2:CHARACTERIZATION OF KINASE-CATALYZED 
BIOTINYLATION 
 
 
Portions of the text, figures, tables and legends in this chapter were reprinted or adapted 
from: Senevirathne, C., Embogama D. M., Anthony, T. A., Fouda, A. E., and Pflum, M. K. 
(2016) The generality of kinase-catalyzed biotinylation, Bioorg Med Chem 24(1):12-9  
As discussed in Chapter 1, ATP-biotin (Figure 1.11) has inherent advantages over the 
other gamma-modified ATP analogs due to the presence of a biotin handle for avidin 
enrichment. Thus, there are many applications of ATP-biotin as a kinase cosubstrate.
70
 To 
exploit ATP-biotin dependent kinase-catalyzed biotinylation for future kinase-substrate 
discovery and cell signaling mapping, characterization of the generality of ATP-biotin as a 
cosubstrate to all kinases is necessary. Since crystal structures of kinases share similar ATP 
binding site, it was hypothesized that ATP-biotin can be accepted by all kinases in human 
kinome. A previous member of our lab (Dr. Chamara Senevirathne) initiated work to test the 
general acceptance of ATP-biotin as cosubstrates by selecting 25 kinases representing all kinase 
sub-families from human kinome. He characterized all kinases qualitatively by western analysis, 
21 kinases quantitatively by Pro-Q analysis and 23 by kinetics. My goal for this collaborative 
project was to complete the study by assessing the biotinylation quantitatively with remaining 
four kinases (CAMK4, ERK1, TGFβR1 and GRK5) and kinetically with two kinases (PKA and 
CK2). The results together suggested that all 25 kinases accept ATP-biotin as a cosubstrate and 
can be used for future protein labeling experiments.
85
 
2.1 Introduction 
2.1.1 Crystal structures of protein kinase active site 
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Crystal structures of many protein kinases such as those of PKA, Casein Kinase 2 (CK2) 
and Insulin receptor kinase (IRK) are reported.
12, 20, 45
 When the crystal structure of CK2 was 
analyzed, a solvent-exposed region was observed at the active site of kinase near γ-phosphate of 
non-hydrolysable ATP -analogue (Figure 2.1). In fact, the solvent exposed region at the γ-
phosphate of ATP was observed for all kinases that were inspected (Figure 1.4a and 2.1). Due to 
inherent similarity between kinase active sites, it was hypothesized that all kinases in general 
should bind and accept γ-phosphate modified of ATP-analogues as cosubstrates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The crystal Structure of CK2. Crystal structure of CK2 (cartoon 
structure) with bound β,γ-Imidoadenosine 5′-triphosphate (AMP-PNP; a non-
hydrolysable ATP -analogue) (ball and stick structure)). The solvent exposed region of 
ATP -analogue is indicated by the arrow (PDB 1DAW). 
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Previous studies from our lab showed that γ-phosphate modified ATP analogs such as 
ATP-biotin act as cosubstrates during kinase-catalyzed labeling of PKA, CK2 and Abl 
(Chapter1, section 1.8.5).
72, 83
  However, thorough methodical analyses of kinase-catalyzed 
labeling with γ-phosphate modified ATP analogs had not yet been performed. Towards this goal, 
ATP-biotin was chosen to test the compatibility of γ-phosphate modified ATP analogs with 
multiple kinases from human kinome tree. 
2.1.2 Human kinome 
According to Manning et al, more than 500 human proteins kinases are known.
5
 All 500 
kinases are classified into seven major families based on the sequence and functional similarities 
in and outside of the catalytic domains to create a human kinome tree (Figure 2.2).
86
 Thus, 
human kinome tree can be used as a reference guide to select kinases to test the general 
compatibility of ATP-biotin. However, testing 500 kinases with ATP-biotin is a daunting task. 
Therefore, 25 kinases spanning the entire human kinome tree, representing all kinase groups, 
were selected for investigation with ATP-biotin as a cosubstrate. In addition, to illustrate a 
general kinase function, both proteins and peptides substrates were included to diversify the 
selected kinase-substrate pairs. Kinases that were selected to examine the compatibility with 
ATP-biotin are listed in Figure 2.2. 
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Figure 2.2: Select kinases used in this study. (a) The human kinome tree with selected kinases 
tested in this work shown as red circles. This figure is reprinted from Manning et al. 2002, Sci, 
298, 5600. Illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com) using Kinome Render. TK: tyrosine kinase; TKL: tyrosine kinase-like; 
STE: homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; CK1: casein kinase 1; AGC: 
containing PKA, PKG, PKC families; CaMK: calcium/calmodulin-dependent protein kinase; 
CMGC: containing CDK, MAPK, GSK3, CLK families; Other: other kinases. (b) The 25 kinases 
tested, along with amino acid specificity, group identity, and peptide, polypeptide, or protein 
substrate(s) used in kinase reactions. In some cases, different substrates were used in 
biotinylation, quantification, and kinetics experiments. 
a
biotinylation, 
b
HPLC or Pro Q 
quantification, 
c
kinetics. MBP-myelin basic protein; Autocamtide-KKALRRQETVDAL-amide; 
CHKtide-KKKVSRSGLYRSPSMPENLNRPR; IGF1Rtide-KKKSPGEYVNIEFG; JAK3tide-
GGEEEEYFELVKKKK; GSK3 peptide-YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE; Axltide-
KKSRGDYMTMQIG; PAKtide-RRRLSFAEPG; kemptide-LRRASLG; p34cdc2 peptide-
KVEKIGEGTYGVVYK-amide. Figure and legend printed with permission.
85
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2.1.3 Characterization of generality of kinase-catalyzed biotinylation by qualitative, 
quantitative, and kinetic methods 
 Three techniques were used to characterize the generality of kinase-catalyzed 
biotinylation. To qualitatively assess kinase-catalyzed biotinylation, western blotting was 
performed after each kinase reaction and biotinylated proteins were visualized by SA-Cy5 
staining. Dr. Chamara Senevirathne performed all qualitative analysis experiments by incubating 
protein kinase substrate pairs with ATP-biotin and analyzing protein biotinylation by western 
blotting and SA-Cy5 staining (Figure 2.3) (Senevirathne, Kona Arachchilage Chamara Indunil 
Bandara, "Development Of Kinase Catalyzed Biotinylation To Study Phosphoproteomics" 
(2013). Wayne State University Dissertations 
698. http://digitalcommons.wayne.edu/oa_dissertations/698). Interestingly, all 25 kinases 
catalyzed kinase-dependent biotinylation of their respective protein substrate (Figure 2.3, lane 3), 
confirming the general acceptance of ATP-biotin as a cosubstrate. As expected, control reaction 
with protein substrate and ATP-biotin without kinase did not show biotinylation (Figure 2.3, lane 
1), confirming that biotinylation is a kinase enzyme-catalyzed modification. 
 To rigorously characterize the generality of kinase-catalyzed biotinylation, it was also 
important to evaluate the efficiency and kinetic parameters of biotinylation reaction. Dr. 
Chamara Senevirathne performed quantitative analyses with 21 kinases and kinetic analyses with 
23 kinases using proteins and peptide substrates (Table A2.1). This chapter contains the 
experiments performed to complete the study by assessing the biotinylation quantitatively with 
the remaining four kinases (CAMK4, ERK1, TGFβR1 and GRK5) and kinetically with two 
kinases (PKA and CK2). 
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Figure 2.3: Kinase-catalyzed biotinylation. Protein (a) or peptide (b) substrates were incubated 
with ATP-biotin alone (lane 1), ATP and kinase (lane 2), or ATP-biotin and kinase (lane 3), prior 
to SDS–PAGE separation and visualization using SA–Cy5 (top gels) to observe biotinylation or 
Sypro ruby (protein) or coomassie (peptide) stain (bottom gels) to assure equal sample loading. 
This image and legend is reprinted with permission.
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2.2 Results and Discussion 
2.2.1 Synthesis of ATP-biotin 
To test the general efficiency of kinase-catalyzed biotinylation, first, ATP-biotin was 
synthesized as follows.
73
 First, biotin was activated by TBTU, and then reacted with 4, 7, 10-
trioxa-1-13-tridecanediamine to produce biotin amine, which was purified with silica flash 
column chromatography. Purified biotin amine was reacted in water with ATP and EDCI to yield 
ATP-biotin. ATP-biotin was purified on a DEAE sephedex-A25 column using a stepwise elution 
of triethylammonium bicarbonate buffer (TEAB) (Scheme 2.1).  
 
 
 
 
 
 
 
 
2.2.2 Quantitative analysis of kinase-catalyzed biotinylation using gel methods 
To characterize the generality of biotinylation, it was important to test the efficiency of 
ATP-biotin-dependent biotinylation compared to ATP dependent phosphorylation. In prior work, 
efficiency of biotinylation with peptide substrates was tested through HPLC analysis.
84-85
 In this 
chapter, experiments performed using gel based methods to calculate efficiency of protein 
substrates are discussed. With the synthesized ATP-biotin, kinase-catalyzed biotinylation was 
Scheme 2.1 – Synthesis of ATP-biotin  
 
ATP-biotin 
Biotin Biotin amine 
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performed with four kinases (CAMK4, ERK1, TGFβR1 and GRK5) by incubating kinase-
substrate pairs with ATP or ATP-biotin separately and analyzing protein products by 16% SDS-
PAGE, followed by Pro-Q phosphoprotein staining.  Myelin basic protein (MBP) was selected as 
the substrate for CAMK4, ERK1 and TGFβR1 kinases, while β-casein protein was selected as 
the substrate for GRK5 kinase. As a control, each protein substrate was incubated in buffer 
without the kinase or cosubstrate to obtain a background signal. 
Pro-Q primarily fluorescently stains proteins containing phosphate groups. Since the 
efficiency of kinase-catalyzed biotinylation with ATP-biotin is quantified comparing to ATP-
dependent kinase-catalyzed phosphorylation, it was essential to create the same phosphoproteins 
with both ATP and ATP-biotin after kinase reaction. To yield similar phosphoprotein products 
for both ATP and ATP-biotin, reactions were treated with 50% TFA after kinase reaction to 
cleave the biotin group. After acid cleavage, protein products were separated on SDS-PAGE and 
analyzed by Pro-Q staining. A strong fluorescent signal for protein substrates were observed 
after kinase reaction with ATP (Figure 2.4, lane 2). The kinase reaction with ATP-biotin 
displayed less fluorescent signal compared to the ATP reaction (Figure 2.4, lane 3 vs. lane 2), but 
a significant signal compared to the negative control (Figure 2.4, lane 3 vs. lane 1).  The 
efficiency of phosphorylation was calculated using a typhoon imager by drawing boxes of same 
size around protein bands with ATP and ATP-biotin and calculating percent conversion with 
ATP-biotin compared to ATP. Fluorescent signal for the negative control was used for 
background correction. At least three independent trials were performed for each kinase to assess 
the reproducibility (Figures A2.1-2.4). When the efficiencies of phosphorylation were compared 
between ATP and ATP-biotin, all four kinases displayed 41%-91% conversion with ATP-biotin 
compared to ATP. Interestingly, all 25 kinases displayed a similar percent range for the 
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Figure 2.4: Quantitative analysis of protein labeling. 
Protein substrates (lane 1) were subjected to kinase-catalyzed phosphorylation with ATP 
(lane 2) or biotinylation with ATP-biotin (lane 3), followed by incubation with 50% TFA, 
SDS–PAGE and Pro-Q Diamond staining (top gel) and Sypro ruby staining (bottom gel). 
The kinase used in each experiment along with the calculated percentage conversion with 
ATP-biotin compared to ATP is shown above each gel. 
conversion (41% - 91%) confirming that kinase-catalyzed biotinylation proceeds with a 
substantial efficiency when compared to natural ATP reaction. 
 
 
 
 
 
 
 
2.2.3 Kinetic analysis of kinase-catalyzed biotinylation  
To further characterize kinase-catalyzed biotinylation, kinetic parameters were obtained 
for all 25 kinases (Table A2.1). Out of 25 kinases, 23 were assessed for kinetics using ADP-Glo 
assay by Dr. Chamara Senevirathne. To obtain kinetic parameters of remaining two kinases 
(PKA and CK2), NADH-coupled enzyme assay was used. The NADH-coupled assay monitors 
the amounts of ADP produced during kinase reaction, through coupled enzymatic reactions. 
Briefly, ADP produced during kinase reaction and added phosphoenol pyruvate (PEP) will first 
be used by pyruvate kinase (PK) to produce pyruvic acid and a small amount of ATP. Then, 
formed pyruvic acid and added NADH will be consumed by lactic dehydrogenase (LDH) to 
yield lactic acid and NAD
+
. Thus, as kinase reaction continues, more ADP will be produced and 
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Scheme 2.2: NADH-coupled enzyme assay. Rate of the kinase reaction is measured by 
the rate of ADP production. Produced ADP will couple with pyruvate kinases and lactate 
dehydrogenase enzymes to consume NADH to NAD+. Consumption of NADH can be 
monitored overtime to determine the rate of kinase reaction. 
more NADH will be consumed by the PK/LDH coupled reaction. The rate of NADH 
consumption is monitored by measuring changes in absorbance of NADH overtime, to calculate 
the initial rate of the kinase reaction. For the experiment, the changes in absorbance of NADH 
overtime was measured with different ATP-biotin concentrations (1, 3, 10, 30, and 100 μM), 
over time. As a control, absorbance measurements were taken over time with different ATP 
concentrations (1, 3, 10, 30, and 100 μM) as well. After initial rate calculations, kinetic 
parameters were obtained by plotting Michaelis–Menton curves using kaleidagraph (Figure 2.5).  
 
 
With kinetic analysis, ATP-biotin displayed similar Km
app
 values compared to ATP with 
only with a 3.3 and 1.2-fold increase values for PKA and CK2 (Table 2.1), respectively. The 
analysis suggests that the gamma-modification does not significantly affect the binding of ATP-
biotin to active site of kinases, compared to ATP. To assess the efficiency of phosphoamidate 
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transfer with ATP-biotin, kcat
app values were compared with ATP. The kcat
app values were 2.0 and 
2.8-fold reduced compared to ATP, with PKA and CK2, respectively (Table 2.1).  Finally, the 
overall catalytic efficiencies (kcat/KM
app
) for biotinylation and phosphorylation reactions were 
compared. As expected PKA and CK2 kinases maintained kcat/KM
app
 values 3 and 6-fold reduced 
compared to ATP (Table 2.1).
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 In conclusion, the kinetic analysis of PKA and CK2 
demonstrated reasonable kinetics with ATP-biotin. When all 25 kinases were analyzed, majority 
of kinases displayed moderately changed values in general for all three kinetic parameters 
(Km
app
, kcat
app
 and (kcat/KM
app
), confirming the generality of effective kinase-catalyzed 
biotinylation reaction (Table A2.1). 
 
 
a
KM
app
 and kcat
app
 were calculated due to limiting substrate concentrations.. Ratios were 
calculated by dividing the value with ATP-biotin by the ATP value. Ratios were calculated by 
dividing the value with ATP by the ATP-biotin value 
 
 
 
 
 
 
 KM
app
 (μM)a kcat
app
 (s
−1
)
a
 kcat/KM
app
 (mM s)
−1
 
 ATP ATP-biotin Ratio ATP ATP-biotin Ratio ATP ATP-biotin Ratio 
PKA 11 ± 4 37 ± 14 3.4 7.5 ± 0.6 3.8 ± 0.6 2.0 686 102 6.7 
CK2 7.4 ± 1.5 9.2 ± 3.3 1.2 0.81 ± .06 0.29 ± 0.04 2.8 110 32 3.5 
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Figure 2.5: Michaelis–Menten kinetic plots (a,c) and rate plots (b,d) generated for PKA 
with ATP (a,b) and with ATP-biotin (c,d). 
 
a b 
c d 
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Figure 2.6: Michaelis–Menten kinetic plots (a,c) and rate plots (b,d) generated for CK2 
with ATP (a,b) and with ATP-biotin (c,d). 
   
 
a b 
c d 
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2.3 Discussion and conclusions 
 The results obtained from qualitative, quantitative, and kinetic experiments with all 25 
kinases confirmed that kinase-catalyzed biotinylation is a general reaction. Percent conversions 
and kinetic parameters calculated for all 25 kinases using gel methods and HPLC are listed in 
Table A2.1. When analyzing the overall data with all 25 kinases, a direct relationship between 
kinetic parameters and percent conversions for each kinase-catalyzed biotinylation reaction was 
not observed. We believe the reason for the difference in percent efficiency and kinetics is the 
time point of the measurement. Percent conversion data were measured under equilibrium 
conditions, while kinetic parameters were obtained under initial rate conditions. Initial rate 
kinetic measurements give a thorough understanding of the compatibility of kinases with ATP-
biotin, compared to ATP. However, kinase-catalyzed biotinylation labeling of phosphoproteins 
for future applications will be carried out at equilibrium conditions. Thus, quantitative percent 
conversion data and qualitative analysis data with western blotting are more significant for 
phosphoprotein labeling and discovery experiments.  
When analyzing the qualitative western blotting data with all 25 kinases (Figure 2.3), we 
can conclude that all kinases are capable of transferring a biotin group to protein substrates using 
an enzymatic mechanism, even though the quantitative percent conversion data for each kinase is 
different for each reaction (Table A2.1). Despite having different efficiencies in percent 
conversions varying from 44% to 96% compared to ATP under equilibrium conditions as shown 
in Table A2.1,
85
 the ability of all kinases to use ATP-biotin as a cosubstrate and transfer a biotin 
group to substrate proteins can be used in general as a labeling method to detect any kinase 
substrates in proteomics applications. Thus, the discovery of the generality of kinase-catalyzed 
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biotinylation, ATP-biotin can be used as a general kinase-substrate labeling technique develop 
tools to detect and identify cellular kinase-substrates.
85
 
 
2.4 Experimental 
 
2.4.1 Materials 
 
Biotin was purchased from Advanced Chemtach. 4,7,10-trioxa-1,13-tridecanediamine, 
diisopropylethylamine (DIPEA), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI), and N, N-dimethylformamide (DMF) were purchased from Acros. Adenosine 5’-
triphosphate (ATP) was purchased from MP biomedicals. Triethylamine, glycerol, sodium 
hydroxide (NaOH), sodium chloride (NaCl), sodium dodecyl sulfate (SDS) were purchased from 
Fisher. Triton X-100 was purchased from Fluka. Trifluoroacetic acid (TFA) was obtained from 
EMD milipore. Kinases (CAMK4, ERK1, TGFβR2, and GRK5) and protein and peptide 
substrates (Myelin Basic Protein (MBP), dephosphorylated Casein protein, Kemptide and CK2 
peptide peptide) were purchased from Promega. c-AMP- dependent protein kinase A catalytic 
subunit alpha (PKA) and casein kinase 2 (CK2) were purchased from New England Biolabs 
(NEB). Immobilin P (PVDF) membrane was bought from Millipore. Sypro Ruby and Pro-Q 
diamond stain was purchased from Invitrogen. β-Nicotinamide adenine dinucleotide, reduced 
disodium salt (NADH), Pyruvate Kinase/Lactic Dehydrogenase enzymes from rabbit muscle 
(PK/LDH) and Phospho(enol)pyruvic acid monopotassium salt  (PEP) were purchased from 
Sigma Aldrich. 
2.4.2 Instrumentation 
 The SDS-PAGE apparatus and mini-transblot electrophoretic transfer cell apparatus for 
western blotting was purchased from BioRad. PAGE gels stained with Sypro Ruby or Pro-Q 
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were visualized using a Typhoon 9210 scanner (Amersham Biosciences). Absorbance values 
(340 nm) for NADH-coupled enzyme assay were measured using a fluorimeter (GENios Plus 
Tecan). 
2.4.3 Synthesis of ATP-biotin 
2.4.3.1 Synthesis of biotin-amine 
In a small round bottom flask (100 mL), biotin (509 mg, 2 mmol) and TBTU (802 mg, 
2.4 mmol) was dissolved in 5 mL of DMF. To the mixture, DIPEA (0.4132 mL, 2.4 mmol) was 
added quickly and the reaction was stirred at room temperature for 45 minutes until a white 
chalky precipitate was observed. The precipitate was then collected through gravity filtration and 
dissolved in DCM (30 ml). The mixture was then added dropwise into a flask containing, 4, 7, 
10-trioxa-1-13- tridecanediamine (2.2 mL, 10 mmol) in DCM (400 mL) and stirred overnight at 
room temperature. Synthesis of biotin-amine was monitored by TLC using a EtOH: DCM: 
NH4OH (3:1:0.5) solvent system with a Rf value of 0.60. Next, DCM was removed by rotorvap/ 
vacuum assisted evaporation. Biotin-amine product was then purified using silica flash 
chromatography using elution conditions, beginning with EtOH/DCM (3:1 v/v) and finishing 
with EtOH/DCM/NH3 (3:1:0.05 v/v/v) to yield biotin-PEG-amine as a solid product (0.6 g, 70% 
yield).  
2.4.3.2 Synthesis of ATP-biotin 
Adenosine 5’-triphosphate disodium salt (27 mg, 0.05 mmol) was dissolved in water (5 
mL), followed by the addition of 1-(3-Dimethylaminpropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI, 383 mg, 2 mmol) to the reaction mixture. Synthesized biotin-PEG-amine (6) (600 mg, 2 
mmol) was then added to the ATP/EDCI solution and the mixture was stirred at room 
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temperature for 2 hours maintaining the pH 5.5-5.8 range. The succession and the completion of 
the reaction was monitored with TLC using the solvent system (6:3:1 iPrOH: NH4OH: H2O Rf 
=0.69). At the end of the reaction the pH was adjusted to 8 using TEAB and purified using pre-
soaked DEAE sephadex-A25 anion exchange resin (5 g). The resin was previously soaked in 
water overnight before using stepwise triethylammonium bicarbonate buffer (TEAB) gradient 
ranging from 5%, 10%, 25%, 37.5%, and 50% TEAB to elute ATP-biotin. Finally, purified ATP-
biotin was lyophilized to yield a TEA salt (white) of ATP-biotin and stored -80 
0
C. 
2.4.4 Quantitative Kinase-catalyzed biotinylation of proteins 
Kinase reaction was performed by incubating protein substrate (0.2 mM) with the kinase 
(Table 2.1) and ATP-biotin (2 mM) in the manufacturer provided buffer at 31
0
C for 2 hours. As 
a control, the kinase and the protein substrate was incubated with ATP (2 mM).  Another 
negative control was performed by incubating protein substrate only in kinase buffer. The final 
volume for each reaction was 25 µl. After kinase reaction, each sample was treated with TFA (25 
µL to produce a 50% TFA final solution) in a final volume of 50µl and heated at 45 
0
C for 15 
minutes with shaking (400rpm). The samples were then evaporated using speed vac, until a dried 
product was obtained. Resulting product was neutralized by adding 1.5 M Tris-base (pH 12) (5 
µL) in water in a final volume of 30µL. To prepare samples for SDS-PAGE, each sample was 
boiled at 95°C for 1 min after adding Laemmli sample buffer (10 µL; 62.5 mM Tris-HCl, pH 6.8, 
25% glycerol, 2% SDS and 0.01% bromophenol blue). Samples were separated by 16% SDS-
PAGE. PAGE gels were analyzed by Sypro Ruby staining (Section 2.4.7) and Pro-Q staining 
(Section 2.4.6). 
2.4.5 SDS-PAGE 
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 SDS polyacrylamide gels were prepared following the protocol in Molecular Cloning, 
Appendix 8.40-8.45. The PAGE gels were prepared as two layers; separating layer and stacking 
layer. First, 4 mL of 16% separating layer was prepared by mixing Tris/SDS buffer mixture (1 
mL; 1.5 M Tris, 0.4% w/v SDS, pH 8.8),  40% w/v 37:1 acrylamide:bisacrylamide (1.6 mL) and 
distilled water (1.6 mL). Then, freshly prepared, 10% ammonium persulfate (40 μL) was added. 
Finally, to initiate polymerization, TEMED (4 μL) was mixed into the solution. The solution was 
then poured into the prepared 1.5 mm thick glass plate PAGE setup. A small amount of methanol 
was poured over the top of separating solution quickly to create a smooth surface before 
polymerization. After allowing the separating layer to solidify over 4 hours, methanol was 
poured off and the separating layer was washed with distilled water twice before pouring the 
stacking layer on top. The 4% staking layer was prepared by mixing Tris/SDS buffer (0.5 mL; 
1.5 Tris HCl, 0.4% w/v SDS, pH 6.8), distilled water (1.24 mL) and 40% w/v 37:1 acrylamide: 
bisacrylamide (0.25 mL), in a final volume of 2 mL. Then freshly prepared 10% ammonium 
persulfate (10 μL) was added. Finally, to initiate polymerization, TEMED (4 μL) was mixed into 
the solution and solution was poured on top of the separating layer. Then a 1.5 mm thickness gel 
comb was inserted quickly and gel was allowed to solidify over 2 hours. After solidification, 
combs were removed and the gel was inserted into gel running chamber apparatus, which was 
filled with a 1X SDS running buffer (1 L; 0.1% SDS, 0.025 M Tris, and 0.25 M glycine (pH 8.3). 
Finally, protein products were loaded into gel, and run at 180 V for 1 hour. 
2.4.6 Pro-Q staining 
 After SDS-PAGE, the gel was incubated overnight in a fixing buffer (100 mL, 50% 
methanol and 10% acetic acid in water) with mild rocking at room temperature. After overnight 
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incubation, fixing buffer was discarded, and the gel was thoroughly washed three times with 100 
mL distilled water for 10 minutes each. Then Pro-Q diamond stain (100 mL) was added to the 
gel container, which was covered with an aluminum foil. The gel was incubated with Pro-Q stain 
for 90 minutes with mild shaking. After the staining period, the Pro-Q stain was removed and the 
gel was washed with destaining buffer, (100 mL; 20% acetonitrile, 50 mM sodium acetate pH 4) 
three times with 30 min each incubation. Finally, the gel was rinsed with distilled water (100 
mL) two times and imaged using a Typhoon imager with excitation and emission wavelengths of 
532 nm and 555 nm, respectively. 
2.4.7 Sypro Ruby Staining 
 After SDS-PAGE, the gel was incubated in a Sypro Ruby fixing buffer (100 mL; 50% 
methanol and 7% acetic acid in water) with mild rocking at room temperature for 20 minutes. 
After fixing, the solution was discarded and the gel was washed with distilled water (100 mL) for 
10 minutes. Then Sypro Ruby stain (100 mL) was added to the gel and incubated overnight in a 
light-protected container. After overnight staining, the Sypro Ruby stain was removed and the 
gel was washed with destaining buffer (100 mL; 10% methanol and 7% acetic acid in water) for 
30 minutes. Then destaining solution was discarded and the gel was washed with distilled water 
(100 mL) to remove residual organic solvents before scanning using Typhoon using at an 
excitation and emission at 450 nm and 610 nm, respectively. 
2.4.8 Gel Image Quantification 
 Percent conversions were calculated by quantifying the signal in each protein band in the 
PAGE using ImageQunt 5.1 software. The same size boxes were drawn on the protein band to 
determine the signal in background, ATP-biotin, and ATP reaction lanes. The signal for 
background was subtracted from signal for both ATP and ATP-biotin reaction lanes. Then 
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percent conversion was calculated by dividing the quantified, background-corrected signal for 
ATP-biotin by the signal for ATP reaction, and multiplying by 100. 
2.4.9 NADH-coupled enzyme assay 
The NADH-dependent enzyme coupled assay was performed by first creating a master 
mixture using, 4 units/mL of pyruvate kinase, 36 units/mL of lactic acid dehydrogenase, 1 mM 
PEP, 0.5 mM NADH, 0.5mg/mL bovine serum albumin, 1.29 mM of kemptide (LRRASLG), 50 
mM HEPES (pH 7.5), 10 mM KC1, 150 mM NaCl, and 10 mM Mg2Cl and in a total volume of 
25 µL, and pre-incubating for 5 minutes with ATP or ATP-biotin with final concentrations of 1, 
3, 10, 30, and 100 μM. After the pre-incubation step, PKA (12 nM) or CK2 (10 nM) was added 
and the absorbance at 340 nm was taken using Tecan fluorometer every 30s for 60 min at 31 
0
C. 
To create rate plots, the concentration of NADH consumed over time was plotted and the initial 
rate was calculated using the slope of the initial linear part of the graph (Figure). Initial rates and 
substrate concentrations (for ATP and ATP-biotin) were used to created Michaelis–Menton plots 
by non-linear regression using Kaleidagraph (v = Vmax
app
[S]/ (KM
app
 + [S]; v = rate of the reaction 
and [S] = substrate concentration).  The KM
app
 and Vmax
app
 values were obtained using the 
Michaelis–Menton plots, while kcat
app
 values were obtained by dividing Vmax
app
 with the 
concentration of the enzyme (Table 2.2). The KM
app
, Vmax
app
 and kcat
app
 values were displayed as 
apparent values since the concentration of the peptide substrates were used was ≤10-fold of the 
substrate KM. 
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Table 2.2 Concentrations of Kinase and Substrate used in Kinase reactions 
 
Kinase  
Quantification
a
 Kinetic Studies
b
 
Kinase (nM) Kinase (nM) 
Peptide/Protein  
Substrate
c
 (µg/µL) 
CAMK4 101 1.3 0.2 
ERK1 182 4.6 0.1 
GRK5 70 10.0 0.1 
TGFβR2 0.118 18.4 0.1 
PKA 150 12.0 0.2 
CK2 166 10.0 0.2 
a
 ProQ quantification studies are shown in Figure 2.4 of the manuscript.  
b
 Kinetic Studies are 
shown in Table 1 of the manuscript.  
c
The peptide or protein substrate used with each kinase for 
each experiment is shown in experimental.   
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CHAPTER 3: KINASE CATALYZED BIOTINYLATION WITH INACTIVATED 
LYSATES  FOR DISCOVERY OF SUBSTRATES (K-BILDS) 
 
 The text, figures, and legends in this chapter were reprinted or adapted from, K-BILDS: 
A kinase substrate discovery tool : Embogama D. M. and Pflum, M. K (Version of Record 
online: 7 DEC 2016 | DOI: 10.1002/cbic.201600511ChemBioChem) 
 Kinase-catalyzed protein phosphorylation governs cellular events through 
signaling. Thus, identifying kinase-substrate relationships will reveal specific details of signaling 
that contribute to normal and diseased cellular events. In this chapter, first, a brief introduction is 
given to current methods available to discover kinase substrates. Then, the synthesis of ATP-
biotin and the development of K-BILDS (Kinase-catalyzed biotinylation with inactivated lysates 
for discovery of substrates) to identify kinase-substrate relationships are discussed. As a proof-
of-concept, KBILDS was first applied to cAMP-dependent protein kinase A to identify 
substrates and to validate the method. Discovered substrates were analyzed by consensus site 
mapping, physical interactome analysis, gene ontology assessment, abundance distribution and 
by an in vitro kinase assay to validate K-BILDS as a substrate discovery tool. 
3.1 Introduction to current methods available to identify kinase-substrates 
 Kinase-substrate identification has attracted the scientific community due to the 
importance of kinase-catalyzed phosphorylation in cells. In order to understand the underlying 
mechanism behind phosphorylation-related disease events, deciphering kinase-substrate 
relationships and mapping cell signaling pathways are necessary. With more than 500 protein 
kinases identified, it is a challenge to decode kinase-substrate relationships, especially due to the 
low abundance, low stoichiometry, and the dynamic nature of  protein phosphorylation.
87
 Thus, 
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many research groups have developed  methods to identify kinase substrates.
88
  The most 
common methods involve identification of protein substrates by kinase assays, protein-protein 
interaction assays and mass spectrometry after immunoprecipitation or metal affinity 
chromatography. However, there are advantages and limitations associated with each of these 
methods and a few will be discussed in this chapter. 
3.1.1 Kinase substrate detection by in-vitro assays using (γ-32P) ATP 
Radio labeled ATP has been used to identify kinase substrates from cellular lysates as 
well as in peptide or protein based microarrays. In methods where cellular lysates were used, 
first endogenous cellular kinases were inhibited with heat inactivation or a kinase inhibitor 
treatment prior to the addition of (γ-32P) ATP for substrate labeling.89 After kinase reaction, 
protein products were analyzed by auto radiography following immunoblotting or mass 
spectrometry to identify individual kinase substrates. During kinase inhibition by heat 
inactivation, lysates were commonly heated to a higher temperature to denature endogenous 
kinase activity. However, the application of heat denatures all cellular proteins, not specifically 
targeting kinase activity. Thus, the discovered substrates might not be in a physiologically 
relevant state for phosphorylation. Treatment with a general kinase inhibitor such as 5'-4-
fluorosulphonylbenzoyladenosine (FSBA) is an alternative approach to inhibit endogenous 
kinases. 
Utility of FSBA as a kinase inhibitor to inactivate endogenous kinases is widely 
reported.
90-92
 FSBA inhibit protein kinases by binding to ATP binding site and reacting with 
nucleophilc residues in the active site.
91
 Specifically, the fluorosulfonyl group of FSBA (Scheme 
3.1) will react with catalytic lysine residues (Figure 1.4b) in the enzyme active site covalently 
48 
 
 
 
and irreversibly to inhibit kinase activity.
93
 Despite the use of FSBA as an inhibitor, radio-
labeled kinase assays exhibit a much higher background phosphorylation signal due to excess 
sensitive radiolabeled ATP. Thus, detecting exogenous kinase specific phosphorylation signal 
can be difficult.  Use of radio labeled (γ-32P) ATP in peptide assays is another approach to detect 
kinase substrate. Here, the ability of a kinase to phosphorylate peptide sequence is monitored 
using (γ-32P) ATP. Even though peptide screening is relatively easy and less expensive, the main 
disadvantage would be the inability to predict actual cellular protein substrates based only on 
sequence information from a small peptide.  
3.1.2 MS based substrate detection after an enrichment 
The other common technique used for kinase-substrate discovery is mass spectrometry
94
 
after an enrichment of phosphoproteins by metal affinity chromatography (Immobilized metal 
affinity chromatography (IMAC) or metal oxide dependent affinity chromatography (MOAC)) or 
immunoprecipitation with phospho-tyrosine antibodies. Enrichment with these techniques 
increases the probability of detecting low abundant phosphoproteins. However, these widely 
used traditional enrichment methods still have limitations due to the bias towards identification 
of high abundant, acidic or phosphotyrosine antibody-dependent phosphoproteins.
95-98
 
99
  These 
techniques will be thoroughly discussed in Chapter 4.12. 
3.1.3 ASKA for kinase substrate discovery 
Shokat and coworkers have developed analogue-sensitive kinase alleles (ASKAs) as 
another approach to identify kinase substrates. In ASKAs, an engineered kinase that will accept 
an unnatural-bulky ATP analog is used to label and identify kinase substrates. In ASKA method, 
the kinase is mutated at the gate keeper amino acid position in ATP binding site to modify the 
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Figure 3.1: General scheme of yeast two hybrid assay for kinase substrate discovery. 
active site to accommodate (γ-32P) N6-modified bulky ATP analogs as cosubstrates. However, 
mutation at the gate keeper amino acid should not affect the activity or the specificity of the 
kinase enzyme.  In addition, all kinases are compatible with the mutation; to date, ASKAs are 
available for roughly 30 kinases, while the kinome comprises more than 500 kinases. Therefore, 
there is a need for new and efficient methods to enrich and identify kinase substrates to expand 
our knowledge of kinase dependent signaling events.   
3.1.4 Kinase-substrate detection by protein-protein interaction assays 
Another common method to identify kinase substrate is to use protein-protein interactions 
to detect kinase substrate interactions. Even though kinase-catalyzed phosphorylation requires 
only a transient interaction between the kinase and the substrate, previous studies have 
successfully used protein-protein interaction assays to detect and identify kinase substrates pairs. 
In fact, based on statistics of kinase-substrate interactions, 95% of substrates typically associate 
with the kinase directly or indirectly, which justify the use of protein-protein interaction assays 
for kinase substrate discovery.  
 
 
 
The yeast two hybrid (Y2H) approach is the foundation for many protein-protein 
interaction dependent kinase discovery assays. In Y2H, DNA binding transcription factors are 
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used to activate transcription in response to bait and prey binding interaction. First, the 
transcription factor is divided into a promoter binding domain and reporter binding activator 
domain.  The bait protein/kinase is attached to a promoter binding half and the prey 
proteins/substrates are attached to reporter binding half of the transcription factor. When 
bait/kinase is incubated with prey/substrate, only the prey/substrate which specifically bind to 
bait/kinase will turn on transcription though attached reporter binding activator domain, giving 
rise to a signal which can be detected by a change in color or absorbance to identify kinase 
substrates (Figure 3.1). Even though protein-protein interaction approach has successfully 
identified kinase substrates, this method suffers from high false discovery rate. Therefore, 
alternatives are still needed for a broad characterization of kinase-substrate relationships.  
In previous work, Pflum lab and others discovered that γ-phosphate modified ATP 
analogs act as cosubstrates to label and modify kinase substrates (Section 1.8). Specifically, ATP 
modified with a biotin tag at γ-phosphate acts as a kinase cosubstrate to transfer a 
phosphoramidyl biotin group onto protein substrates (Section 1.85) (Figure 1.10).
71,85
  Kinase-
catalyzed biotinylation has been used to visualize proteins, but has not yet been exploited in 
kinase-substrate identification.  Here in this chapter, we report the development of a new method 
for kinase substrate identification entitled, "Kinase-catalyzed Biotinylation with Inactivated 
Lysates for Discovery of Substrates" (K-BILDS). 
3.2 Results and Discussion 
3.2.1 K-BILDS 
In the K-BILDS method, endogenous cellular kinases in lysates are first inactivated by 
incubating with the covalent inhibitor, FSBA (5′-(4-fluorosulfonylbenzoyl) adenosine 
51 
 
 
 
hydrochloride).
90, 100-101
 FSBA reacts with a catalytic lysine in the kinase active site to 
irreversibly inhibit activity (Figure 3.2B).
90
 Removal of excess FSBA is followed by the 
incubation with an exogenous active kinase and ATP-biotin to biotinylate kinase substrates in the 
lysates. As a control, FSBA-treated lysates were incubated with ATP-biotin without exogenous 
active kinase. Biotinylated proteins are then enriched using streptavidin resin, separated by SDS-
PAGE, and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Figure 
3.2A). The biotinylated proteins identified are candidate kinase substrates, which must be 
validated in secondary studies.    
To establish K-BILDS as a substrate identification tool, a proof-of-concept study was 
performed focusing on a well-studied kinase, PKA (cAMP dependent protein kinase A/ 
PRKACA). PKA is a serine/threonine kinase that regulates multiple cellular events, such as 
signaling, transcription, metabolism, transport and homeostasis as discussed more in chapter 
1.5.1.
102
 Importantly, PKA has many known kinase substrates, which will test the utility of K-
BILDS.   
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Figure 3.2: A) K-BILD Workflow.  In the K-BILD workflow, cell lysates were first treated 
with FSBA to inactivate kinases, followed by removal of excess FSBA by filtration. Kinase-
inactivated lysates were treated with ATP-biotin in the presence (top, kinase reaction) or 
absence (bottom, control reaction) of exogenous active kinase to generate biotinylated kinase 
substrates. Then biotinylated proteins were enriched using avidin resin, separated by SDS-
PAGE, and subsequently analyzed by LC-MS/MS to identify biotinylated protein in the 
kinase but not control reaction. orange/red: kinases, blue: substrates, grey: cellular proteins. 
B) Structure of FSBA 
A) 
B) 
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Figure 3.3 Kinase-catalyzed biotinylation of FSBA-treated lysates with PKA. HeLa cell 
lysates were treated with DMSO (lanes 1 and 2) or FSBA (lanes 3 and 4). Subsequently, 
samples were filtered to remove FSBA, and then ATP-biotin (lane 2, 3, and 4) and PKA (lane 
4) were added. After kinase reaction, protein products were separated by SDS-PAGE and 
stained with SA-Cy5 to visualize biotinylation (top) and Sypro Ruby for total protein analysis 
(bottom). Repetitive trails are shown in Figure B3.1. 
3.2.2 Kinase-catalyzed biotinylation with FSBA-treated lysates 
To develop K-BILDS, endogenous cellular kinase activity was first inhibited by FSBA 
treatment. Lysates were treated with FSBA and then incubated with ATP-biotin to observe 
possible residual endogenous kinase activity. As a positive control, untreated (DMSO) HeLa 
lysates were also incubated with ATP-biotin. As expected, kinase-catalyzed biotinylation was 
observed with untreated HeLa lysates (Figure 3.3, lane 2, SA-Cy5). In contrast, only a low level 
of 
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biotinylation was observed with FSBA-treated lysates (Figure 3.3, lane 3, SA-Cy5), consistent 
with kinase inactivation by FSBA. After FSBA inactivation, lysates were subjected to kinase-
catalyzed biotinylation using ATP-biotin and exogenous active PKA. A small increase in biotin 
signal was observed in the presence of PKA (Figure 3.3, lane 4, SA-Cy5, see brackets), 
compared to inactivated lysates incubated with ATP-biotin alone (Figure 3.3, lane 3, SA-Cy5). 
When comparing biotinylation with PKA versus all cellular kinases (Figure 3.3, lane 4 vs. 2, SA-
Cy5), the small signal observed with PKA biotinylation suggested selective biotinylation of PKA 
substrates only. Next, K-BILDS was applied to PKA on a larger scale for substrate identification 
using MS/MS analysis. 
3.2.3 K-BILDS with PKA 
 To identify PKA substrates in a full K-BILDS experiment, FSBA-treated cell lysates 
were incubated with ATP-biotin with or without PKA. Biotinylated proteins were then enriched 
using avidin resin and separated by SDS-PAGE. The proteins enriched in PKA reaction 
compared to the control reaction are not visually apparent (Figure 3.4, lane 4 vs. lane 3). 
Therefore, the whole lanes (lane 3 and lane 4) were in-gel digested with trypsin and analyzed by 
LC-MS/MS (liquid chromatography-tandem mass spectrometry). Proteins enriched in the PKA 
reaction (Figure 3.4, lane 4, Sypro Ruby) were compared to the control reaction (Figure 3.4, lane 
3, Sypro Ruby) to generate a list of candidate substrate hits. 
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Figure 3.4 Kinase-catalyzed biotinylation of FSBA-treated lysates with PKA. HeLa cell 
lysates were treated with DMSO (lanes 1 and 2) or FSBA (lanes 3 and 4). Subsequently, 
samples were filtered to remove FSBA, and then ATP-biotin (lane 2, 3, and 4) and PKA (lane 
4) were added. After kinase reaction, protein products were separated by SDS-PAGE and 
stained with SA-Cy5 to visualize biotinylation (top) and Sypro Ruby for total protein analysis 
(top). 
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3.2.4 Analysis of MS/MS data to generate a K-BILDS hits list  
 To identify PKA candidate substrates, spectral count ratios were calculated by dividing 
the number of peptide spectra for each protein in the PKA reaction by the number of spectra of 
that protein in the negative (no PKA) control. As a first screen, the spectral count ratio was 
calculated independently for each trial and only proteins that displayed a spectral count ratio of 
≥1.0 in both trials were selected. Then, as a second more rigorous screen, the spectral counts of 
each protein in both trials were summed and a new ratio was calculated by dividing the summed 
number of spectral counts for each protein in the PKA reactions by the summed number of 
spectral counts of that protein in the negative (no PKA) controls (Table B3.1, Figure B3.3-3.6). 
The final 279 K-BILDS hit proteins displayed summed spectral count ratios of ≥1.2 (Table 
B3.1). The 1.2-fold summed spectra count ratio cut-off was chosen because known PKA 
substrates were observed at enrichment levels as low as 1.2-fold (Table B3.1, see GFPT1 
protein). 
3.2.5 K-BILDS identified previously known PKA substrates 
In two independent trials, 279 proteins were reproducibly enriched in the PKA reactions 
and identified as candidate PKA substrates. To compare previously known substrates of PKA to 
K-BILDS candidate hits, the phosphosite-plus database and published research journals were 
searched. Fifty-six proteins are previously documented PKA substrates
102-109
, including 25 from 
phosphosite Plus that have been validated both in vitro and in vivo (Table 3.1). The isolation of 
known PKA substrates validated K-BILDS for kinase substrates identification.   
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a
 Proteins in the PKA K-BILDS hit list (Table S1) were compared to known PKA substrates 
from Phosphosite Plus and the literature. The 56 proteins listed here are known PKA substrates, 
with the first 25 identified from Phosphosite plus (bold text). Substrates from Phosphosite plus 
were validated both in vitro and in vivo, while the others were identified using in vitro assays 
only. 
b
 The Gene name for each substrate is given. 
c
 The species indicates which homolog of the 
substrate was previously used in PKA substrate validation studies (human – human isoform; rat – 
rat isoform; bovine – bovine isoform). d NASP was found previously in a microarray-based 
substrate discovery method,
110
 but had not yet been validate 
 
3.2.6 Interactome analysis of PKA candidate hits 
 According to statistics on kinase complexes, roughly 95% of known PKA substrates 
either directly associate with PKA or indirectly interact with PKA through three or fewer other 
intermediate proteins (three degrees of separation).
111-112
 Thus, to further analyze the 279 K-
Substrate
b 
Species
 
Substrate
b 
Species
 
Substrate
b 
Species
 
AKAP12 human ACTN1 Rat HNRNPK rat 
DDB1 human CP Rat PFKM rat 
FLNA human PDIA6 Rat PFKP rat 
GFPT1 human RPN1 Rat RPS14 rat 
GPKOW human ZYX Rat SBDS rat 
HLA-A human KLC1 Bovine TKT rat 
MSN human HDAC1 human UBE2o rat 
PDE3A human EGFR human FLNB human 
PRKACA human ACACA human SH3GL1 Human 
PSMC5 human AP2M1 Rat SRRM2 Human 
PTBP1 human MAP4 Rat NUCB1 Human 
PTPN11 human MTHFD1 Rat HSPA4L Human 
SPTBN1 human NMT1 Rat LRRC47 human 
TGM2 human PYCRL Rat CTTN human 
YWHAZ human RPL28 Rat PSMA8 human 
DPYSL2 mouse RPLP2 Rat XPO1 human 
NACA mouse RPS10 Rat YWHAE human 
SSB mouse RPS16 Rat NA
SP
d
 
human 
YWHAH mouse RPS24 Rat   
Table 3.1: Previously known PKA substrates among the K-BILDS hits
a 
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BILDS hits, a PKA interactome analysis was conducted. The 279 K-BILDS hits were compared 
to protein-protein interaction data in the GeneMANIA database to identify direct and indirect 
interacting proteins of PKA.
113
   Remarkably, 78% of K-BILDS hits interact with PKA 
(PRKACA) within three degrees of separation (Figure 3.5a). Furthermore, fourteen direct 
interacting hits (Figure 3.5a, inner circle, blue) and thirty-seven indirect interacting hits (Figure 
3.5a, outer circle, blue) are previously documented PKA substrates.  In fact, fifty-one out of 
fifty-six known substrates are present in the PKA interactome (91%), as predicted.
111-112
  
Therefore, the PKA-centered interactome established that the majority of K-BILDS hits are 
direct or indirect interacting proteins and, as a result, likely PKA substrates. 
In addition to identifying novel substrates, several protein complexes were discovered using K-
BILDS. Substrate-containing complexes were discovered by analyzing the PKA K-BILDS 
interactome using MCODE in the Cytoscape program. In addition to identifying all 14-3-3 
family members (Figure 3.5b), proteins belonging to the proteasome core (Figure 3.5c) and 
ribosome (Figure 3.5d) were identified by K-BILDS as candidate PKA substrates. Previous 
literature reported that PKA-dependent phosphorylation regulates proteasome and ribosome 
function,
114-115
 consistent with these proteasome and ribosomal proteins being PKA substrates. 
The interactome analysis showed that K-BILDS not only identified kinase substrates, but 
alsouncovered complexes containing substrates, which will assist in defining the full activity of 
kinases in a cell. 
 
 
 
   
A) 
59 
 
 
 
Figure 3.5: Interactome analysis of candidate PKA substrates from the K-BILDS study. (a) The 
279 hits enriched in K-BILD PKA reactions but not in the negative controls (Table S1) were 
analyzed using GeneMANIA in Cytoscape to identify physical protein-protein interactions 
between PKA and K-BILD substrate hits. From 279, 78% (214 hits) are represented in the 
interactome. The inner circle represents direct interactors of PKA (PRKACA), while the outer 
circles represent indirect interactors within the distance of ≤3 interacting proteins. The thickness 
and the length of the lines are arbitrary drawn for clarity. The full interactome, including the 59 
proteins that either interact indirectly with PKA beyond three degrees of separation or have no 
documented interaction with PKA, is shown Figure B3.7. (b) All seven 14-3-3 proteins were 
identified by K-BILDS as candidate PKA substrate. (c) Candidate PKA substrate of the 
proteosome core identified by K-BILD. (d) Candidate PKA substrate in the ribosome complex 
identified by K-BILD.  PKA (PRKACA), known PKA substrates, and the three substrates 
validated here are indicated in red, blue, and purple, respectively, while all remaining candidate 
substrates shown in green.  
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3.2.7 Abundance and gene ontology analysis of K-BILDs hits 
An abundance analysis of K-BILDS hits was performed to assess how protein quantities 
in a cell can affect the ability of K-BILDS to identify substrates. The abundance of K-BILDS 
hits in HeLa cells was compared to the abundances of total proteins in HeLa using Pax-db 
database (pax-db.org).
116
 The observed abundance range for K-BILDS hits varied from 0.7-9000 
ppm (Figure 3.6). The range of abundances of K-BILDS hits was comparable to the distribution 
of all cellular proteins (0.1-10,000 ppm), confirming that K-BILDS identified proteins 
irrespective of abundance. Interestingly, some of the K-BILDS hits were low abundance 
proteins, such as transcription factors and signaling molecules.  
Next, to gain functional insight into K-BILDS candidate PKA substrates, the 279 hit 
proteins were analyzed by gene ontology (GO). GO analysis categorized K-BILDS hits into 
twelve biological processes, including metabolism, cellular enzymatic functions, and localization 
(Figure B3.8). The fact that PKA controls diverse cellular events, including all twelve identified 
biological processes, provided further evidence that candidate K-BILDS hits contain potential 
PKA substrates. 
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Figure 3.6: Abundance distribution of 273 hits out of 279 K-BILD hits. The cellular 
abundances of each of the 279 K-BILD hit proteins were obtained from Pax-db.  Data were 
missing in the database for PLS3, POLDIP2, CLUH, GPC1, CP and CASP1. Kaliedograph was 
used to generate the plot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.8 Kinase consensus site mapping 
 In addition, K-BILDS hits were further analyzed by Scansite to detect PKA consensus 
motifs (R/K-R/K-X-S/T). Scansite is a web program that searches kinase phospho motifs in 
proteins and predicts sites have a higher probability of being phosphorylated by a particular 
kinase.  The program predicts the occurrence of kinase consensus sites by using values for each 
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amino acid at each position comparative to the predicted phosphosites from a constructed peptide 
library. Gratifyingly, 91% of K-BILDS hits contained possible PKA consensus sites. The 
presence of PKA consensus sites among the K- BILDS hits strongly implicates the candidate 
proteins as PKA substrates 
3.2.9 In vitro validation of novel PKA hits 
Based on the global physical interactome (Figure 3.5a) and biological functions of 
proteins (Figure A3.4), three candidate hits were selected for biochemical validation. According 
to the Genemania database, NASP (Nuclear Autoantigenic Sperm Protein (Histone-Binding)) is a 
directly interacting protein of PKA (Figure 3.5a).
110,117
 It is also a possible PKA substrate 
according to phosphosite plus curated MS/MS data and phosphonetworks.
110
 However, NASP 
has not been validated as a direct PKA substrate. Here, an in vitro kinase assay was performed 
by incubating NASP with ATP and PKA. Phosphorylated protein products were analyzed by 
SDS-PAGE and Pro-Q phosphoprotein stain. NASP was phosphorylated by PKA (Figure 3.7a, 
lane 2, Pro-Q) compared to the negative control without PKA (Figure 3.7a, lane 1, Pro-Q). The 
facts that NASP physically interacts and coexpresses with PKA in HeLa cells is consistent with 
NASP being a substrate of PKA.
118,119
 
As a second K-BILDS hit for validation, we studied BAG3, which is an indirect 
interactor of PKA (Figure 3.5a). In vitro kinase assays were performed by incubating BAG3 with 
ATP and PKA. Pro-Q analysis of the phosphorylated products confirmed that Bag3 is 
phosphorylated by PKA (Figure 3.7b, lane 4, Pro-Q). Bag3 is Bcl2 family protein that regulates 
several biological processes, including apoptosis.
120
 BAG3 functions as an anti-apoptotic protein 
through other Bcl-2 family proteins, such as Bcl2 (B-cell lymphoma 2). Phosphorylation of Bcl2 
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by PKA causes Bcl2 inactivation and induction of apoptosis.
121
 However, no phosphorylation 
events have directly linked BAG3 to its anti-apoptotic function. Given the precedence of PKA in 
regulating apoptosis, we hypothesize that phosphorylation of BAG3 by PKA might play a role in 
regulating its anti-apoptotic function as well. 
122
   
YWHAQ is another indirect interacting protein of PKA (Figure 3.5a) that was selected 
for validation. YWHAQ is a member of the 14-3-3 family, which are adaptor proteins involved 
in cell signaling.   Interestingly, all seven 14-3-3 isoforms (YWHA proteins) were identified by 
K-BILDS as potential PKA substrates (Figure 3.5b). Three isoforms (YWHAE, YWHAH, and 
YWHAZ) are previously documented PKA substrates. 
103-104
  In vitro kinase assays confirmed 
that YWHAQ is phosphorylated after incubation with PKA (Figure 3.7c, lane 6, Pro-Q) in 
contrast to a reaction without PKA (Figure 3.7c, lane 5, Pro-Q), confirming that YWHAQ is a 
substrate of PKA. Previous reports have claimed that all 14-3-3 (YWHA) proteins act as 
adaptors and regulate the function of PKA.
123
  Based on the K-BILDS results, we hypothesize 
that phosphorylation of all seven YWHA (14-3-3) isoforms may be involved in signaling 
mediated by PKA. As a conclusion, In vitro kinase assay followed by Pro-Q analysis with 
selected candidates, NASP, BAG3 and YWHAQ proteins, confirmed that all three candidate 
substrates are PKA substrates. 
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3.3 Conclusions 
 In conclusion, this study established K-BILDS for kinase substrate identification using 
PKA as a well-studied model system. Fifty-six previously known PKA substrates and more than 
200 candidate substrates were identified, demonstrating the success of the method. In vitro 
validation confirmed that BAG3, NASP and YWHAQ are PKA substrates, suggesting that K-
BILDS efficiently identified new PKA substrates. While K-BILDS represents a useful kinase 
substrate discovery tool, we must emphasize that validation studies are critical to confirm that 
putative substrates are modified by PKA. Moreover, thorough in cellulo or in vivo studies are 
needed to explore the physiological relevance of PKA phosphorylation on the function of 
identified substrates. Nevertheless, given the general ability for kinases to accept ATP-biotin as a 
cosubstate,
85
 K-BILDS represents an enabling tool to identify substrates of any protein kinase
Figure 3.7:  Validation of select K-BILDS hits as PKA substrates using in vitro 
kinase assays. NASP (a), BAG3 (b), or YWHAQ (c) were incubated with ATP either 
without (lanes 1, 3, and 5) or with PKA (lanes 2, 4, and 6) before SDS-PAGE 
separation and protein visualization with ProQ phosphoprotein stain (top) or Sypro 
Ruby total protein stain (bottom).  Full gel images and repetitive trials are shown in 
Figures B3.9-3.11. 
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3.4 Experimental section 
3.4.1 Materials 
 Adenosine 5’-triphosphate (ATP) was purchased from MP biomedicals. Sodium chloride 
(NaCl), and sodium dodecyl sulfate (SDS) were purchased from Fisher. Triton X-100 was 
purchased from Fluka. Centriprep columns were obtained from EMD milipore. Iodoacetamide, 
TCEP (tris(2-carboxyethyl)phosphine), proteomics grade trypsin, FSBA, and ammonium 
biocarbonate was purchased from Sigma. HeLa S3 cells were obtained from National Cell 
Culture Center (Biovest), 1X protease inhibitor cocktail was purchased from GenDepot, and 
streptavidin resin was bought from Genscript. cAMP-dependent catalytic subunit of PKA and 
PKA buffer were obtained from NEB. BAG3 and YWHAQ were purchased from Prospectbio 
and NASP was from Origene. Immobilin P, PVDF membrane was purchased from Millipore. 
Sypro Ruby and Pro-Q diamond stain was bought from Invitrogen. 
3.4.2 Instrumentation 
 The absorbance of ATP and ATP-biotin was measure using UV-Vis spectrophotometer 
(Shimadzu 2101 PC). The SDS-PAGE apparatus was purchased from BioRad. Western blotting 
apperatus; Mini-transblot electrophoretic transfer cell, was purchased from Bio-Rad. PAGE gels 
were visualized using Typhoon 9210 scanner (Amersham Biosciences).  
3.4.3 HeLa cell lysis procedure 
HeLa cells (20 X 10
6
) obtained from National Cell Culture Center (Biovest) were lysed in 
lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, and 1X 
protease inhibitor cocktail (GenDepot); 2 mL) at 4°C for 20 minutes. Cell debris was removed 
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by centrifugation at 4°C for 20 minutes. The protein concentration of the lysates was measured 
by Bradford assay (BioRad). HeLa cell lysates were aliquoted and stored at -80 
0
C until use. 
3.4.4 Kinase-inactivation of HeLa lysates using FSBA 
For kinase inactivation, HeLa lysates (200 µg or 1 mg) were diluted to 2 mg/mL with 
lysis buffer and then treated with FSBA (10 mM with a final concentration of 20% DMSO) at 
31°C for 2 hours with 800 rpm shaking. As a control, untreated lysates were prepared by adding 
DMSO to 20% concentration. The total volumes were 100 µL for a 200 µg scale reaction or 500 
µL for a 1 mg scale reaction. After kinase inactivation, samples were centrifuged for 2 min at 1 
rcf to remove any precipitate. Excess FSBA was further removed by diluting the resulting 
supernatant using four volumes with PKA/DTT buffer (500 µL for a 200 µg scale reaction or 
2mL for a 1 mg scale reaction; 50 mM Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, and 2 mM 
DTT) and filtering through a 3 KDa centriprep spin column (Milipore) twice at 14,200 rcf for 45 
min. The resulting FSBA-treated HeLa lysates were used immediately or stored at -80
0 
C until 
further use. 
3.4.5 Kinase-catalyzed biotinylation with FSBA-treated lysates with PKA 
FSBA-treated HeLa lysates (~200 µg) were incubated with ATP-biotin (2 mM) and PKA 
(1250 U, catalytic subunit of cAMP-dependent Protein Kinase, NEB) at 31°C for 2 hours. 
Control reactions were performed by incubating FSBA-treated or untreated lysates with ATP-
biotin (2 mM) only. The total volume of each reaction was 30 µL. After kinase reaction, samples 
were boiled at 95°C for 1 min in Laemmli sample buffer (10 µL; 62.5 mM Tris-HCl, pH 6.8, 
25% glycerol, 2% SDS and 0.01% bromophenol blue) and separated by 12% SDS-PAGE. Total 
proteins were assessed by Sypro Ruby staining (Invitrogen), whereas biotinylation was assessed 
using SA-Cy5 staining (Invitrogen).  Data are shown in Figures 2 and S1.   
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3.4.6 K-BILDS with PKA 
FSBA-treated lysates (~1 mg) were incubated with ATP-biotin (2 mM) and PKA (2500 
U) at 31°C for 2 hours. A negative control was performed by incubating FSBA-treated lysates 
(~1 mg) with ATP-biotin (2 mM) only. The total volume of each reaction was 60 µL. After 
kinase reaction, samples were diluted with phosphate binding buffer (300 µL; 0.1 M phosphate 
pH 7.2, 0.15 M NaCl) and excess ATP-biotin was removed by filtering through 3 KDa centriprep 
spin columns (Milipore) at 14,200 rcf for 45 min twice. After filtration, samples were diluted 
with phosphate binding buffer to a total volume of 300 µL and then incubated with streptavidin 
resin (200 µL, Genscript) for 1 hour at room temperature with rotation. The streptavidin resin 
was washed twice with phosphate binding buffer (400 µL) before use. After incubation, the resin 
was washed ten times with phosphate binding buffer (400 µL) and then five times with water 
(400 µL). The avidin bound proteins were eluted by boiling the resin in 2% SDS in water (200 
µL) for 7 minutes. The elute was concentrated using a speedvac (Thermo scientific). The 
concentrated elute was boiled in Laemmli sample buffer (final volume 40 µL) at 95°C for 1 min 
and separated by 12% SDS-PAGE. Total proteins were assessed by Sypro Ruby, whereas 
biotinylation was assessed using SA-Cy5 staining, according to the manufacturers protocols 
3.4.7 SDS-PAGE (Section 2.4.5) 
3.4.8 Western blotting and SA-Cy5 staining protocol 
After SDS-PAGE, proteins were initially transferred to PVDF membrane (immobilon P, 
Milipore) following the below procedure. Methanol pre-soaked PVDF membrane was stacked 
along with the polyacrylamide gel in between two blotting papers, inside a mini-transblot 
electrophoretic transfer apparatus (Bio rad) and transferred at 90 V for 2 hours, in CAPS buffer ( 
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0.01 M CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) at pH 10.5, with 10% methanol). 
After protein transfer, the membrane was air dried for 10 minutes and soaked in methanol 
(100%) for 2 min. Methanol pre-soaked membrane was then incubated with a blocking buffer 
(10 mL, 5% w/v, non-fat milk power in PBST (2.7 mM KCl, 137 mM NaCl, 2 mM KH2PO4, 10 
mM Na2HPO4, pH 7.4 with 0.1% Tween-20)), overnight at room temperature. After overnight 
blocking step, membrane was washed three times with PBST (10 mL) to get rid of excess 
blocking buffer, and incubated with streptavidin Cy-5 (1:2000 dilution in blocking buffer), for 1 
hour at room temperature. After streptavidin Cy-5 staining, membrane was washed once with 
PBST (10 m L) for 5 minutes, and visualized using Typhoon 9400 scanner at 650 excitation and 
670 emission wavelengths. 
3.4.9 Sypro Ruby staining protocol (Section 2.4.7) 
3.4.10 Pro-Q staining protocol (Section 2.4.6) 
3.4.11 In-gel trypic digestion  
In-gel tryptic digestion was performed by following a previously published protocol.
124
 
First, Sypro Ruby stained gel was removed from the destaining buffer and washed with distilled 
water (100 mL) for 3 hours. Then both PKA reaction (Figure 3.4, lane 4) and negative control 
(Figure 3.4, lane 3) lanes from Sypro Ruby gel was excised and cut into 1mm
3
 sized cubes and 
transferred to 1.5 mL low binding tubes. Gel pieces were covered in 1:1 mixture of 50 mM 
NH4HCO3: acetonitrile (200 µL) for 15 minutes and removed. Then 200 µL of pure acetonitrile 
was added to gel pieces and incubated for 5 minutes until the gel pieces were white and 
dehydrated. Then acetonitrile was removed and 50 mM NH4HCO3 (200 µL) was added and 
incubated at room temperature for 2 minutes until the gel pieces became rehydrated. Then 
acetonitrile (200 µL) was added to the same solution and incubated for 15 minutes. After 
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incubation, solution was again removed and pure acetonitrile (200 µL) was added again and 
incubated for 5 minutes until the gel pieces were white and shrunk. The acetonitrile was 
aspirated and gel samples were dried using speedvac. Then fresh 25 mM TCEP (tris (2 
carboxyethyl) phosphine) in 50 mM NH4HCO3 (100 µL) was added to dried gel pieces and 
incubated for 10 minutes at room temperature. Then solution was aspirated and fresh 55 mM 
iodoacetamide in 50 mM NH4HCO3 (100 µL) was added to the same gel pieces and incubated in 
dark for 30 minutes with mild rocking. The solution was discarded and gel pieces were again 
washed with 1:1 mixture of 50 mM NH4HCO3: acetonitrile (200 µL), twice for 15 minutes each 
and removed. Then pure acetonitrile (200 µL) was added to gel pieces and incubated for 5 
minutes until the gel pieces were white and dehydrated. The acetonitrile was aspirated and gel 
samples were dried using speedvac. Then trypsin solution (20 µg/mL) was prepared by 
dissolving one 20 mg trypsin vial (Sigma) in 1 mM HCl (100 µL), followed by subsequent 
addition of 40 mM NH4HCO3 and 9% acetonitrile in water (900 µL). The trypsin solution was 
added to cover gel pieces (200 µl) and incubated in a humid 37
0
 C incubator for 16 hours or 
overnight. The next day, 0.1 % formic acid (5 µL) was added to the trypsin solution and 
sonicated at 37
0
 C for 10 minutes. The solution was then transferred to low binding protein tubes. 
To remaining gel pieces, 0.5 % formic acid in 70% acetonitrile (100 µL) was added and 
transferred to the same low bind tubes and speed vac to dryness to obtain dried peptides.  
3.4.12 LC-MS/MS analysis 
 LC-MS/MS analysis of the tryptic peptides were performed by Dr. Joseph Cruso at 
Proteomics facility of Wayne State University. 
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 Digested peptides were initially separated using reverse phase C18 columns (Acclain 
PepMap 100 C18 prep column and PepMapRSLC C18 analytical column, Thermoscientific) in 
Easy nLC-1000 UHPLC system (Thermo). The separation was performed using linear gradient 
beginning with 95% buffer A in water  with 0.1% formic acid  and 5% buffer B in acetonitrile 
until the gradient was 90% buffer A and 10% buffer B. The gradient was changed over 30 
minute period to 68% buffer A and 32% buffer B using a low flow rate with 300 nL/ min. 
Separated peptides were then ionized using Nanospray Flex Ion Source (Proxeon Biosystems 
A/S) and analyzed on Q-Exactive mass spectrometer  on positive mode (Thermo). MS1 profiling 
was performed in a 375-1600 m/z range at a resolution of 70,000. MS2 fragmentation was 
carried out on the top fifteen ions using a 1.6 m/z window and normalized collision energy of 29 
using higher energy collision induced dissociation (HCD) with a dynamic exclusion of 15s. Peak 
lists were generated using Proteome Discoverer (Thermo, version 1.4). MS2 spectra were scored 
using Mascot (Matrix Science; version 2.4.0) and Sequest HT against human protein sequences 
within the UniProt database and scrambled decoy database. Then data were imported into 
Scaffold software. Proteins were considered a positive identification if they achieved a ≤1% FDR 
(false discovery rate).  Identified hits are shown in Tables A3.1.  
3.4.13 MS/MS data analysis to generate K-BILDS hit list 
 To identify PKA candidate substrates, spectral count ratios were calculated by dividing 
the number of peptide spectra for each protein in the PKA reaction by the number of spectra of 
thatprotein in the negative (no PKA) control. As a first screen, the spectral count ratio was 
calculated independently for each trial and only proteins that displayed a spectral count ratio of 
≥1.0 in both trials were selected. Then, as a second more rigorous screen, the spectral counts of 
each protein in both trials were summed and a new ratio was calculated by dividing the summed 
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number of spectral counts for each protein in the PKA reactions by the summed number of 
spectral counts of that protein in the negative (no PKA) controls (Table A3.1). The final 279 K-
BILDS hit proteins displayed summed spectral count ratios of ≥1.2 (Table A3.1). The 1.2-fold 
summed spectra count ratio cut-off was chosen because known PKA substrates were observed at 
enrichment levels as low as 1.2-fold. 
3.4.14 Interactome analysis  
 The previously identified physical protein-protein interaction data among K-BILDS hits 
were mapped with Cytoscape 3.3.0, using the GeneMANIA application (Figure 3.5). The 
GeneMANIA application uses published protein-protein interaction data from BioGrid and 
available literature. Protein complexes were identified using the MCODE application in 
Cytoscape (Figure 3.5). 
3.4.15 In vitro kinase reaction 
 In vitro kinase reactions were carried out by incubating BAG3 (1 µg, Prospectbio) or 
YWHAQ (1 µg, Prospectbio) proteins with ATP (2 mM, MP Biomedicals) and PKA (2500 U) in 
PKA buffer (50mM Tris-HCL, 10 mM MgCl2, pH 7.5) at 31°C for 3 hours. Negative controls 
were performed by omitting PKA from the reaction.  A positive control was carried out by 
incubating MBP (2 µg, Invitrogen) with ATP (2 mM) and PKA (2500 U) in PKA buffer at 31°C 
for 3 hours.  In the case of NASP, the material purchased from Origene was phosphorylated.  
Dephosphorylated NASP was initially generated by treating NASP (1 µg, Origene) with CIP (10 
U, Calf Intestinal Phosphatase, NEB) in CIP buffer (50 mM Potassium Acetate, 20 mM Tris-
acetate, 10 mM Magnesium Acetate and 100 μg/mL BSA) at 31°C for 3 hours, followed by 
addition of sodium orthovanadate (40 mM, Sigma) to inhibit CIP.  Then kinase reaction was then 
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carried out by incubating the dephosphorylated NASP generated in the previous reaction with 
ATP (2 mM), sodium orthovanadate (40 mM), and PKA (2500 U) in PKA buffer at 31°C for 3 
hours. Total volume for all kinase reactions were 20 µL.  After kinase reaction, protein products 
were analyzed by SDS-PAGE (12%). The gel was stained with Pro-Q (Invitrogen) to visualize 
phosphoproteins, whereas Sypro Ruby (Invitrogen) was used to confirm equal protein loading.  
Data is shown in Figures 3.7, A3.5, A3.6 and A3.7. 
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CHAPTER 4: KINASE-CATALYZED BIOTINYLATION TO MAP SIGNALING          
(K-BMAPS) 
 
Signaling cascades are important to transmit extra-cellular signals to intra-cellular 
environment. Kinases play a fundamental role in signaling cascades since kinase-catalyzed 
phosphorylation can modify proteins as a switch, functionally and structurally. Appropriate 
kinase signaling should take place for the well being of cells since aberrant kinase activity can 
cause pathological conditions. Mapping signaling cascades by detecting kinase substrates can 
improve our understanding of kinase biology and identify new therapeutic targets to treat kinase-
dependent pathologies. Prior to identifying kinase substrates through MS/MS analysis, 
enrichment is necessary to improve sensitivity and efficiency of phosphoprotein detection. Here, 
kinase-catalyzed biotinylation was used as an enrichment tool to discover phosphoproteins and 
map signaling cascades by analyzing a network of kinase activity. The method developed is 
entitled, "kinase-catalyzed biotinylation to map signaling: K-BMAPS". As a proof-of-concept K-
BMAPS was applied to EGF cell signaling to map the pathway and to validate the method. 
4.1 Introduction 
4.1.1 Previous methods to detect phosphoproteins 
Reversible phosphorylation catalyzed by kinases plays a major role in signaling by 
regulating activity, localization, degradation, and complex formation of phosphoproteins.
7
 Thus, 
understanding how, where, and what phosphorylation events take place during signaling is a 
major scientific interest. However, detection of phosphoproteins by MS or other gel methods is a 
challenge due to the low abundances and low stoichiometry of phosphorylated proteins in 
cells.
125
 In addition, detection of phosphoproteins from a cell lysates can be masked by ion 
suppression of phosphate containing groups and competing non-phosphorylated proteins in the 
background.
125-126
 Therefore, an enrichment of phosphorylated proteins prior to analysis is 
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necessary for efficient detection.
127-129
 There are many methods available to enrich 
phosphorylated proteins. A few of these phosphoprotein enrichment methods are discussed in 
this chapter. 
4.1.1.1 Immobilized metal affinity chromatography (IMAC) 
Due to the presence of negative charges on phosphate groups, phosphoproteins exhibit a 
high affinity to tri-valent metal ions such as Zn
2+
, Ga
3+
 and Fe
3
, permitting ions to be used in 
metal affinity columns to pull down and purify phosphoproteins.
127
 Although IMAC offers a 
useful enrichment protocol, there are a few drawbacks associated with the enrichment. One of 
the drawbacks is the heavy bias towards purifying acidic peptides and proteins.
130
 In addition, 
peptides that contain cysteine and histidines can co-elute with acidic peptides or proteins, thus 
reducing selectivity.
130
 Furthermore, there is a bias towards enriching multiply phosphorylated 
peptides instead of singly or doubly phosphorylated versions.
130
 Some of the problems with bias 
were solved by the esterification of the acidic amino acids before IMAC purification. However 
these methods require significant level of sample manipulation and time commitment to detect 
phosphorylated proteins.
126
   
4.1.1.2 Metal oxide affinity chromatography (MOAC) 
MOAC is an improved alternative approach compared to IMAC for phosphopeptide or 
protein purification.
131
 TiO2-MOAC is the most widely used metal oxide affinity 
chromatography technique for enrichment.
131
 In MOAC, the affinity of phosphate groups to 
metal oxide is utilized to develop the enrichment technique. Studies have reported MOAC offers 
more selectively towards purification of phosphopeptides than IMAC.
131
 However, some reports 
have claimed that the experimental conditions are not at the optimal level, which causes 
problems with the reproducibility of enrichment data.
126
 Thus, it is necessary to explore 
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alternative approaches to detect phosphoproteins to improve reproducibility, sensitivity, and 
coverage of phosphoprotein detection. 
 
4.1.1.3 Gamma-modified ATP analogs 
 
One alternative approach to detect and enrich phosphoproteins is to use modified ATP 
analogs as cosubstrates. Recently, the Pflum lab and several other research groups developed 
gamma-modified ATP analogs for phosphoprotein detection.
132-134
 A more detailed discussion of 
the available gamma-modified ATP analogs can be found in Chapter 1. Out of different of 
gamma-modified ATP analogs, ATP-biotin has been characterized for its selectivity by a variety 
of biochemical methods. Experiments performed earlier in Pflum lab have confirmed the 
phosphatase insensitivity and the generality of kinase-catalyzed biotinylation.
84-85
 Thus, kinase-
catalyzed biotinylation should allow phosphoproteins to be labeled with a phosphatase-resistant 
stable biotin tag by all active kinases for subsequent enrichment to characterize kinase cell 
signaling.  
4.1.2 Characterization of kinase cell signaling 
Characterization of kinase cell signaling is vital since phosphorylation regulates a myriad 
of cellular activities such as proliferation, adhesion and differentiation.
36
 EGFR signaling is one 
of the most widely explored kinase cell signaling pathways in humans, possibly due to the 
extensive use of EGFR pathway in cells and the association of EGFR kinase dependent 
diseases.
37-42
  
4.1.2.1 Immediate EGFR signaling  
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Figure 4.1: Canonical early EGFR signaling network.
3
 More details on each 
RAS/RAF/MEK/ERK, PI3K/AKT and STAT signaling is given in text. This figure was 
drawn by adapting from Nat Rev Cancer 2010, 10 (9), 618-29.
3
 
 
. 
 
EGFR signaling regulates a variety of biological events through binding to its ligand, 
epidermal growth factor (EGF) (Figure 4.1). Upon binding of EGF to the ectodomain of EGFR, 
the receptor undergoes dimerization to activate its tyrosine kinase domain.
135
 During 
dimerization and ligand induced phosphorylation, the N-terminus of the kinase domain of one 
EGFR interacts with the C-terminus of the kinase domain of the another EGFR.
135
 Activated, 
dimeric EGFR phosphorylates tyrosine phosphosites on its C-terminus and creates binding sites 
for adaptor proteins and transducers to initiate a signaling pathway to transmit extracellular EGF 
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signal to cell interior (Figure 4.1). Binding of EGF to EGFR will eventually activate three 
canonical cell signaling pathways (Figure 4.1) comprising RAS/RAF/MEK/ERK, PI3K/AKT 
and JAK/STAT by phosphorylating a variety of downstream substrates.
136
  
EGFR regulated RAS/RAF/MEK/ERK signaling controls cell survival and 
proliferation.
137
 The pathway initiates when EGFR bound adaptor proteins, SHC, GRB2 and 
SOS, recruit and bind to RAS and BRAF to activate MEK/ERK signaling. Activated ERK 
regulates transcriptional activation leading to cell transformation or proliferation. Upon EGF 
stimulation, ERK gets phosphorylated within 60 seconds. Thus, RAS/RAF/MEK signaling 
occurs very early in the EGFR cascade. Recent studies have further revealed that over time 
activated phospho-ERK acts as a negative feedback loop to regulate EGFR through threonine 
phosphorylation to diminish EGFR signaling and promote EGFR ubiquitination and 
degradation.
138-139
 Thus, phosphorylation of proteins in the RAS/RAF/MEK/ERK signaling is 
highly sensitive to the duration of stimuli.
139
 
Another EGF-triggered signaling route in EGFR cascade, is the PI3K/AKT pathway 
which regulate cell growth, survival, migration and invasion. PI3K docks onto EGFR through its 
regulatory p85 protein and produces phosphatidylinositol 3, 4, 5-triphosphates as secondary 
messengers. These secondary messengers assist phosphorylation and activation of AKT. 
Activated AKT phosphorylates several downstream substrates, including mTOR and regulate 
cell growth, survival and invasion.
3, 139
 
JAK/STAT activation is another route to transmit EGFR dependent signals. Here, STAT 
(Signal transducers and activators of transcription) interacts with phosphotyrosine groups on 
EGFR and becomes activated through dimerization. Dimerized STAT molecules migrate to the 
nucleus to modulate transcriptional activation. Taken together, previous studies suggest that the 
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RAS/RAF/MEK/ERK, PI3K/AKT and JAK/STAT canonical EGFR signaling events take place 
as an immediate response to EGF stimulation.
3, 42
  
4.1.2.2 Continuous signaling of EGFR  
EGFR can further transmit signals to additional signaling routes beyond 
RAS/RAF/MEK/ERK, PI3K/AKT and JAK/STAT, depending on the duration of signaling. 
Continuous EGFR signaling and EGFR overexpression are associated with epithelial–
mesenchymal transition (EMT) signaling. Studies have revealed that continuous EGFR signaling 
downregulates E-cadherin to promote EMT by reducing cell-cell adhesion and increasing cell 
migration and invasiveness.
139
  For cell migration and invasion, the assembly and disassembly of 
focal adhesion complexes are also critical. Focal adhesions are protein complexes containing 
integrin, talin and couple of other protein elements (Figure 4.2), which form connections 
between cell interior and extracellular matrix.
1
 Focal adhesion kinase (FAK) plays a role in 
regulating cell-adhesion and migration. Some reports have demonstrated upstream MAPK/ERK 
signaling enhance protease calpain-2 activity, which causes calpain-mediated proteolysis of FAK 
to cause focal-adhesion disassembly (Figure 4.2).
1
 Other reports have demonstrated that upon 
continuous EGF stimulation, FAK become dephosphorylated and inactivated to modulate focal 
adhesion dissemble and cell motility.
140
 Regardless, continuous EGF-signaling causes changes in 
the morphology and the composition of focal adhesions to facilitate cell-migration (Figure 4.2). 
However, detail molecular mechanisms behind the phosphorylation events that take place during 
EGF-triggered focal adhesion disassembly is still not complete. 
All in all, these previous studies on EGFR signaling suggest that, in addition to immediate 
canonical EGFR signaling, continuous signaling events, such as EMT and focal adhesion, are 
also regulated by EGF stimulation.  
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Figure 4.2: Continuous EGFR signaling events. EGF regulated focal adhesion disassembly. 
This figure is drawn by adapting from Nat Rev Mol Cell Biol 2002, 3 (4), 233-45.
1
 
 
 
 
In this Chapter we report the development of an enrichment method entitled, K-BMAPS (kinase-
catalyzed biotinylation to map signaling) to identify dynamically regulated phosphoproteins in 
the highly explored EGFR pathway. Our results demonstrate that kinase-catalyzed biotinylation 
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Scheme 4.1: K-BMAPS workflow. K-BMAPS was applied to the EGFR pathway. HeLa cells 
were untreated or treated with EGF (100ng/µl) for 5 min, followed by cell lysis. Treated and 
untreated lysates were incubated with ATP-biotinto generate biotinylated kinase substrates. 
Then biotinylated proteins were enriched using avidin resin, separated by SDS-PAGE, and 
subsequently analyzed by LC-QE MS/MS to identify proteins enriched in treated but not in 
untreated control reaction. 
 
 
 
 
                 
 
 
 
 
 
 
with stimulated-cell lysates can be used to detect phosphoproteins to map immediate and 
continuous signaling events mediated by heterogeneous kinase networks in cell lines. 
4.2 Results 
4.2.1 K-BMAPS workflow 
 In the K-BMAPS methodology, first confluent cells were grown in the presence or 
absence of growth factor/small molecule to activate the signaling pathway (Scheme 4.1). 
Subsequently, cells were lysed to generate stimulated and non-stimulated lysates, which were 
then used in kinase-catalyzed biotinylation with ATP-biotin (Scheme 4.1). Biotinylated proteins 
were then enriched using streptavidin resin, separated by SDS-PAGE, and analyzed by liquid 
chromatography-Q Exactive-tandem mass spectrometry (LC-QE MS/MS) (Scheme 4.1). 
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The labeling of phosphoproteins with biotin was performed in lysates due to the unavailability of 
an efficient method to transfer ATP-biotin into cells at the time these experiments were 
performed. Since ATP-biotin was not in the cells to biotinylate kinase substrates when initially 
stimulated, it is possible that some early and transient signaling phosphoproteins will not 
enriched. However, kinase-catalyzed biotinylation performed after stimulation and lysis may 
provide valuable information about the dynamic immediate and continuous late signaling events 
taking place in response to stimuli in cells. 
 As a proof-of-concept, K-BMAPS was first applied to the extensively studied EGFR 
signaling pathway to validate the method and to map the pathway. Recent studies on EGFR 
signaling have increased our understanding and the coverage of EGFR network. However, many 
of these studies on EGFR signaling were performed using traditional enrichment based mass 
spectrometry focusing on early signaling immediately after EGF stimulation, not necessarily 
focusing on the complete early and late downstream effects of kinase activity. Even though 
previous studies on early signaling are important, new methods are needed to augment the 
studies focusing on continuous phosphorylation. Thus,. K-BMAPS represents an ideal alternative 
technique by identifying dynamic kinase substrates in both early and late signaling events.  
4.2.2 Kinase-catalyzed biotinylation with EGFR stimulated cell lysates 
 To initially develop K-BMAPS, kinase-catalyzed biotinylation of EGFR stimulated cell 
lysates was performed with analysis of protein products by gel methods. An increased signal for 
biotinylation was observed with EGF-treated lysates incubated with ATP-biotin (Figure 4.4, lane 
3) compared to the untreated control reaction (Figure 4.4, lane 2), confirming specific 
biotinylation of EGFR pathway substrates. 
82 
 
 
Figure 4.4: Kinase-catalyzed biotinylation of EGFR stimulated lysates. EGFR stimulated 
(lane 3) and non-stimulated (lane 2) lysates were incubated with ATP-biotin (lanes 2 and 
3), After kinase reaction, protein products were separated by SDS-PAGE and stained with 
SA-Cy5 to visualize biotinylation (top) and Sypro Ruby for total protein analysis (bottom. 
Repetitive trials are shown in Figure C4.1). 
 
 
 
 Immunoblotting with pTyr 1068 EGFR antibody confirmed the presence of 
phosphorylated active EGFR in the lysates (Figure 4.5, lane 2), suggesting active EGFR 
signaling during kinase-catalyzed biotinylation. Immunoblotting with EGFR antibody confirmed 
the presence of equal amount of EGFR in lysates (Figure 4.5, compare lanes 1 and 2). With these 
successful initial results, K-BMAPS was applied on a larger scale for substrate identification and 
EGFR pathway mapping 
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4.2.3 K-BMAPS (kinase-catalyzed biotinylation to map signaling) with EGF-treated cell 
lysate                                                                                                                                                     
 For substrate identification, K-BMAPS was performed on a large scale using EGF-treated 
lysates. After kinase reaction, streptavidin-enriched biotinylated substrates were analyzed by gel 
methods to confirm successful enrichment. Increased amounts of proteins were eluted with EGF-
treated lysates (Figure 4.6, lane 6, Sypro Ruby and SA-Cy5), compared to the untreated negative 
control (Figure 4.6, lane 5, Sypro Ruby and SA-Cy5), suggesting selective biotinylation and  
enrichment of EGFR signaling pathway substrates.  
 To specify the proteins bands that are enriched on EGF-stimulated lane, a zoomed image 
of a similar experiment is shown in Figure 4.7. Blue color brackets represent proteins that do not 
exhibit a huge difference in signaling in both lanes, while red color brackets show EGF-
stimulated proteins enriched compared to the negative control. Increased protein bands were 
observed at multiple molecular weights spanning the entire lane (Figure 4.7, lane 2). Thus, to 
Figure 4.5: Presence of activated EGFR in lysates during kinase-catalyzed biotinylation. 
EGF-treated (lane 2) and untreated (lane 1) lysates were immuno blotted with p Tyr1068 
EGFR antibody to confirm active EGFR pathway (Top). Immunoblotting with EGFR 
antibody was done to confirm equal loading (Bottom). Replicate trials are shown in Figure 
C4.2. 
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Figure 4.6: Gel image from full K-BMAPS experiment. EGF-treated and untreated 
lysates were incubated with ATP-biotin. After kinase reaction, protein products 
enriched with avidin resin. The in-put (lane 1 and 2), flow through (lane 3 and 4) and 
the elution (lane 5 and 6) from each reaction was separated by SDS-PAGE and 
visualized with Sypro Ruby (top) for total protein or SA-Cy5 for biotinylation. 
Replicates are shown in Figure C4.3. 
identify substrates, in-gel tryptic digestion and MS/MS analysis was performed of both the 
control (Figure 4.7, lane 1) and EGF-treated lanes (Figure 4.7, lane 2). 
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Figure 4.7: A zoomed Sypro Ruby image of elutes after avidin enrichment of proteins. 
Similar to last two lanes of Figure 4.6. EGF-treated and untreated lysates were incubated 
with ATP-biotin. After kinase reaction, protein products were enriched with avidin resin and 
elution for EGF-treated (lane 2) and untreated (lane 1) reactions were separated by SDS-
PAGE and stained with Sypro Ruby for total protein analysis.  
 
     1             2 
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4.2.4 K-BMAPS discovered previously known early EGFR pathway substrates  
To identify EGFR pathway substrates, spectral count ratios were calculated by dividing 
the number of peptide spectra for each protein in the EGF-treated lane by the number of spectra 
of that protein in the untreated control. The spectral count ratio was calculated independently for 
each trial and only proteins that displayed a spectral count ratio of ≥2.0 in both trials were 
selected. The ≥2.0-fold spectra count ratio cut-off was chosen because known EGFR substrates 
were observed at enrichment levels as ≥2-fold. From this analysis, 266 proteins reproducibly 
enriched in EGFR stimulated reactions compared to the unstimulated control reactions with a ≥2 
spectral count ratio cutoff were chosen as candidate EGFR pathway substrates.  
A literature search was performed comparing these 266 hits proteins to previously 
detected EGFR pathway phosphoproteins. Several previous studies identified EGFR-depended 
early phosphoproteins using traditional enrichment based mass spectrometry techniques. When 
K-BMAPS hits were compared to previously discover early EGF signaling molecules, only 25 
known EGFR pathway substrates and 56 direct interactors of EGFR were identified.
141-143
 (Some 
of the previously documented EGFR pathway components, both known substrates and known 
direct interactors, are categorized in Table 4.1). However, when experimental designs of 
previous EGFR phosphoproteomics studies were compared to that of K-BMAPS, a clear 
difference in the protocol was observed. Most of the previous studies were performed by mass 
spectrometry based phosphoproteomics using EGF-stimulated lysates treated with a phosphatase 
inhibitor and with enrichment methods such as phosphotyrosine antibody dependent 
immunoprecipitation, MOAC, or IMAC. Each method of enrichment has its own biases towards 
identification of specific groups of proteins as discussed in the introduction. But the most crucial 
difference comparing K-BMAPS to previously published methods is the addition of ATP-biotin 
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after stimulation, which will identify the late effects of EGF-triggered kinase network. Late 
kinase activity can lead to identification of downstream EGFR signaling molecules that have not 
been identified before. Thus only a ~10% coverage of early EGFR pathway phosphoproteins 
would be expected.
142-143
 
 
 
 
 
a
. K-BMAPS hits proteins were compared to literature to find substrates of EGFR 
pathway. Thirty substrates have been identified, including the 24 listed on the Table 4.1. These 
substrates have been identified through MS/MS analysis after affinity/IMAC or MOAC 
purification using EGF stimulated mammalian cells.
144-146
 
b
 By comparing K-BMAPS hits with GENEMania database, 56 direct interactors of 
EGFR were identified, with 40 direct interactors are listed on the Table 4.1. 
 
4.2.5 Validation of K-BMAPS by DAVID enrichment analysis  
To validate K-BMAPS as a screen to detect EGFR pathway phosphoproteins, an 
enrichment analysis was performed using the bioinformatics tool DAVID (Database for 
Annotation, Visualization and Integrated Discovery).
147-148
 DAVID is a functional annotation 
tool that can be used to understand biological meaning behind a set of proteins. However, when 
Substr
ates
a 
Substr
ates
a 
Direct 
interactors
b 
Direct 
interactors
b 
Direct 
interactors
b
 
Direct 
interactors
b
 
EGFR TUBA1C AP2A1 HSP90AB1 PLAA TUBA4A 
EPS15 ATP1C ATP2A2 HSP90B1 PPP2R1A TUBB3 
MTOR TUBB2A ATP6V1H IARS PRKDC TUBB4B 
SHIP2 ITGB4 CSE1L IPO4 PSMD4 TUBB6 
NIBL1 ALDOA DARS IPO5 PTPRJ IPO7 
MAP4 DAB2 DYNC1H1 IQGAP1 RANGAP1 IPO8 
PKM AHNAK EPRS ITGA5 RBM10 IPO9 
CTF8A EIF4G1 GBF1 KPNA1 SMC2 USP9X 
HUWE1 FLNB GCN1L1 MET TELO2 XPO1 
AP2M1 MYH9 HCFC1 NCAPG2 TNPO1 XPO5 
ENO1 TLN1 HSP90AA1 PHGDH TTI2 XPO7 
Table 4.1: Previously known EGFR pathway proteins among KBMAPS hits 
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classifying the function of a protein list, DAVID considers previously known related proteins, 
not necessarily phosphoproteins. Since K-BMAPS list contains only phosphoproteins, not all 
functionally related proteins, it is possible to detect a fewer number of hits in the DAVID 
assigned pathway. Despite these concerns, DAVID analysis was performed with 
phosphoproteins identified in each trial separately, in addition to the overlapping K-BMAPS hit 
list. Functional annotation of the overlapping K-BMAPS hit list with KEGG pathway analysis 
using DAVID resulted in EGF-regulated focal adhesion as a top functional pathway (P-value 
9.1E-5). KEGG analysis with the two independent individual trials separately, did not give any 
EGF-regulated pathways as hits. Thus, enrichment analysis also confirmed that the selected 266 
protein overlapping hit list as the highest confidence data set for K-BMAPS analysis. Finding 
focal adhesion (disassembly), which is a continuous late signaling event of EGFR signaling 
(section 4.1.4.2), as the highly enriched pathway further corroborates our hypothesis that K-
BMAPS detects mostly continuous EGFR signaling. 
4.2.6 Functional analysis of K-BMAPS hits  
Another functional analysis of all 266 K-BMAPS hit proteins were performed using 
PANTHER gene ontology. Interestingly, multiple EGFR-dependent functional categories of 
proteins were observed in the hit list, including protein kinases, kinase modulators, phosphatases, 
ubiquitin modifiers, GEF/GAPS and small GTPases. Several protein kinases were identified 
from K-BMAPS (Table 4.2). Of these proteins, MTOR, ILK, and PKM have been linked with 
EGFR signaling events, while CDK12 and CDK13 have not yet been linked to EGFR signaling. 
CDK12 and CDK 13 has a known function during transcription by phosphorylating RNA 
polymerase during transcriptional activation.
149
 And CDK13 has a direct interaction with 
CDK12. Thus, it can be hypothesized that CDK12 and CDK13 might be involved in EGFR-
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mediated downstream transcriptional   regulation. Furthermore, multiple transcription regulators 
were also observed in K-BMAPS hit list, including transcription factors, transcription cofactors, 
and transcription modulators. Most of the transcription regulators have a previous relationship 
with EGFR signaling. 
 Small GTPases and GTPase regulators, such as nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs), play a key role in EGF-dependent signaling.
150-152
 Five small 
GTPases, including IPO7, IPO8 and IPO9, which also function as transporters, were enriched 
upon EGF stimulation. Even though, these GTPase transporters have not yet been associated 
with EGFR-dependent phosphorylation events, they are known to directly interact with EGFR 
receptor. In addition, the importance of GTPase activity in regulating EGF-regulated MEK/ERK 
signaling also suggests a previously unrecognized EGFR-dependent phosphorylation of these 
five small GTPases.  
 In addition, multiple GTPase activating proteins and guanine nucleotide exchange 
factors,
153
 which have known functions in regulating early RAS/ERK1/2 pathway kinases by 
turning them on and off as a switch, were also enriched in EGF-treated reaction. Multiple 
ubiquitin modifiers, including HUWEI and UBRs, were also detected in EGF-treated K-BMAPS 
hit list, confirming the previously known role of ubiquitin modifiers in late EGFR signaling and 
EGFR turnover. Detection of phosphoproteins related to above mention functional categories 
confirmed the ability of K-BMAPS to detect and map previously known phosphorylation 
dependent signaling events in the EGFR signaling pathway.
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Phospha
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Kinases Kinase 
modulat
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n 
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s 
GEFS 
/GAPS 
 
Small 
GTPases 
GTF3C2 EP300 PPP2R5
A 
MTOR MADD KCMF1 GBF1 IPO7 
CEBPZ NCOR1 MYPN ILK IKBKAP TRIM33 ARHGE
F2 
IPO8 
PRRC2A SMARC
A4 
PTPRJ PKM RPRD2 UBR4 DOCK5 IPO9 
CNOT1 SLTM INPPL1 CDK12 ECM29 UBR5 ARFGEF
2 
DNMIL 
TCERG1 MED1  CDK13 CCDC88
B 
HUWE1 IQGAP1 GNL2 
TFEB   ADPGK AKAP13 USP9X ARHGA
P1 
 
GTF3C1     UBQLN
1 
GAPVD
1 
 
PRRC2B     UBA1   
PRRC2C     CLTC   
Table 4.2: EGFR dependent multiple functional categories of K-BMAPS hits, according 
to Panther classifications. 
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Figure 4.8: a) Immunoblotting with phos-ERK1/2 (Thr 202/ Tyr 204) antibody to confirm 
the presence of active ERK1/2 in immediate and late lystaes.  B) Immunoblotting with 
phos-AKT (Ser 473) antibody to confirm the presence of active AKT1 in immediate and 
late lysates. Replicate trials are shown in Figure C4.4 and 4.5 
4.2.7 Validation of downstream AKT and ERK signaling by immunoblotting  
When the 266 K-BMAPS hits were analyzed, early signaling molecules, such as AKT1, 
ERK1/2 and JAK1, were not detected. However, roughly 20 AKT and ERK1/2 substrates were 
found in the hit protein list. To rationalize these findings, it was speculated that the 
phosphorylated active forms of AKT1 and ERK1/2 are present in EGF-treated lysates, which use 
ATP-biotin as a cosubstrate to label substrates. It was further hypothesized that the active 
phosphorylation of AKT1 and ERK1/2 occurred during immediate EGFR signaling and thus 
would not be available for biotinylation again during later kinase signaling.
141
 The prediction 
suggested that AKT1 and ERK1/2 would not be detected by K-BMAPS.  
 
 
 
 
 
 
 To test this hypothesis, immunobloting of lysates were performed with EGF-treated and 
untreated lysates to detect the phosphorylated form of AKT1 and ERK1/2 kinases. Monitoring of 
the phosphorylation states of ERK1/2 and AKT1 was performed with EGF-treated and untreated 
lysates under two conditions. First, we observed fresh lysates immediately after stimulation. 
Second, we detected phosphorylation with lysates after an incubation period equivalent to ATP-
biotin labeling reaction time. Immunoblotting with phosphorylated ERK1/2 antibody (Threonine 
a b 
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202/ Tyrosine 204) will detect the levels of ERK1 and ERK2 kinases in cells when it is dually 
phosphorylated at Threonine 202/ Tyrosine 204 site on ERK1 and Threonine 185 and Tyrosine 
187 site of ERK2.
154
 Immunoblotting with phosphorylated AKT1 (Serine 473) antibody will 
detect cellular levels AKT1 when phosphorylated at serine 473 site.
155
 These antibodies were 
specifically selected for screening because these sites are phosphorylated during EGF treatment 
and these antibodies have been customarily used to monitor the active status of EGFR 
cascade.
154-156
 Immunoblotting with p-ERK1/2 (Threonine 202/ Tyrosine 204) and p-AKT1 
(Serine 473) antibodies with stimulated lysates immediately after lysis showed positive signal for 
p-ERK1/2 (Figure 4.8 a, lane 2) and p-AKT1 kinases (Figure 4.6 b, lane 2) in EGF-treated 
lysates. However, the signal for phosphorylated kinases disappeared with the incubation of 
lysates for the ATP-biotin reaction time (Figure 4.8 a and b, lane 4). Active phosphatases in 
lysates are responsible for the dephosphorylation of ERK1/2 and AKT1 during the incubation. 
Disappearance of phosphate groups from ERK1/2 and AKT1 suggests that                                                           
upstream kinases are no longer active. Without active kinases to phosphorylate ERK1/2 and 
AKT1 with ATP-biotin, the proteins will not be biotinylated and will not be enriched by K-
BMAPS. 
 Furthermore, it can be speculated that during late kinase-catalyzed biotinylation, ATP-
biotin transfers a phosphatase insensitive biotin tag to protein kinases. That substrate kinases will 
be biotinylated and constitutively activated due to the inability of phosphatases to cleave the 
phosphobiotinyl group. EGFR is one of the proteins in the K-BMAPS hit list, which undergoes 
both phosphorylation and biotinylation, symptomatic of continuous late signaling mediated 
through EGFR-dependent mechanism.
141-142
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Figure 4.9: Immunoblotting of enriched EGF-treated and untreated lysates for selected kinases. 
The EGF-treated (lanes 2, 4, 6) and untreated (lanes 1, 3, 5) lysates were subjected to streptavidin 
pulled down, and the input (lanes 1 and 2), follow-through (lanes 3 and 4) and elutes (lane 5 and 
6) of biotinylated proteins were probed for EGFR, AKT1 and ERK1 using respective antibodies. 
Replicate trials are shown in Figure C4.6, C4.7, and C4.8 
4.2.8 Validation of mass spectrometric data by immunoblotting 
 To validate the mass spectrometry-based enrichment data, immune blotting experiments 
were performed with three selected kinases after enrichment. For validation, EGFR, ERK1/2 and 
AKT1 proteins were selected. EGFR was selected for validation as a positive control, as it was 
enriched by K-BMAPS. Successful immunoblotting with EGFR will confirm that EGFR is in 
fact enriched by K-BMAPS validating the selected MS/MS hit list. Immunoblotting with 
ERK1/2 and AKT1 were performed as negative controls to confirm the absence of immediate 
phosphoproteins in K-BMAPS MS/MS hit list.  
 The EGF-treated and untreated lysates were subjected to kinase reaction and streptavidin 
pulled down. The input, follow-through, and elute fractions of streptavidin enrichment were 
94 
 
 
probed for EGFR, AKT1 and ERK1/2 using respective antibodies. Mass spectrometry results 
with K-BMAPS displayed an enrichment of EGFR, with a higher abundance/spectral count for 
EGFR in EGF-treated lane compared to untreated lane, for both trials. Immunoblotting with anti-
EGFR showed signal for protein in the input, flow through and elute. The signal for EGFR was 
similar for both untreated and EGF-treated input samples confirming equal protein loading 
(Figure 4.9, lane 1 and 2). However, an increase signal for EGFR was observed in EGF-treated 
elute compared to untreated elute, confirming enrichment of biotinylated EGFR in EGF-treated 
lysates (Figure 4.9, lane 5 and 6). The immunoblotting data validated the mass spectrometry-
derived enrichment results for EGFR.  
 In addition to EGFR, AKT1 and ERK1/2 were also tested by immunoblotting to confirm 
the absence of AKT1 and ERK1/2 in mass spectrometry results. The signal for AKT1 and ERK 
was similar for both untreated and EGF-treated input, flow through and elute samples after 
streptavidin purification (Figure 4.7, ERK1/2 gel and AKT1 blot), confirming the absence of 
enriched biotinylated AKT or ERK in EGF-treated lysates. Taken together, immunoblotting of 
EGFR, AKT1 and ERK1 antibodies validated the mass spectrometric K-BMAPS enrichment 
data. 
4.2.9 Comprehensive network mapping of K-BMAPS hits 
Network mapping of the K-BMAPS hits was performed to understand the relationship of 
EGFR to other phosphoproteins based on previously known interactions in GeneMANIA 
application using Cytoscape 3.3.0. A network was generated originating from EGFR, and 
incorporating previously known phosphorylation and physical interactions of EGFR to other 
related pathway proteins. Gratifyingly, out of the 266 protein hit list, the EGFR protein itself 
displayed the highest number of direct interactions compared to the other hits, confirming the 
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enrichment of proteins surrounding EGFR. Network construction was then expanded to 
downstream protein kinases representing them as hub proteins (Figure 4.10 red). The rest of the 
proteins were organized as substrates of those protein kinases based on previously known 
phosphorylation, protein-protein interaction, or signaling pathway relationships. Many substrate 
proteins interacting with ERK1/2, PI3K/AKT/MTOR and focal adhesion-integrin-ILK-
dependent pathways were identified and mapped surrounding their respective kinase. In addition, 
phosphoproteins belonging to the same functional category, such as ubiquitination and 
transcription, were mapped together to improve the readability of the map (Figure 4.10). Proteins 
that were unable to be incorporated based on downstream protein kinase, but displayed an 
indirect interaction with EGFR through other proteins, were represented as indirect interators of 
EGFR (Figure 4.10, outer green circle).  
 The above analysis allowed network mapping of ~80% of the K-BMAPS hits as either as 
a direct or indirect interactors of EGFR, confirming the ability of K-BMAPS to detect 
phosphoproteins and map cellular pathways. The organization of functional categories of K-
BMAPS hits in the network analysis illustrates that K-BMPS mostly detected continuous 
signaling events regulated by EGFR. The transcriptional activation, ubiquitination and integrin 
signaling, where focal adhesion assembly and disassembly is controlled, are previously 
documented continuous signaling events regulated by EGFR, confirming our hypothesis that K-
BMAPS detects mostly the continuous late signaling. 
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Figure 4.10:  Comprehensive network mapping of K-BMAPS hits. All 266 hits were assessed 
using GeneMANIA and literature for physical and functional interactions with EGFR and 
other downstream kinases in EGFR pathway. Hit proteins with a direct known 
phosphorylation or protein-protein interaction with EGFR or other hub kinases (red) were 
displayed inside the circle (blue), proteins associated with ubiquitination (pink), proteins 
associated with transcription (orange). Hit proteins that do not directly interact, however 
display an indirect association with EGFR are shown in the outer circle of the map (green). 
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4.3 Conclusions and future directions 
 In summary, we developed a kinase substrate enrichment tool to identify phosphoproteins 
and map cell signaling pathways entitled K-BMAPS (kinase-catalyzed biotinylation to map 
signaling). Analysis of biotinylated EGF-treated lysates by gel methods after streptavidin 
purification confrimed increased protein signal, suggesting selective enrichment of EGFR 
pathway related proteins. When streptavidin purification was followed by MS/MS analysis, 266 
hit proteins were reproducibly identified with high confidence (≥2 spectral count ratio) in two 
independent trials. Since, biotinylation was performed after lysis of EGF-treated cells, it was 
speculated that some or most of the immediate signaling phosphoproteins might not be 
biotinylated and be absent in the K-BMAPS hit list. As expected, some of the very early 
signaling kinases such as ERK1/2 and AKT1, were not enriched in K-BMAPS hit list. However, 
many substrates of these kinases were enriched (Figure 4.10). To rationalize the presence of 
biotinylated substrates of ERK1/2 and AKT1, and the absence of biotinylated ERK1/2 and 
AKT1 kinases in K-BMAPS hits, an immunoblotting experiment was performed with the 
immediate and late lysates to confirm the presence of active phosphorylated forms of ERK1/2 
and AKT1 kinases. Experiments confirmed the presence of active phosphorylated ERK1/2 and 
AKT1 kinases only in immediate lysates (Figure 4.8). Further, the disappearance of phosphate 
groups from ERK1/2 and AKT1 kinases in late lysates (Figure 4.8) after incubation for the 
kinase reaction time suggested that the upstream kinases that phosphorylate ERK1/2 and AKT1 
are no longer active to transmit the signal to phosphorylate ERK1/2 and AKT1 again. Without 
active kinases to phosphorylate ERK1/2 and AKT1, the proteins will not be biotinylated and will 
not be enriched by K-BMAPS. 
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Next, the MS/MS enrichment observed for EGFR and lack of enrichment seen with ERK1/2 and 
AKT1 were further validated by immunoblotting with anti-EGFR, anti-AKT1 and anti-ERK1/2 
using elutes of EGF-treated and untreated samples after streptavidin purification. 
Immunoblotting experiments were able to validate that EGFR was biotinylated while ERK1/2 
and AKT1 were not biotinylated. Literature confirms the phosphorylation of EGFR during 
continuous signaling to promote ubiquitination and receptor degradation. Late phosphorylation 
of EGFR is reported to occur even after ~45 minutes of initial stimulation, in contrast no reports 
document a phosphorylation of ERK1/2 and AKT1 after initial EGF stimulation.  
 The results of bioinformatics enrichment analysis with DAVID was consistnat with 
continuous late EGF-dependent signaling events observed by K-BMAPS. Additionally, to 
observe a bigger picture of the complete kinase network events, an interactome map was 
generated by cytoscape, using previously known pathway information, phosphorylation, and 
protein-protein interaction data (Figure 4.10). Network mapping was able to account for 80% of 
K-BMAPS hits as part of EGFR interactome and confirmed that K-BMAPS detects moslty 
continous EGFR signaling. 
 Establishing K-BMAPS as a tool to map signaling pathway by identifying kinase 
substrates will help broaden the knowledge of kinase signaling pathways and biology. 
Incorporation of kinase inhibitors into K-BMAPS experiments in the future will allow kinase 
inhibitor profiling by detecting direct targets and off target effects of inhibitors on signaling. 
Thus, K-BMAPS can be used as a pharmacological tool for inhibitor profiling. As a future 
direction, performing K-BMAPS in live cells using cell permeabilization of ATP-biotin will 
allow detection of immediate as well as late continuous signaling events, helping to cover a 
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broader kinase network and unraveling previously unknown valuable kinase-substrate 
relationships.  
 Taken together, application of K-BMAPS to EGFR signaling pathway validated K-
BMAPS as a a general tool to map continuous kinase signaling routes. Future application of K-
BMAPS in cells to signaling cascades under normal and diseases states will help unravel hidden 
signaling routes that plays an important role is pathologies. In conclusion, we believe K-BMAPS 
will shed a new light on to the daunting task of mapping complex cell signaling cascades. 
4.4 Experimental section 
4.4.1 Materials 
 EGF recombinant human protein and Ham’s F-12 nutrient mix was obtained from Life 
Technologies. EGFR receptor antibody (#2232), Phospho-EGF receptor (Tyr1068) antibody 
(#3777), p44/42 MAPK (Erk1/2) antibody (#4695P), Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) antibody (#4376S), AKT1 antibody (#2938S) and Phospho-AKT1 (Ser473) 
antibody (#4695P) was purchaced from Cell Signaling. Sodium hydroxide (NaOH), sodium 
chloride (NaCl) and, sodium dodecyl sulfate (SDS) were purchased from Fisher. Triton X-100 
was purchased from Fluka. Trifluoroacetic acid (TFA) and centriprep columns were obtained 
from EMD Milipore. Iodoacetamide, TCEP (tris(2-carboxyethyl)phosphine), proteomics grade 
trypsin, and ammonium biocarbonate was purchased from Sigma. 1X protease inhibitor cocktail 
was purchased from GenDepot, and streptavidin resin was bought from Genscript. Immobilin P 
PVDF membrane were purchased from Millipore. Sypro Ruby and Pro-Q diamond stain was 
obtained from Invitrogen. 
4.4.2 Instrumentation 
As described in Chapter 3, section 3.5.2. 
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4.4.4 EGF treatment of HeLa cells and EGF-treated and untreated lysate preparation 
 HeLa cells (5×10
6
) were grown in F-12 media containing 10% FBS, 9 units of penicilin, 
and 9 units of streptomycin at 37 
0
C in 5% CO2 humidified incubator until 80% confluent. Cells 
were then starved by incubating with serum-free F-12 media for 16 hours at 37 
0
C in 5% CO2 
humidified incubator. After serum starvation, cells were treated with EGF (100 ng/mL, in serum 
free F-12 media) for 5 minutes and washed with DPBS (20 mL, 8 mM Na2HPO4, 1.5 mM 
KH2PO4, pH 7.4, 137.9 mM NaCl, 2.6 mM KCl) two times to remove EGF.  As a control, 
starved cells were washed washed with DPBS (20 mL; 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 
7.4, 137.9 mM NaCl, 2.6 mM KCl) two times to remove media. Finaly, cells were collected by 
scraping in ice cold DPBS (5 mL) and centrifuged at 1000 rpm for 5 min at 4 
o
C. Cell pellets 
were quickly frozen at -80 
0
C until further use or were immediately lysed by incubating with 
lysis buffer (150 µL; 50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 10% glycerol, and 
1X protease inhibitor cocktail (GenDepot)) for 30 minutes on ice. Protein lysates were collected 
by centrifugation at 13,200 rpm for 15 minutes at 4 
0
C to remove cell debris. Lysates were 
aliquoted and stored at -80 
0
C until further use. The protein concentrations of the lysates were 
determined by Bradford assay (BioRad). 
4.4.5 Kinase-catalyzed biontinylation of EGF-stimulated lysates 
 EGF-treated HeLa lysates (~100 µg total protein) were incubated with ATP-biotin (2 
mM) at 31°C for 1 hour. Control reactions were performed by incubating untreated lysates with 
ATP-biotin (2 mM). The total volume of each reaction was 30 µL. After kinase reaction, samples 
were boiled at 95°C for 1 min in Laemmli sample buffer (10 µL; 62.5 mM Tris-HCl, pH 6.8, 
25% glycerol, 2% SDS, 0.01% bromophenol blue, and 2.5% β-mercaptoethanol) and separated 
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by 12% SDS-PAGE. Total proteins were assessed by Sypro Ruby staining (Invitrogen), whereas 
biotinylation was assessed using SA-Cy5 staining (Invitrogen) of western blot.  
4.4.6 K-BMAPS with EGF-stimulated lysates 
 EGF-treated lysates (~500 µg total protein) were incubated with ATP-biotin (2 mM) at 
31°C for 1 hour. A negative control was performed by incubating untreated lysates (~500 µg 
total protein) with ATP-biotin (2 mM). The total volume of each reaction was 60 µL. After 
kinase reaction, samples were diluted with phosphate binding buffer (300 µL; 0.1 M phosphate 
pH 7.2, 0.15 M NaCl) and excess ATP-biotin was removed by filtering through 3 KDa centriprep 
spin columns (EMD Milipore) at 14,200 rcf for 45 min twice. After filtration, samples were 
diluted with phosphate binding buffer to a total volume of 300 µL and then incubated with 
streptavidin resin beads (200 µL, Genscript) for 1 hour at room temperature with rotation. The 
streptavidin resin was washed twice with phosphate binding buffer (400 µL) before use to 
remove storage solution. After 1 hour incubation, the bound resin was washed ten times with 
phosphate binding buffer (400 µL) and then five times with water (400 µL) to remove 
nonspecifically bound proteins. The avidin bound proteins were eluted by boiling the resin in 2% 
SDS in water (200 µL) for 7 minutes. The elute was concentrated using a speedvac (Thermo 
scientific). The concentrated elute was boiled in Laemmli sample buffer (final volume 40 µL) at 
95°C for 1 min and separated by 12% SDS-PAGE. Total proteins were assessed by Sypro Ruby, 
whereas biotinylation was assessed using SA-Cy5 staining, according to the manufacturers 
protocols. 
4.4.7 In-gel tryptic digestion  
(Chapter 3, section 3.5.11) 
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4.4.8 LC-MS/MS analysis  
(Chapter 3, section 3.5.12) 
4.4.9 MS/MS data analysis to generate K-BMAPS hit list 
 Spectral count ratios were calculated by dividing the number of peptide spectra for each 
protein in the EGF-treated sample by the number of spectra of that protein in the untreated 
control. The spectral count ratio was calculated independently for each trial and only proteins 
that displayed a spectral count ratio of ≥2.0 in both trials were selected as K-BMAPS hit list 
(Selected 266 proteins are listed in Table C 4.1). 
4.4.10 Comprehensive network analysis of K-BMAPS hits 
 The previously identified physical protein-protein interaction data among K-BMAPS hits 
were mapped with Cytoscape 3.3.0, using the GeneMANIA application (Figure 4.10). Then 
protein kinases were considered as hub proteins and the rest of the proteins were organized 
surrounding the most related kinases based on previously known phosphorylation, protein-
protein interaction, or pathway relationships. 
4.4.11 Immunoblotting of lysates for phosphorylated ERK1 and phosphorylated AKT1 
 EGF-treated and untreated lysates were prepared as described in section 4.4.4. EGF-
treated and untreated lysates (~100 µg total protein from each) were incubated at 31
0
 C for 1 
hour in a total volume of 30 µL each. Incubated lysates represented late reaction. Then, EGF-
treated and untreated incubated lysates (late reaction) and EGF-treated and untreated fresh 
lysates representing early immediate reaction (~100 µg total protein from each, 30 µL total 
volume each) were boiled at 95°C for 1 min in Laemmli sample buffer (10 µL) and separated by 
12% SDS-PAGE and western analysis was performed. Proteins were transferred to PVDF 
membrane following western blotting protocol (Chapter 3.5.8). To observed phosphorylated 
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ERK1, membrane was incubated with pERK1/2 primary antibody (1:500, cell signaling) and to 
observe phosphorylated AKT1, membrane was incubated with phospho-AKT1 primary antibody 
(1:1000, cell signaling), in BSA buffer (10 mL; 5% w/v, BSA in PBST (2.7 mM KCl, 137 mM 
NaCl, 2 mM KH2PO4, 10 mM Na2HPO4, pH 7.4 with 0.1% Tween-20)) overnight at 4
0
 C with 
rocking. The membrane was washed with PBST (10 mL; 2.7 mM KCl, 137 mM NaCl, 2 mM 
KH2PO4, and 10 mM Na2HPO4, pH 7.4 with 0.1% Tween-20) twice for 5 minutes each to 
remove unbound antibody. Secondary HRP antibody was diluted in BSA buffer (10 mL, 1:1000) 
and incubated with the membrane at room temperature for 2 hours. After incubation, membrane 
was washed with PBST (10 mL) two times, 10 minutes each. Finally HRP substrate (1 mL, 
Thermofisher) was added to the membrane to develop HRP signal on proteins. The membrane 
was visualized by Typhoon 9400 scanner in chemiluminescens mode. To confirm equal amounts 
of total ERK1/2 and total AKT1, a similar protocol was followed, but with the ERK1/2 primary 
antibody (1:1000, cell signaling) and with AKT1 primary antibody (1:1000, cell signaling) in 
BSA buffer, respectively. 
4.4.12 Immunoblotting of elutes (after enrichment) for EGFR, AKT1 and ERK1/2 
 The experiment was carried out as described in Chapter 4, section 4.4.6, except at the end 
the concentrated elute, 10% of the input and 10% of the follow-through was boiled in Laemmli 
sample buffer (final volume 40 µL) at 95°C for 1 min and separated by 10% SDS-PAGE. Then 
western blotting (Chapter 3, Section 3.5.8) was performed to transfer proteins to PVDF 
membrane. To observed pEGFR, membrane was incubated with pEGFR primary antibody 
(1:500, cell signaling), to observe pAKT1 membrane was incubated with pAKT primary 
antibody (1:500, cell signaling), and to observed pERK1/2 the membrane was incubated with 
pEGFR primary antibody (1:500, cell signaling), in BSA buffer (10 mL) overnight at 4
0
 C with 
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rocking. The membranes were washed with PBST (10 mL) twice for 5 minutes each to remove 
unbound antibody. Secondary HRP antibody was diluted in BSA buffer (10 mL, 1:1000) and 
incubated with membranes at room temperature for 2 hours. After incubation, membranes were 
washed with PBST (10 mL) for two times, 10 minutes each. Finally HRP substrate (1 mL, 
Thermofisher) was added on to membranes to develop HRP signal on proteins to visualize by 
Typhoon 9400 scanner in chemiluminescens mode. To observed the total EGFR, AKT1 and 
ERK1/2 level, similar protocol was followed, but with EGFR primary antibody (1: 1000, cell 
signaling), AKT1 primary antibody (1:1000, cell signaling) and ERK1/2 primary antibody 
(1:1000, cell signaling) in BSA buffer. 
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APPENDIX A: Supporting data for chapter 2 
 
Table A2.1: Quantitative conversion percentages and kinetic constants for kinases with 
ATP and ATP-biotin 
 
 
 
 
 
 
 
 
 
a
 Conversion percentages were determined from the quantitative ATP-biotin reactions. The 
ADP-GloTM assay was used for the kinetics measurements with all kinases, except CK2 and 
PKA where the NADH-dependent enzyme coupled assay was used.. 
b
 KM 
app 
and kcat 
app 
were calculated due to limiting substrate concentrations. 
c 
Ratios were calculated by dividing the value with ATP-biotin by the ATP value. 
d
 Ratios were calculated by dividing the value with ATP by the ATP-biotin value. 
e 
Kinetics measurements are not available (NA) with recombinant Abl kinase because the 
manufacturer discontinued its production. 
f
 With AKT and ASK kinases, under conditions suitable for ATP-biotin kinetics determinations, 
the rate versus [ATP] plots at higher concentrations did not intersect the y 
axis near zero, indicating that the concentrations were too high to observe the true initial rates. 
Therefore, the kcat values represent a lower limit. 
g
 In the case of Aurora kinases with ATP, the curvatures of the rate versus [ATP] plots were not 
linear , allowing for an estimation of an upper limit for the KM value. 
h
 Rate data with GSK3β and ATP-biotin were most consistent with product inhibition, which 
prevented determination of kinetics
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2.1 Gel image with three independent trials for quantitative analysis of protein labeling by 
CAMK4 kinase and MBP. 
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Figure A2.1:  
Repetitive trials for Pro-Q based quantitative analysis experiment with ATP and ATP-biotin with 
CAMK4 kinase enzyme and MBP substrate. Three repetitive trials shows, which are labeled at 
the top. The percent conversion is indicated below the gel image for each trial. 
 
 
2.2 Gel image with three independent trials for quantitative analysis of protein labeling by 
ERK1 kinase and MBP. 
 
Pro-Q 
Sypro Ruby 
  41%                    39%                      44% 
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Figure A2.2:  
Repetitive trials for Pro-Q based quantitative analysis experiment with ATP and ATP-biotin with 
ERK1 kinase enzyme and MBP substrate. Three repetitive trials are labeled at the top. The 
percent conversion is indicated below the gel image for each trial. 
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2.3 Gel image with three independent trials for quantitative analysis of protein labeling by 
GRK5 kinase and casein protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.3:  
Repetitive trials for Pro-Q based quantitative analysis experiment with ATP and ATP-biotin with 
GRK5 kinase enzyme and casein substrate. Four repetitive trials are shown, which are labeled at 
the top. The percent conversion is indicated below the gel image for each trial. 
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2.4 Gel image with three independent trials for quantitative analysis of protein labeling by 
TGFβR2 kinase and MBP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.4:  
Repetitive trials for Pro-Q based quantitative analysis experiment with ATP and ATP-biotin with 
TGFβR2 kinase enzyme and MBP substrate. Three repetitive trials are shown, which are labeled 
at the top. The percent conversion is indicated below the gel for each trial. 
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APPENDIX B: : Supporting data for chapter 3 
3.1 Replicates of kinase-catalyzed biotinylation with PKA and FSBA-treated lysates 
Trial 1 
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Trial 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.1: Replicates of kinase-catalyzed biotinylation with PKA and FSBA-treated 
lysates. HeLa cell lysates were treated with DMSO (lane 1 and 2) or FSBA (lane 3 and 4). 
Subsequently, samples were filtered to remove excess FSBA and then ATP-biotin (lane 2, 3, and 
4) and PKA (lane 4) were added. After kinase reaction, protein products were separated by SDS-
PAGE and stained with SA-Cy5 to visualize biotinylation (top) and Sypro Ruby for total protein 
analysis (bottom).  Two trials are shown in parts A and B, with the third trial shown in Figure 
3.3. 
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3.2 Replicate trial of K-BILDS experiment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.2: Gel image from the full K-BILDS experiment. The kinase reaction was 
carried out using FSBA-treated lysates, ATP-biotin, and PKA (lane 2 and 4). The negative 
control was performed by incubating FSBA-treated lysates with ATP-biotin only (lane 1 and 3). 
After kinase reaction, biotinylated proteins were enriched using streptavidin resin. Flow through 
and elution from each reaction was separated by SDS-PAGE.  Total proteins were visualized by 
Sypro Ruby stain (top) or biotinylated proteins were observed using Streptavidin-Cy5 (SA-Cy5, 
bottom).  
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Table B3.1: PKA K-BILDS candidate substrate hit list
a
 
N
o.
b
 Protein 
Gene 
Name 
Spectral 
Counts
c
 
Sum of spectral 
counts in both trials Trial 1 
Trial 
2 
N
eg 
P
K
A 
N
e
g 
P
K
A 
Tot
al 
Neg
d
 
Tot
al 
PK
A
e
 
Ratio 
PKA/
Neg
f
 
1 Melanoma-associated antigen D2  
MAGE
D2 0 3 0 2 0 5 ∞ 
2 
Biorientation of chromosomes in cell 
division protein 1-like 1  
BOD1
L1 0 3 0 1 0 4 ∞ 
3 Enhancer of mRNA-decapping protein 4  EDC4 0 5 0 2 0 7 ∞ 
4 Treacle protein OS=Homo sapiens  TCOF1 0 2 0 2 0 4 ∞ 
5 
Receptor-type tyrosine-protein 
phosphatase F  PTPRF 0 2 0 1 0 3 ∞ 
6 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial  
MCCC
2 0 4 0 3 0 7 ∞ 
7 Lysine-specific demethylase 5C  
KDM5
C 0 2 0 1 0 3 ∞ 
8 Palladin OS=Homo sapiens  
PALL
D 0 5 0 1 0 6 ∞ 
9 Splicing factor 3B subunit 1  SF3B1 0 6 0 2 0 8 ∞ 
10 Dynamin-2 OS=Homo sapiens  DNM2 0 2 0 1 0 3 ∞ 
11 Tumor suppressor p53-binding protein 1  
TP53B
P1 0 2 0 1 0 3 ∞ 
12 DNA polymerase delta catalytic subunit  POLD1 0 4 0 2 0 6 ∞ 
13 
Elongator complex protein 3 OS=Homo 
sapiens  ELP3 0 2 0 1 0 3 ∞ 
14 Aconitate hydratase, mitochondrial  ACO2 0 2 0 2 0 4 ∞ 
15 Kanadaptin OS=Homo sapiens  
SLC4A
1AP 0 3 0 1 0 4 ∞ 
16 
Protein IWS1 homolog OS=Homo 
sapiens  IWS1 0 2 0 2 0 4 ∞ 
17 Importin-9 OS=Homo sapiens  IPO9 0 3 0 1 0 4 ∞ 
18 Mitochondrial ribonuclease P protein 1 
TRMT
10C 0 4 0 1 0 5 ∞ 
19 WD repeat-containing protein 61  
WDR6
1 0 3 0 1 0 4 ∞ 
20 3-ketoacyl-CoA thiolase, peroxisomal  
ACAA
1 0 3 0 2 0 5 ∞ 
21 ADP-ribosylation factor 1  ARF1 0 1 0 5 0 6 ∞ 
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22 
Serine/threonine-protein phosphatase 6 
regulatory subunit 3  
PPP6R
3 0 2 0 1 0 3 ∞ 
23 
Protein-glutamine gamma-
glutamyltransferase 2  TGM2 0 2 0 1 0 3 ∞ 
          
24 
Lysosome-associated membrane 
glycoprotein 2 
LAMP
2 0 1 0 2 0 3 ∞ 
25 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3  PLOD3 0 2 0 2 0 4 ∞ 
26 
G patch domain and KOW motifs-
containing protein  
GPKO
W 0 3 0 1 0 4 ∞ 
27 
BAG family molecular chaperone 
regulator 3 BAG3 0 2 0 1 0 3 ∞ 
28 Inverted formin-2 OS=Homo sapiens  INF2 0 2 0 1 0 3 ∞ 
29 Aminoacylase-1  ACY1 0 2 0 1 0 3 ∞ 
30 Creatine kinase U-type, mitochondrial  
CKMT
1A 0 1 0 2 0 3 ∞ 
31 
Sodium/potassium-transporting ATPase 
subunit beta-1  
ATP1B
1 0 3 0 2 0 5 ∞ 
32 Tubulin alpha-1C chain  
TUBA
1C 0 79 0 70 0 149 ∞ 
33 
Ubiquitin domain-containing protein 
UBFD1  
UBFD
1 0 2 0 1 0 3 ∞ 
34 
5'-nucleotidase domain-containing 
protein 1  
NT5D
C1 0 2 0 2 0 4 ∞ 
35 Exosome complex component RRP4  
EXOS
C2 0 1 0 2 0 3 ∞ 
36 MARCKS-related protein  
MARC
KSL1 0 2 0 1 0 3 ∞ 
37 
Ubiquitin fusion degradation protein 1 
homolog  UFD1L 0 2 0 1 0 3 ∞ 
38 
GDP-fucose protein O-
fucosyltransferase 1  
POFU
T1 0 2 0 1 0 3 ∞ 
39 Glypican-1  GPC1 0 1 0 2 0 3 ∞ 
40 
cAMP-dependent protein kinase 
catalytic subunit alpha  
PRKA
CA 0 10 1 9 1 19 19 
41 60S acidic ribosomal protein P2  RPLP2 0 2 1 13 1 15 15 
42 Epidermal growth factor receptor  EGFR 0 7 1 3 1 10 10 
43 
RNA polymerase-associated protein 
RTF1 homolog  RTF1 0 7 1 2 1 9 9 
44 A-kinase anchor protein 12  
AKAP
12 0 6 1 2 1 8 8 
45 
Peptidyl-prolyl cis-trans isomerase 
FKBP5  FKBP5 1 4 0 3 1 7 7 
46 Pre-mRNA-processing-splicing factor 8  PRPF8 0 3 1 4 1 7 7 
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47 Nuclear pore complex protein Nup88 NUP88 0 4 1 3 1 7 7 
48 
Ribonucleoside-diphosphate reductase 
large subunit  RRM1 1 4 0 2 1 6 6 
49 Tryptophan--tRNA ligase, cytoplasmic  WARS 1 3 0 3 1 6 6 
50 Proteasomal ATPase-associated factor 1  PAAF1 1 2 0 4 1 6 6 
51 Guanine deaminase GDA 0 3 1 3 1 6 6 
52 Polymerase delta-interacting protein 2  
POLDI
P2 0 4 1 2 1 6 6 
53 UDP-glucose 4-epimerase  GALE 1 4 0 1 1 5 5 
54 Uridine 5'-monophosphate synthase  UMPS 1 3 0 2 1 5 5 
55 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1  
SLC9A
3R1 1 2 0 3 1 5 5 
56 39S ribosomal protein L2, mitochondrial  
MRPL
2 0 1 1 4 1 5 5 
57 Transcription elongation factor SPT6  
SUPT6
H 0 2 1 3 1 5 5 
58 
Alpha-ketoglutarate-dependent 
dioxygenase FTO FTO 0 3 1 2 1 5 5 
59 Monocarboxylate transporter 4  
SLC16
A3 0 3 1 2 1 5 5 
60 
EH domain-binding protein 1-like 
protein 1  
EHBP1
L1 0 3 1 2 1 5 5 
61 Testin  TES 1 6 1 4 2 10 5 
62 Unconventional myosin-Ie  
MYO1
E 2 12 1 2 3 14 4.67 
63 Clustered mitochondria protein homolog  CLUH 0 5 2 4 2 9 4.5 
64 
E2/E3 hybrid ubiquitin-protein ligase 
UBE2O  
UBE2
O 0 6 2 3 2 9 4.5 
65 
Chromodomain-helicase-DNA-binding 
protein 4 CHD4 0 12 4 5 4 17 4.25 
66 
Probable ATP-dependent RNA helicase 
DDX47  
DDX4
7 1 2 0 2 1 4 4 
67 
Cat eye syndrome critical region protein 
5  CECR5 0 1 1 3 1 4 4 
68 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit  
DDOS
T 0 1 1 3 1 4 4 
69 
Cation-independent mannose-6-
phosphate receptor IGF2R 0 4 2 4 2 8 4 
70 Protein O-GlcNAcase  
MGEA
5 0 2 1 2 1 4 4 
71 TIP41-like protein  TIPRL 0 2 1 2 1 4 4 
72 Dr1-associated corepressor 
DRAP
1 0 2 1 2 1 4 4 
73 Clathrin light chain B  CLTB 0 2 1 2 1 4 4 
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74 
Tyrosine-protein phosphatase non-
receptor type 11  
PTPN1
1 1 8 2 4 3 12 4 
75 Thymidylate synthase  TYMS 1 7 2 5 3 12 4 
76 
Isovaleryl-CoA dehydrogenase, 
mitochondrial  IVD 1 5 1 3 2 8 4 
77 Talin-1 TLN1 0 33 
1
2 13 12 46 3.83 
78 Tubulin beta-6 chain  
TUBB
6 12 28 0 16 12 44 3.67 
79 Acetyl-CoA carboxylase 1  
ACAC
A 0 6 3 5 3 11 3.67 
80 Mannose-6-phosphate isomerase  MPI 1 6 2 5 3 11 3.67 
81 Zyxin  ZYX 1 9 4 9 5 18 3.6 
82 Spectrin beta chain, non-erythrocytic 1  
SPTBN
1 0 8 4 6 4 14 3.5 
83 
Squamous cell carcinoma antigen 
recognized by T-cells 3  SART3 0 4 2 3 2 7 3.5 
84 
cGMP-inhibited 3',5'-cyclic 
phosphodiesterase A  PDE3A 1 4 1 3 2 7 3.5 
85 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2  PLOD2 2 10 2 4 4 14 3.5 
86 Kinesin light chain 1  KLC1 1 5 1 2 2 7 3.5 
87 Isoleucine--tRNA ligase, cytoplasmic  IARS 0 15 7 9 7 24 3.43 
88 Ceruloplasmin  CP 0 4 3 6 3 10 3.33 
89 
Eukaryotic translation initiation factor 4 
gamma 1  
EIF4G
1 0 12 6 8 6 20 3.33 
90 Actin-related protein 2  
ACTR
2 0 6 3 4 3 10 3.33 
91 Ubiquitin carboxyl-terminal hydrolase 7  USP7 1 9 3 4 4 13 3.25 
92 Valine--tRNA ligase  VARS 3 21 9 18 12 39 3.25 
93 Myoferlin  MYOF 0 9 5 7 5 16 3.2 
94 Protein ERGIC-53 
LMAN
1 1 2 0 1 1 3 3 
95 Spartin  SPG20 1 2 0 1 1 3 3 
96 NHL repeat-containing protein 2  
NHLR
C2 1 2 0 1 1 3 3 
97 
Ubiquitin carboxyl-terminal hydrolase 
47  USP47 1 2 0 1 1 3 3 
98 Serpin B4  
SERPI
NB4 0 1 1 2 1 3 3 
99 Low-density lipoprotein receptor  LDLR 0 1 1 2 1 3 3 
10
0 
NADPH:adrenodoxin oxidoreductase, 
mitochondrial  FDXR 0 1 1 2 1 3 3 
10
1 
Ankyrin repeat and zinc finger domain-
containing protein 1  
ANKZ
F1 0 1 1 2 1 3 3 
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10
2 Dual specificity protein phosphatase 12  
DUSP1
2 0 1 1 2 1 3 3 
10
3 Caspase-1  CASP1 0 1 1 2 1 3 3 
10
4 
Histone-lysine N-methyltransferase 
SETD7  SETD7 0 1 1 2 1 3 3 
10
5 Proteasome subunit alpha type-1  
PSMA
1 1 3 1 3 2 6 3 
10
6 Chondroitin sulfate proteoglycan 4  CSPG4 0 11 9 15 9 26 2.89 
10
7 Filamin-B  FLNB 3 74 
3
8 41 41 115 2.81 
10
8 Prelamin-A/C  LMNA 2 7 3 7 5 14 2.8 
10
9 
Probable ATP-dependent RNA helicase 
DDX5  DDX5 4 7 0 4 4 11 2.75 
11
0 Filamin-A  FLNA 2 96 
5
4 57 56 153 2.73 
11
1 Protein RCC2  RCC2 3 11 4 8 7 19 2.71 
11
2 Microtubule-associated protein 4  MAP4 3 21 
1
0 14 13 35 2.69 
11
3 LanC-like protein 1  
LANC
L1 1 5 2 3 3 8 2.67 
11
4 
Asparagine synthetase [glutamine-
hydrolyzing]  ASNS 1 4 2 4 3 8 2.67 
11
5 Endophilin-A2  
SH3GL
1 2 5 1 3 3 8 2.67 
11
6 
Thioredoxin domain-containing protein 
5  
TXND
C5 1 6 4 7 5 13 2.6 
11
7 Cytoplasmic FMR1-interacting protein 1  
CYFIP
1 2 4 0 1 2 5 2.5 
11
8 Parafibromin  CDC73 2 4 0 1 2 5 2.5 
11
9 
Mini-chromosome maintenance 
complex-binding protein  
MCMB
P 2 3 0 2 2 5 2.5 
12
0 Proteasome subunit alpha type-3  
PSMA
3 0 1 2 4 2 5 2.5 
12
1 Proteasome subunit alpha type-7-like  
PSMA
8 0 1 2 4 2 5 2.5 
12
2 
C-Jun-amino-terminal kinase-interacting 
protein 4  SPAG9 0 2 2 3 2 5 2.5 
12
3 
Hydroxysteroid dehydrogenase-like 
protein 2  HSDL2 0 5 4 5 4 10 2.5 
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12
4 
Serine/arginine repetitive matrix protein 
2  
SRRM
2 1 5 3 5 4 10 2.5 
12
5 
Multiple inositol polyphosphate 
phosphatase 1 
MINPP
1 1 2 1 3 2 5 2.5 
12
6 Translationally-controlled tumor protein  TPT1 1 2 1 3 2 5 2.5 
12
7 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, 
mitochondrial  
MTHF
D2 1 3 1 2 2 5 2.5 
12
8 Proteasome subunit alpha type-4  
PSMA
4 1 3 1 2 2 5 2.5 
12
9 Exportin-1  XPO1 4 16 5 6 9 22 2.44 
13
0 
Bifunctional glutamate/proline--tRNA 
ligase  EPRS 5 37 
1
9 21 24 58 2.42 
13
1 Protein transport protein Sec24C  
SEC24
C 3 9 2 3 5 12 2.4 
13
2 SWI/SNF complex subunit SMARCC2  
SMAR
CC2 0 11 9 10 9 21 2.33 
13
3 Calponin-2  CNN2 1 4 2 3 3 7 2.33 
13
4 Purine nucleoside phosphorylase  PNP 1 4 2 3 3 7 2.33 
13
5 
Alkyldihydroxyacetonephosphate 
synthase, peroxisomal  AGPS 2 4 1 3 3 7 2.33 
13
6 AP-2 complex subunit mu  
AP2M
1 1 3 2 4 3 7 2.33 
13
7 Serine/threonine-protein kinase PAK 2  PAK2 1 2 2 5 3 7 2.33 
13
8 ATP-dependent RNA helicase A  DHX9 2 14 8 9 10 23 2.3 
13
9 Nucleobindin-1  
NUCB
1 0 3 4 6 4 9 2.25 
14
0 Chloride intracellular channel protein 4  CLIC4 1 5 3 4 4 9 2.25 
14
1 Rab GDP dissociation inhibitor beta GDI2 2 6 2 3 4 9 2.25 
14
2 Proteasome activator complex subunit 3  PSME3 2 8 7 12 9 20 2.22 
14
3 DNA damage-binding protein 1  DDB1 4 19 
1
0 12 14 31 2.21 
14
4 COP9 signalosome complex subunit 3 COPS3 2 5 3 6 5 11 2.2 
14
5 Nucleoside diphosphate kinase A  NME1 2 5 3 6 5 11 2.2 
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14
6 40S ribosomal protein S24  RPS24 2 5 6 12 8 17 2.12 
14
7 Adenylyl cyclase-associated protein 1  CAP1 4 6 4 11 8 17 2.13 
14
8 Protein disulfide-isomerase A4  PDIA4 5 8 6 15 11 23 2.09 
14
9 Peroxiredoxin-2  
PRDX
2 3 5 8 18 11 23 2.09 
15
0 Arfaptin-1  
ARFIP
1 2 3 0 1 2 4 2 
15
1 Ribosome maturation protein SBDS  SBDS 0 1 2 3 2 4 2 
15
2 
Structural maintenance of chromosomes 
protein 1A  
SMC1
A 0 5 7 9 7 14 2 
15
3 
Leucine-rich repeat-containing protein 
47  
LRRC4
7 0 3 4 5 4 8 2 
15
4 Sialic acid synthase  NANS 1 5 4 5 5 10 2 
15
5 
Glycylpeptide N-
tetradecanoyltransferase 1  NMT1 1 4 3 4 4 8 2 
15
6 Protein HEXIM1  
HEXI
M1 1 4 3 4 4 8 2 
15
7 Splicing factor 3A subunit 3  SF3A3 1 4 3 4 4 8 2 
15
8 
Serine/threonine-protein phosphatase 2A 
55 kDa regulatory subunit B alpha 
isoform  
PPP2R
2A 2 7 4 5 6 12 2 
15
9 Adenosylhomocysteinase 2  
AHCY
L1 1 3 3 5 4 8 2 
16
0 Actin-like protein 6A  
ACTL6
A 2 3 1 3 3 6 2 
16
1 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial  
OXCT
1 1 3 2 3 3 6 2 
16
2 Nodal modulator 1  
NOMO
1 2 6 3 4 5 10 2 
16
3 Protein arginine N-methyltransferase 5  
PRMT
5 3 5 2 5 5 10 2 
16
4 
26S proteasome non-ATPase regulatory 
subunit 12  
PSMD
12 3 7 4 7 7 14 2 
16
5 Heat shock 70 kDa protein 4L  
HSPA4
L 2 4 2 4 4 8 2 
16
6 
Dihydrolipoyl dehydrogenase, 
mitochondrial  DLD 2 4 2 4 4 8 2 
16
7 N-acetyl-D-glucosamine kinase  NAGK 2 4 2 4 4 8 2 
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16
8 
Succinate dehydrogenase [ubiquinone] 
iron-sulfur subunit, mitochondrial  SDHB 1 2 1 2 2 4 2 
16
9 Ran-specific GTPase-activating protein  
RANB
P1 1 2 1 2 2 4 2 
17
0 Tubulin-folding cofactor B  TBCB 1 2 1 2 2 4 2 
17
1 
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial  
HMGC
L 1 2 1 2 2 4 2 
17
2 3-mercaptopyruvate sulfurtransferase  MPST 1 2 1 2 2 4 2 
17
3 Golgi reassembly-stacking protein 2  
GORA
SP2 1 2 1 2 2 4 2 
17
4 60S ribosomal protein L35  RPL35 3 5 5 11 8 16 2 
17
5 Radixin  RDX 0 12 
1
6 18 16 30 1.88 
17
6 Arginine--tRNA ligase, cytoplasmic  RARS 6 12 7 12 13 24 1.85 
17
7 Src substrate cortactin  CTTN 2 5 4 6 6 11 1.83 
17
8 EF-hand domain-containing protein D2  EFHD2 3 4 3 7 6 11 1.83 
17
9 
Inosine-5'-monophosphate 
dehydrogenase 1  
IMPD
H1 3 4 3 7 6 11 1.83 
18
0 Leukocyte elastase inhibitor  
SERPI
NB1 2 5 3 4 5 9 1.8 
18
1 Splicing factor 3B subunit 3  SF3B3 8 22 
1
1 12 19 34 1.79 
18
2 Phospholipase D3  PLD3 3 4 1 3 4 7 1.75 
18
3 Cytosol aminopeptidase  LAP3 1 3 3 4 4 7 1.75 
18
4 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1  RPN1 4 7 4 7 8 14 1.75 
18
5 Golgi integral membrane protein 4 
GOLI
M4 2 4 2 3 4 7 1.75 
18
6 
Plasminogen activator inhibitor 1 RNA-
binding protein  
SERBP
1 11 20 
1
2 20 23 40 1.74 
18
7 
Heterogeneous nuclear 
ribonucleoprotein D0  
HNRN
PD 6 8 5 11 11 19 1.73 
18
8 40S ribosomal protein S16  RPS16 4 6 7 13 11 19 1.73 
18
9 Poly [ADP-ribose] polymerase 1  PARP1 2 6 5 6 7 12 1.71 
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19
0 Nuclear autoantigenic sperm protein  NASP 2 5 5 7 7 12 1.71 
19
1 
Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, 
mitochondrial  
PDHA
1 3 7 4 5 7 12 1.71 
19
2 
C-1-tetrahydrofolate synthase, 
cytoplasmic  
MTHF
D1 12 26 
1
5 20 27 46 1.70 
19
3 
3-hydroxyacyl-CoA dehydrogenase 
type-2  
HSD17
B10 13 26 
1
4 20 27 46 1.70 
19
4 40S ribosomal protein S10  RPS10 1 3 5 7 6 10 1.67 
19
5 Splicing factor 1  SF1 3 7 9 13 12 20 1.67 
19
6 Pyrroline-5-carboxylate reductase 3  
PYCR
L 2 3 1 2 3 5 1.67 
19
7 60S ribosomal protein L28  RPL28 2 3 4 7 6 10 1.67 
19
8 Hypoxia up-regulated protein 1  
HYOU
1 1 18 
2
7 28 28 46 1.64 
19
9 Thymidine kinase, cytosolic  TK1 5 6 3 7 8 13 1.63 
20
0 Clusterin  CLU 3 8 7 8 10 16 1.6 
20
1 Mitotic checkpoint protein BUB3  BUB3 2 4 3 4 5 8 1.6 
20
2 
Ornithine aminotransferase, 
mitochondrial  OAT 2 4 3 4 5 8 1.6 
20
3 Poly(U)-binding-splicing factor PUF60  PUF60 2 3 3 5 5 8 1.6 
20
4 
Peptidyl-prolyl cis-trans isomerase 
FKBP4  FKBP4 9 20 
1
5 18 24 38 1.58 
20
5 F-actin-capping protein subunit alpha-1  
CAPZ
A1 4 6 3 5 7 11 1.57 
20
6 Histone deacetylase 1  
HDAC
1 4 6 3 5 7 11 1.57 
20
7 
26S proteasome non-ATPase regulatory 
subunit 4  
PSMD
4 3 5 4 6 7 11 1.57 
20
8 
Inosine-5'-monophosphate 
dehydrogenase 2 
IMPD
H2 14 21 
1
8 29 32 50 1.56 
20
9 Integrin beta-1  ITGB1 3 8 
1
5 20 18 28 1.56 
21
0 Exportin-2  CSE1L 11 20 9 11 20 31 1.55 
21
1 3-ketoacyl-CoA thiolase, mitochondrial  
ACAA
2 5 9 8 11 13 20 1.54 
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21
2 Serine--tRNA ligase, cytoplasmic  SARS 1 3 5 6 6 9 1.5 
21
3 Plastin-3  PLS3 7 9 3 6 10 15 1.5 
21
4 
Ubiquitin carboxyl-terminal hydrolase 
14  USP14 2 4 4 5 6 9 1.5 
21
5 14-3-3 protein gamma  
YWHA
G 6 8 4 7 10 15 1.5 
21
6 Splicing factor 3A subunit 1  SF3A1 14 23 
1
6 22 30 45 1.5 
21
7 Dihydropyrimidinase-related protein 2  
DPYS
L2 6 9 6 9 12 18 1.5 
21
8 Hsc70-interacting protein  ST13 4 6 4 6 8 12 1.5 
21
9 Neutral amino acid transporter B(0)  
SLC1A
5 2 3 2 3 4 6 1.5 
22
0 Catalase CAT 5 8 3 4 8 12 1.5 
22
1 14-3-3 protein eta  
YWHA
H 6 9 5 7 11 16 1.45 
22
2 Far upstream element-binding protein 1  FUBP1 12 14 6 12 18 26 1.44 
22
3 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  
GNB2
L1 8 13 
1
7 23 25 36 1.44 
22
4 Peroxiredoxin-4  
PRDX
4 10 11 6 12 16 23 1.44 
22
5 26S protease regulatory subunit 4  
PSMC
1 8 14 8 9 16 23 1.44 
22
6 
Electron transfer flavoprotein subunit 
alpha, mitochondrial  ETFA 17 29 
2
0 24 37 53 1.43 
22
7 
Polyadenylate-binding protein-
interacting protein 1  PAIP1 3 5 4 5 7 10 1.43 
22
8 Proteasome activator complex subunit 1  PSME1 6 7 8 13 14 20 1.43 
22
9 26S protease regulatory subunit 8  
PSMC
5 7 13 
1
2 14 19 27 1.42 
23
0 14-3-3 protein theta 
YWHA
Q 8 10 
1
1 17 19 27 1.42 
23
1 14-3-3 protein zeta/delta  
YWHA
Z 8 13 9 11 17 24 1.41 
23
2 Importin subunit alpha-7  
KPNA
6 1 2 4 5 5 7 1.4 
23
3 
Bifunctional ATP-dependent 
dihydroxyacetone kinase/FAD-AMP 
lyase (cyclizing) DAK 4 7 6 7 10 14 1.4 
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23
4 
Non-POU domain-containing octamer-
binding protein  NONO 6 10 9 11 15 21 1.4 
23
5 
Eukaryotic translation initiation factor 3 
subunit G  EIF3G 6 10 9 11 15 21 1.4 
23
6 
2,4-dienoyl-CoA reductase, 
mitochondrial  
DECR
1 3 4 2 3 5 7 1.4 
23
7 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
ACAD
S 3 4 2 3 5 7 1.4 
23
8 Partner of Y14 and mago  WIBG 5 8 5 6 10 14 1.4 
23
9 Enoyl-CoA hydratase, mitochondrial  ECHS1 9 15 
1
4 17 23 32 1.39 
24
0 Far upstream element-binding protein 2  
KHSR
P 12 17 6 8 18 25 1.38 
24
1 
Erythrocyte band 7 integral membrane 
protein  STOM 10 13 
1
1 16 21 29 1.38 
24
2 
Pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15  
DHX1
5 6 7 2 4 8 11 1.38 
24
3 26S protease regulatory subunit 6B  
PSMC
4 5 9 
1
1 13 16 22 1.38 
24
4 DNA replication licensing factor MCM5  MCM5 3 5 5 6 8 11 1.38 
24
5 
Nascent polypeptide-associated complex 
subunit alpha, muscle-specific form  NACA 3 5 5 6 8 11 1.38 
24
6 14-3-3 protein beta/alpha  
YWHA
B 9 12 7 10 16 22 1.38 
24
7 Polypyrimidine tract-binding protein 1  PTBP1 8 12 8 10 16 22 1.38 
24
8 
26S proteasome non-ATPase regulatory 
subunit 14  
PSMD
14 4 6 4 5 8 11 1.38 
24
9 
6-phosphogluconate dehydrogenase, 
decarboxylating  PGD 13 22 
1
4 15 27 37 1.37 
25
0 Ribonuclease inhibitor  RNH1 6 8 5 7 11 15 1.36 
25
1 Protein arginine N-methyltransferase 1  
PRMT
1 5 9 9 10 14 19 1.36 
25
2 Protein disulfide-isomerase A6  PDIA6 8 11 9 12 17 23 1.35 
25
3 Phosphoglycerate kinase 1  PGK1 38 66 
5
2 55 90 121 1.34 
25
4 
Phosphatidylethanolamine-binding 
protein 1  PEBP1 1 2 5 6 6 8 1.33 
25
5 
HLA class I histocompatibility antigen, 
A-34 alpha chain  HLA-A 3 5 6 7 9 12 1.33 
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25
6 Transketolase  TKT 14 23 
1
9 21 33 44 1.33 
25
7 Copine-1  CPNE1 6 9 6 7 12 16 1.33 
25
8 Alpha-actinin-1  
ACTN
1 13 27 
3
3 34 46 61 1.33 
25
9 14-3-3 protein epsilon  
YWHA
E 17 23 
1
5 19 32 42 1.31 
26
0 40S ribosomal protein S14  RPS14 4 5 6 8 10 13 1.3 
26
1 14-3-3 protein sigma  SFN 10 14 
1
8 22 28 36 1.29 
26
2 60S ribosomal protein L29  RPL29 5 7 9 11 14 18 1.29 
26
3 4F2 cell-surface antigen heavy chain  
SLC3A
2 7 10 
1
1 13 18 23 1.28 
26
4 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  SDHA 8 12 
1
0 11 18 23 1.28 
26
5 Ras-related protein Rab-6A  
RAB6
A 4 5 
1
1 14 15 19 1.27 
26
6 
Heterogeneous nuclear 
ribonucleoprotein K  
HNRN
PK 37 55 
4
0 42 77 97 1.26 
26
7 Glucosidase 2 subunit beta  
PRKC
SH 11 17 
1
6 17 27 34 1.26 
26
8 
Probable ATP-dependent RNA helicase 
DDX17  
DDX1
7 8 9 4 6 12 15 1.25 
26
9 
Peptidyl-prolyl cis-trans isomerase 
FKBP10  
FKBP1
0 4 5 4 5 8 10 1.25 
27
0 Serpin H1  
SERPI
NH1 10 12 7 9 17 21 1.24 
27
1 Ubiquilin-2  
UBQL
N2 4 5 5 6 9 11 1.22 
27
2 Multifunctional protein ADE2  PAICS 9 11 
1
4 17 23 28 1.22 
27
3 
ATP-dependent 6-phosphofructokinase, 
muscle type  PFKM 8 10 6 7 14 17 1.21 
27
4 Moesin  MSN 13 18 
2
6 29 39 47 1.21 
27
5 Pyruvate carboxylase, mitochondrial  PC 19 28 
3
1 32 50 60 1.2 
27
6 6-phosphofructokinase type C  PFKP 20 27 
2
1 22 41 49 1.2 
27
7 Lupus La protein  SSB 16 17 
2
0 26 36 43 1.19 
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27
8 Annexin A2  
ANXA
2 31 41 
3
2 33 63 74 1.17 
27
9 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1  GFPT1 8 9 
1
0 12 18 21 1.17 
 
a  
Proteins and spectral count data for two independent trials of PKA K-BILD.  The 
proteins highlighted in light blue are known PKA substrates according to Phosphosite Plus and 
the literature.  The three proteins highlighted in light purple were validated as PKA substrates in 
this study (BAG3, NASP and YWHAQ). 
 b 
Proteins were ordered based on the ratio value in the 
last column, with the higher ratios towards the top and infinity (zero peptide spectra in the 
negative control reaction) as the highest ratio. 
b
 Spectral counts for peptides observed in the 
negative control reaction or PKA reaction for two independent trials is shown. 
c 
Shown is the 
sum of the two negative control trials.
 d 
Shown is the sum of the two PKA reaction trials. 
e
 
Shown is the ratio of the sum of spectral counts observed for that protein in PKA reactions 
divided by the sum of spectral counts for that protein in the negative control reactions.  Infinity 
indicates that zero peptide spectra were observed in the negative control reaction.   
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 Representative LC-MS/MS data for PRKACA (PKA or KAPCA).   
 
Trial 1 
 
A. Trial 1 
 
 
 
 
 
 
 
B. Spectrum of one representative peptide from part A, with the sequence NLLQVDLTKR. 
  
 
 
 
 
 
 
KAPCA_HUMAN (100%), 40,591.4 Da
cAMP-dependent protein kinase catalytic subunit alpha OS=Homo sapiens GN=PRKACA PE=1 SV=2
8 exclusive unique peptides, 9 exclusive unique spectra, 10 total spectra, 69/351 amino acids (20% coverage)
M G N A A A A K K G S E Q E S V K E F L A K A K E D F L K K W E S P A Q N T A H
L D Q F E R I K T L G T G S F G R V M L V K H K E T G N H Y A M K I L D K Q K V
V K L K Q I E H T L N E K R I L Q A V N F P F L V K L E F S F K D N S N L Y M V
M E Y V P G G E M F S H L R R I G R F S E P H A R F Y A A Q I V L T F E Y L H S
L D L I Y R D L K P E N L L I D Q Q G Y I Q V T D F G F A K R V K G R T W T L C
G T P E Y L A P E I I L S K G Y N K A V D W W A L G V L I Y E M A A G Y P P F F
A D Q P I Q I Y E K I V S G K V R F P S H F S S D L K D L L R N L L Q V D L T K
R F G N L K N G V N D I K N H K W F A T T D W I A I Y Q R K V E A P F I P K F K
G P G D T S N F D D Y E E E E I R V S I N E K C G K E F S E F
imm(L)
a2-NH3
a2
y1
b2
y2
b3
y3 b4
y4 y5
y6
y7
y8
N L L Q V D L T K R
R K T L D V Q L L N
m/z
R
e
la
ti
v
e
 I
n
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n
s
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y
0%
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50%
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100%
0 200 400 600 800 1000
600.36 m/z, 2+, 1,198.71 Da,  (Parent Error: 1.9 ppm)
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Trial 2 
C.  Trial 2 
 
 
 
 
 
 
D. Spectrum of one representative peptide from part C, with the sequence NLLQVDLTKR. 
 
 
 
 
 
Figure B3.3: Representative LC-MS/MS data for PRKACA (PKA or KAPCA).  A) and C) 
PRKACA (KAPCA) prmary sequence and peptide coverage (yellow highlighted sequence) for 
two trials. B) & D) Selected spectrum for one peptide in each trial. 
 
 
 
 
 
KAPCA_HUMAN (100%), 40,591.4 Da
cAMP-dependent protein kinase catalytic subunit alpha OS=Homo sapiens GN=PRKACA PE=1 SV=2
6 exclusive unique peptides, 6 exclusive unique spectra, 9 total spectra, 67/351 amino acids (19% coverage)
M G N A A A A K K G S E Q E S V K E F L A K A K E D F L K K W E S P A Q N T A H
L D Q F E R I K T L G T G S F G R V M L V K H K E T G N H Y A M K I L D K Q K V
V K L K Q I E H T L N E K R I L Q A V N F P F L V K L E F S F K D N S N L Y M V
M E Y V P G G E M F S H L R R I G R F S E P H A R F Y A A Q I V L T F E Y L H S
L D L I Y R D L K P E N L L I D Q Q G Y I Q V T D F G F A K R V K G R T W T L C
G T P E Y L A P E I I L S K G Y N K A V D W W A L G V L I Y E M A A G Y P P F F
A D Q P I Q I Y E K I V S G K V R F P S H F S S D L K D L L R N L L Q V D L T K
R F G N L K N G V N D I K N H K W F A T T D W I A I Y Q R K V E A P F I P K F K
G P G D T S N F D D Y E E E E I R V S I N E K C G K E F S E F
522.3?
imm(L)
imm(D) a2-NH3
a2
y1
b2y2
b3y3 y4 y5 y6
y7
N L L Q V D L T K
K T L D V Q L L N
m/z
R
e
la
ti
v
e
 I
n
te
n
s
it
y
0%
25%
50%
75%
100%
0 200 400 600 800 1000
522.31 m/z, 2+, 1,042.61 Da,  (Parent Error: 2.5 ppm)
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Representative LC-MS/MS data for NASP 
 
A.  Trial 1 
 
B. Spectrum of one representative peptide from part A, with the sequence EVSEEQPVVTLEK. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NASP_HUMAN (100%), 85,235.5 Da
Nuclear autoantigenic sperm protein OS=Homo sapiens GN=NASP PE=1 SV=2
4 exclusive unique peptides, 4 exclusive unique spectra, 5 total spectra, 65/788 amino acids (8% coverage)
M A M E S T A T A A V A A E L V S A D K I E D V P A P S T S A D K V E S L D V D
S E A K K L L G L G Q K H L V M G D I P A A V N A F Q E A A S L L G K K Y G E T
A N E C G E A F F F Y G K S L L E L A R M E N G V L G N A L E G V H V E E E E G
E K T E D E S L V E N N D N I D E E A R E E L R E Q V Y D A M G E K E E A K K T
E D K S L A K P E T D K E Q D S E M E K G G R E D M D I S K S A E E P Q E K V D
L T L D W L T E T S E E A K G G A A P E G P N E A E V T S G K P E Q E V P D A E
E E K S V S G T D V Q E E C R E K G G Q E K Q G E V I V S I E E K P K E V S E E
Q P V V T L E K Q G T A V E V E A E S L D P T V K P V D V G G D E P E E K V V T
S E N E A G K A V L E Q L V G Q E V P P A E E S P E V T T E A A E A S A V E A G
S E V S E K P G Q E A P V L P K D G A V N G P S V V G D Q T P I E P Q T S I E R
L T E T K D G S G L E E K V R A K L V P S Q E E T K L S V E E S E A A G D G V D
T K V A Q G A T E K S P E D K V Q I A A N E E T Q E R E E Q M K E G E E T E G S
E E D D K E N D K T E E M P N D S V L E N K S L Q E N E E E E I G N L E L A W D
M L D L A K I I F K R Q E T K E A Q L Y A A Q A H L K L G E V S V E S E N Y V Q
A V E E F Q S C L N L Q E Q Y L E A H D R L L A E T H Y Q L G L A Y G Y N S Q Y
D E A V A Q F S K S I E V I E N R M A V L N E Q V K E A E G S S A E Y K K E I E
E L K E L L P E I R E K I E D A K E S Q R S G N V A E L A L K A T L V E S S T S
G F T P G G G G S S V S M I A S R K P T D G A S S S N C V T D I S H L V R K K R
K P E E E S P R K D D A K K A K Q E P E V N G G S G D A V P S G N E V S E N M E
E E A E N Q A E S R A A V E G T V E A G A T V E S T A C
199.1?
217.1?
346.1?
a2-H2O
internal PV
a2
internal PVV y7+1
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b2 y2
b3 y3
y4
y5
y7
y9 y11
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743.89 m/z, 2+, 1,485.76 Da,  (Parent Error: 1.8 ppm)
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C.  Trial 2 
 
 
 
 
D. Spectrum of one representative peptide from part C, with the sequence mAVLNEQVK. 
 
Figure B3.4: Representative LC-MS/MS data for NASP.  A) and C) NASP primary sequence 
and peptide coverage (yellow highlighted sequence) for two trials. B) & D) Selected spectrum 
for one peptide in each trial.  m= oxidized methionine (M+16).   
 
 
 
 
 
 
NASP_HUMAN (100%), 85,235.5 Da
Nuclear autoantigenic sperm protein OS=Homo sapiens GN=NASP PE=1 SV=2
7 exclusive unique peptides, 7 exclusive unique spectra, 7 total spectra, 73/788 amino acids (9% coverage)
M A M E S T A T A A V A A E L V S A D K I E D V P A P S T S A D K V E S L D V D
S E A K K L L G L G Q K H L V M G D I P A A V N A F Q E A A S L L G K K Y G E T
A N E C G E A F F F Y G K S L L E L A R M E N G V L G N A L E G V H V E E E E G
E K T E D E S L V E N N D N I D E E A R E E L R E Q V Y D A M G E K E E A K K T
E D K S L A K P E T D K E Q D S E M E K G G R E D M D I S K S A E E P Q E K V D
L T L D W L T E T S E E A K G G A A P E G P N E A E V T S G K P E Q E V P D A E
E E K S V S G T D V Q E E C R E K G G Q E K Q G E V I V S I E E K P K E V S E E
Q P V V T L E K Q G T A V E V E A E S L D P T V K P V D V G G D E P E E K V V T
S E N E A G K A V L E Q L V G Q E V P P A E E S P E V T T E A A E A S A V E A G
S E V S E K P G Q E A P V L P K D G A V N G P S V V G D Q T P I E P Q T S I E R
L T E T K D G S G L E E K V R A K L V P S Q E E T K L S V E E S E A A G D G V D
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A V E E F Q S C L N L Q E Q Y L E A H D R L L A E T H Y Q L G L A Y G Y N S Q Y
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524.28 m/z, 2+, 1,046.54 Da,  (Parent Error: 1.0 ppm)
130 
 
 
Representative LC-MS/MS data for BAG3 
Trial 1 
A.   
 
 
 
 
 
B. Spectrum of one representative peptide from part A, with the sequence AAPSTAPAEATPPK. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAG3_HUMAN (100%), 61,593.2 Da
BAG family molecular chaperone regulator 3 OS=Homo sapiens GN=BAG3 PE=1 SV=3
2 exclusive unique peptides, 2 exclusive unique spectra, 2 total spectra, 35/575 amino acids (6% coverage)
M S A A T H S P M M Q V A S G N G D R D P L P P G W E I K I D P Q T G W P F F V
D H N S R T T T W N D P R V P S E G P K E T P S S A N G P S R E G S R L P P A R
E G H P V Y P Q L R P G Y I P I P V L H E G A E N R Q V H P F H V Y P Q P G M Q
R F R T E A A A A A P Q R S Q S P L R G M P E T T Q P D K Q C G Q V A A A A A A
Q P P A S H G P E R S Q S P A A S D C S S S S S S A S L P S S G R S S L G S H Q
L P R G Y I S I P V I H E Q N V T R P A A Q P S F H Q A Q K T H Y P A Q Q G E Y
Q T H Q P V Y H K I Q G D D W E P R P L R A A S P F R S S V Q G A S S R E G S P
A R S S T P L H S P S P I R V H T V V D R P Q Q P M T H R E T A P V S Q P E N K
P E S K P G P V G P E L P P G H I P I Q V I R K E V D S K P V S Q K P P P P S E
K V E V K V P P A P V P C P P P S P G P S A V P S S P K S V A T E E R A A P S T
A P A E A T P P K P G E A E A P P K H P G V L K V E A I L E K V Q G L E Q A V D
N F E G K K T D K K Y L M I E E Y L T K E L L A L D S V D P E G R A D V R Q A R
R D G V R K V Q T I L E K L E Q K A I D V P G Q V Q V Y E L Q P S N L E A D Q P
L Q A I M E M G A V A A D K G K K N A G N A E D P H T E T Q Q P E A T A A A T S
N P S S M T D T P G N P A A P
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729.04 m/z, 3+, 2,184.11 Da,  (Parent Error: 0.82 ppm)
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Trial 2 
 
C.  
 
 
 
 
 
D. Spectrum of one representative peptide from part C, with the sequence SSLGSHQLPR. 
 
 
 
Figure B3.5: Representative LC-MS/MS data for BAG3.  A) and C) BAG3 primary sequence 
and peptide coverage (yellow highlighted sequence) for two trials. B) & D) Selected spectrum 
for one peptide in each trial. 
 
 
 
 
BAG3_HUMAN (99%), 61,593.2 Da
BAG family molecular chaperone regulator 3 OS=Homo sapiens GN=BAG3 PE=1 SV=3
1 exclusive unique peptides, 1 exclusive unique spectra, 1 total spectra, 10/575 amino acids (2% coverage)
M S A A T H S P M M Q V A S G N G D R D P L P P G W E I K I D P Q T G W P F F V
D H N S R T T T W N D P R V P S E G P K E T P S S A N G P S R E G S R L P P A R
E G H P V Y P Q L R P G Y I P I P V L H E G A E N R Q V H P F H V Y P Q P G M Q
R F R T E A A A A A P Q R S Q S P L R G M P E T T Q P D K Q C G Q V A A A A A A
Q P P A S H G P E R S Q S P A A S D C S S S S S S A S L P S S G R S S L G S H Q
L P R G Y I S I P V I H E Q N V T R P A A Q P S F H Q A Q K T H Y P A Q Q G E Y
Q T H Q P V Y H K I Q G D D W E P R P L R A A S P F R S S V Q G A S S R E G S P
A R S S T P L H S P S P I R V H T V V D R P Q Q P M T H R E T A P V S Q P E N K
P E S K P G P V G P E L P P G H I P I Q V I R K E V D S K P V S Q K P P P P S E
K V E V K V P P A P V P C P P P S P G P S A V P S S P K S V A T E E R A A P S T
A P A E A T P P K P G E A E A P P K H P G V L K V E A I L E K V Q G L E Q A V D
N F E G K K T D K K Y L M I E E Y L T K E L L A L D S V D P E G R A D V R Q A R
R D G V R K V Q T I L E K L E Q K A I D V P G Q V Q V Y E L Q P S N L E A D Q P
L Q A I M E M G A V A A D K G K K N A G N A E D P H T E T Q Q P E A T A A A T S
N P S S M T D T P G N P A A P
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541.29 m/z, 2+, 1,080.57 Da,  (Parent Error: 1.3 ppm)
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Representative LC-MS/MS data for YWHAQ (1433T).   
 
A.  Trial 1 
 
 
 
 
 
 
B. Spectrum of one representative peptide from part A, with the sequence YLAEVACGDDRK. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1433T_HUMAN (100%), 27,765.4 Da
14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1
5 exclusive unique peptides, 6 exclusive unique spectra, 7 total spectra, 75/245 amino acids (31% coverage)
M E K T E L I Q K A K L A E Q A E R Y D D M A T C M K A V T E Q G A E L S N E E
R N L L S V A Y K N V V G G R R S A W R V I S S I E Q K T D T S D K K L Q L I K
D Y R E K V E S E L R S I C T T V L E L L D K Y L I A N A T N P E S K V F Y L K
M K G D Y F R Y L A E V A C G D D R K Q T I D N S Q G A Y Q E A F D I S K K E M
Q P T H P I R L G L A L N F S V F Y Y E I L N N P E L A C T L A K T A F D E A I
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C.  Trial 2 
 
 
 
 
D. Spectrum of one representative peptide from part C, with the sequence 
AVTEQGAELSNEER. 
 
 
Figure B3.6: Representative LC-MS/MS data for YWHAQ (1433T).  A) and C) YWHAQ 
sequence and peptide coverage (yellow highlighted sequence) for two trials. B) & D) Selected 
spectrum for one peptide in each tri 
 
 
 
 
1433T_HUMAN (100%), 27,765.4 Da
14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1
12 exclusive unique peptides, 14 exclusive unique spectra, 14 total spectra, 137/245 amino acids (56% coverage)
M E K T E L I Q K A K L A E Q A E R Y D D M A T C M K A V T E Q G A E L S N E E
R N L L S V A Y K N V V G G R R S A W R V I S S I E Q K T D T S D K K L Q L I K
D Y R E K V E S E L R S I C T T V L E L L D K Y L I A N A T N P E S K V F Y L K
M K G D Y F R Y L A E V A C G D D R K Q T I D N S Q G A Y Q E A F D I S K K E M
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Figure B3.7: Full interactome of 279 K-BILDS hits. The 279 hits enriched in K-BILD PKA 
reactions but not in the negative controls (Table S1) were analyzed using GeneMANIA in 
Cytoscape to identify physical protein-protein interactions between PKA and K-BILD substrate 
hits. a) The inner circle represents direct interactors of PKA (PRKACA), while the middle circles 
represent indirect interactors within the ≤3 three degrees of protein separation. b) The outer most 
cirlce represents proteins interacting with PKA indirectly with more than 3 degrees of protein 
separation. c) Proteins not present in databases as interacting with PKA are also shown.  The 
thickness and the length of the lines are arbitrarily drawn for clarity.  
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Figure B3.8: Gene ontology (GO) analysis of K-BILD hits. K-BILD hits were 
categorized using PANTHER Gene Ontology biological processes.  The biological processes 
associated with the PKA K-BILDS kits are listed on the right, with the number of genes in each 
category shown in the histogram.   
 
 
 
 
 
 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.9: A) Three replicates of the in vitro PKA assay with NASP. In vitro validation was 
performed by first dephosphorlyating NASP with CIP, then incubating with the phosphatase 
inhibitor sodium vandadate, recombinant PKA, and ATP.  A negative control reaction was 
carried out by incubating without PKA. A positive control reaction was also included where the 
known PKA substrate myelin basic protein (MBP) was used in place of NASP.  After reaction, 
samples were separated on SDS-PAGE and analyzed by Pro-Q (top) for phopshoprotein and 
Sypro Ruby (bottom) for total protein as a loading control.  The three trials are indicated at the 
top of the gel images.   B) Cropped images of Figure S5A showing all three trials but only lanes 
in the absence (lanes 1, 3, and 5) or presence of PKA (lanes 2, 4, and 6). Trial 1 is shown in 
Figure 3.7a of the text. 
 
 
 
     
B 
A 
A 
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Figure B3.10: A) Three replicates of the in vitro PKA assay with BAG3. In vitro validation was 
performed by incubating BAG3 with recombinant PKA and ATP. A negative control reaction 
was carried out by incubating without PKA. A positive control reaction was also included where 
the known PKA substrate myelin basic protein (MBP) was used in place of BAG3.  After 
reaction, samples were separated on SDS-PAGE and analyzed by Pro-Q (top) for phopshoprotein 
and Sypro Ruby (bottom) for total protein as a loading control.  The three trials are indicated at 
the top of the gel images.   B) Cropped images of Figure S6A showing all three trials but only 
lanes in the absence (lanes 1, 3, and 5) or presence of PKA (lanes 2, 4, and 6). Trials 2 is shown 
in Figure 3.7b of the text. 
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Figure B3.11 A) Three replicates of the in vitro PKA assay with YWHAQ. In vitro validation 
was performed by incubating YWHAQ with recombinant PKA and ATP. A negative control 
reaction was carried out by incubating without PKA. A positive control reaction was also 
included where the known PKA substrate myelin basic protein (MBP) was used in place of 
YWHAQ.  After reaction, samples were separated on SDS-PAGE and analyzed by Pro-Q (top) 
for phopshoprotein and Sypro Ruby (bottom) for total protein as a loading control.  The three 
trials are indicated at the top of the gel images.   B) Cropped images of Figure S7A showing all 
three trials but only lanes in the absence (lanes 1, 3, and 5) or presence of PKA (lanes 2, 4, and 
6). Trials 1 is shown in Figure 3.7c of the text. 
B 
A 
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APPENDIX C: : Supporting data for chapter 4 
4.1 Replicates of kinase-catalyzed biotinylation with EGF-treated and untreated lysates 
A) Trial 2 
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B) Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.1: Kinase-catalyzed biotinylation of EGF-treated lysates. EGF-treated (lane 3) 
and untreated (lane 1 and 2) lysates were incubated with ATP-biotin (lane 2 and 3). After kinase 
reaction, protein products were separated by SDS-PAGE and stained with SA-Cy5 to visualize 
biotinylation (top) and Sypro Ruby for total protein analysis (bottom). Trial 1 is shown in Figure 
4.4. 
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4.3 Replicates of immunoblotting of fresh lysates with phospho-Tyr1068 EGFR to confirm 
the presence of active EGFR on lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.2: Presence of activated EGFR in lysates during kinase-catalyzed 
biotinylation. EGF-treated (lane 2, 4, and 6) and untreated (lane 1, 3, and 5) lysates 
were immunoblotted with pTyr1068 EGFR antibody to confirm active EGFR 
pathway (Top). Immunoblotting with EGFR antibody was done to confirm equal 
loading (Bottom). Same lysates used in Figure C4.3 are used in here. Trial 1 is 
shown in Figure 4.5. 
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4.3 Replicates of full K-BMAPS experiment with EGF-treated lysates 
A) Trial 2 
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B) Trial 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.3: Gel image from full K-BMAPS experiment. EGF-treated and untreated 
lysates were incubated with ATP-biotin. After kinase reaction, protein products enriched with 
avidin resin. The in-put (lane 1 and 2), flow through (lane 3 and 4) and the elution (lane 5 and 6) 
from each reaction was separated by SDS-PAGE and visualized with Sypro Ruby (bottom) for 
total protein or SA-Cy5 for biotinylation. Trial 1 is shown in Figure 4.6. 
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4.4 Replicates of immunoblotting of immediate and late lysates with phosphorylated-AKT 
antibody to confirm the presence of active AKT on lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.4: a) Immunoblotting with phos-AKT (Ser 473) antibody to confirm the 
presence of active AKT1 in immediate (fresh) and late (incubated at 31
0
C for 1 
hour) lysates. Trial 1 is shown in Figure 4.8a. 
 
Trial 2 Trial 3 
145 
 
 
4.5 Replicates of immunoblotting of immediate and late lysates with phosphorylated 
ERK1/2 antibody to confirm the presence of active ERK1/2 on lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.5: a) Immunoblotting with phos-ERK1/2 (Thr 202/ Tyr 204) antibody to 
confirm the presence of active ERK1/2 in immediate and late (incubated at 31
0
C for 
1 hour) lysates. Trial 1 is shown in Figure 4.8b. 
Trial 2 Trial 3 
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4.6 Replicates of immunoblotting of eluates of K-BMAPS with EGFR antibody to confirm 
the enrichemnt of EGFR  
 
 
 
 
 
 
 
 
 
 
 
  
Figure C4.6: Immunoblotting of enriched EGF-treated and untreated lysates for 
EGFR. The EGF-treated (lanes 2, 4, 6) and untreated (lanes 1, 3, 5) lysates were 
subjected to streptavidin pulled down, and the input (lanes 1 and 2), follow-through 
(lanes 3 and 4) and elutes (lane 5 and 6) of biotinylated proteins were probed for 
EGFR, using EGFR antibody. Replicates of data shown in Figure 4.9. 
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4.7 Replicates of immunoblotting of eluates of K-BMAPS with ERK1/2 antibody to confirm 
the absence or non enrichment of ERK1/2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.7: Immunoblotting of enriched EGF-treated and untreated lysates for 
ERK1/2. The EGF-treated (lanes 2, 4, 6) and untreated (lanes 1, 3, 5) lysates were 
subjected to streptavidin pulled down, and the input (lanes 1 and 2), follow-through 
(lanes 3 and 4) and elutes (lane 5 and 6) of biotinylated proteins were probed for 
ERK1/2 using ERK1/2 antibody. Replicates of data shown in Figure 4.9. 
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4.8 Replicates of immunoblotting of eluates of K-BMAPS with EGFR antibody to confirm 
the enrichemnt of AKT1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.8: Immunoblotting of enriched EGF-treated and untreated lysates for 
AKT1. The EGF-treated (lanes 2, 4, 6) and untreated (lanes 1, 3, 5) lysates were 
subjected to streptavidin pulled down, and the input (lanes 1 and 2), follow-through 
(lanes 3 and 4) and elutes (lane 5 and 6) of biotinylated proteins were probed for 
AKT1 using respective antibodies. Replicates of data shown in Figure 4.9. 
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Table C4.1: EGFR pathway dependent K-BMAPS candidate hit list 
a
 
 
No
b
 Gene name 
Spectral counts
c
 Spectral count ratio
d
 
Trial 1 Trial 2 Trial 1 Trial 2 
EGF Neg EGF Neg EGF Neg 
1 RPRD2 104 0 5 0 ∞ ∞ 
2 KIF5B 60 0 1 0 ∞ ∞ 
3 UBA1 50 0 2 0 ∞ ∞ 
4 CNOT1 42 0 4 0 ∞ ∞ 
5 GART 37 0 2 0 ∞ ∞ 
6 EPS15 38 0 2 0 ∞ ∞ 
7 PPP1R13L 37 0 3 0 ∞ ∞ 
8 MYPN 30 0 1 0 ∞ ∞ 
9 SMARCA4 27 0 2 0 ∞ ∞ 
10 DDX19A 31 0 2 0 ∞ ∞ 
11 SKIV2L2 19 0 7 0 ∞ ∞ 
12 SLTM 24 0 3 0 ∞ ∞ 
13 GBF1 23 0 4 0 ∞ ∞ 
14 USP9X 15 0 5 0 ∞ ∞ 
15 HCFC1 21 0 2 0 ∞ ∞ 
16 LAMB1 18 0 1 0 ∞ ∞ 
17 TLN1 17 0 1 0 ∞ ∞ 
18 MADD 23 0 3 0 ∞ ∞ 
19 AKAP13 13 0 3 0 ∞ ∞ 
20 MTOR 14 0 1 0 ∞ ∞ 
21 ARHGAP1 17 0 2 0 ∞ ∞ 
22 RBM10 22 0 1 0 ∞ ∞ 
23 NUP188 7 0 4 0 ∞ ∞ 
24 SMARCA5 12 0 7 0 ∞ ∞ 
25 MCM2 18 0 1 0 ∞ ∞ 
26 CAMSAP2 13 0 3 0 ∞ ∞ 
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27 ILK 11 0 1 0 ∞ ∞ 
28 POLA1 14 0 1 0 ∞ ∞ 
29 SMC3 14 0 1 0 ∞ ∞ 
30 DIAPH1 7 0 12 0 ∞ ∞ 
31 ITGA1 19 0 1 0 ∞ ∞ 
32 NCOR1 17 0 3 0 ∞ ∞ 
33 KDM1A 17 0 2 0 ∞ ∞ 
34 UNC80 2 0 1 0 ∞ ∞ 
35 ZC3H18 12 0 2 0 ∞ ∞ 
36 NUP133 13 0 2 0 ∞ ∞ 
37 CYFIP1 8 0 1 0 ∞ ∞ 
38 KNOP1 18 0 1 0 ∞ ∞ 
39 GPS1 14 0 1 0 ∞ ∞ 
40 RBM19 16 0 1 0 ∞ ∞ 
41 EPB41L3 4 0 1 0 ∞ ∞ 
42 DOCK5 8 0 1 0 ∞ ∞ 
43 DNMT1 3 0 1 0 ∞ ∞ 
44 TFEB 10 0 1 0 ∞ ∞ 
45 RAPH1 10 0 1 0 ∞ ∞ 
46 POLR2B 9 0 2 0 ∞ ∞ 
47 EIF5B 10 0 3 0 ∞ ∞ 
48 INPPL1 4 0 4 0 ∞ ∞ 
49 HSPA13 13 0 1 0 ∞ ∞ 
50 TBCD 11 0 2 0 ∞ ∞ 
51 TTI2 5 0 1 0 ∞ ∞ 
52 DHX37 4 0 3 0 ∞ ∞ 
53 TOP2A 1 0 4 0 ∞ ∞ 
54 EFTUD2 11 0 2 0 ∞ ∞ 
55 LARP4 12 0 1 0 ∞ ∞ 
56 SKIV2L 1 0 4 0 ∞ ∞ 
57 MEF2D 11 0 1 0 ∞ ∞ 
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58 GSR 9 0 1 0 ∞ ∞ 
59 EARS2 9 0 1 0 ∞ ∞ 
60 CHERP 10 0 1 0 ∞ ∞ 
61 ZBTB21 6 0 1 0 ∞ ∞ 
62 AGRN 2 0 3 0 ∞ ∞ 
63 KPNA1 17 0 2 0 ∞ ∞ 
64 PRPF40A 3 0 1 0 ∞ ∞ 
65 SMARCD1 8 0 2 0 ∞ ∞ 
66 CLCC1 11 0 1 0 ∞ ∞ 
67 PDE3A 3 0 3 0 ∞ ∞ 
68 DLD 8 0 1 0 ∞ ∞ 
69 ITGA2 3 0 3 0 ∞ ∞ 
70 EDEM3 4 0 1 0 ∞ ∞ 
71 RTCB 6 0 1 0 ∞ ∞ 
72 GMPS 2 0 2 0 ∞ ∞ 
73 NPEPPS 1 0 6 0 ∞ ∞ 
74 NCAPD3 3 0 1 0 ∞ ∞ 
75 GATB 4 0 1 0 ∞ ∞ 
76 DHX36 3 0 1 0 ∞ ∞ 
77 HTATSF1 2 0 4 0 ∞ ∞ 
78 PSMD5 7 0 1 0 ∞ ∞ 
79 ABCC1 2 0 1 0 ∞ ∞ 
80 IPO8 4 0 1 0 ∞ ∞ 
81 VPS4A 5 0 1 0 ∞ ∞ 
82 ALDH3B1 6 0 2 0 ∞ ∞ 
83 EHD4 2 0 1 0 ∞ ∞ 
84 PPP2R5A 2 0 1 0 ∞ ∞ 
85 CASC3 4 0 1 0 ∞ ∞ 
86 PTPRJ 1 0 2 0 ∞ ∞ 
87 IKBKAP 1 0 3 0 ∞ ∞ 
88 HELLS 2 0 1 0 ∞ ∞ 
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89 PABPN1 4 0 1 0 ∞ ∞ 
90 TSSC1 2 0 1 0 ∞ ∞ 
91 LSM14B 1 0 2 0 ∞ ∞ 
92 DNM1L 1 0 2 0 ∞ ∞ 
93 FAM129B 1 0 2 0 ∞ ∞ 
94 MYL12B 1 0 2 0 ∞ ∞ 
95 IPO4 33 0 19 1 ∞ 19 
96 GAPVD1 46 0 8 1 ∞ 8 
97 NCOR2 17 0 7 1 ∞ 7 
98 FLNB 22 0 27 4 ∞ 6.75 
99 SNRNP200 40 0 13 2 ∞ 6.5 
100 CSPG4 2 0 19 3 ∞ 6.33333
3 
101 FAM120A 26 0 12 2 ∞ 6 
102 KIF1C 1 0 6 1 ∞ 6 
103 GTF3C1 4 0 5 1 ∞ 5 
104 NCAPD2 2 0 10 2 ∞ 5 
105 FANCI 3 0 9 2 ∞ 4.5 
106 ASCC3 22 0 4 1 ∞ 4 
107 CYP51A1 21 0 4 1 ∞ 4 
108 BMS1 8 0 4 1 ∞ 4 
109 MET 2 0 4 1 ∞ 4 
110 KARS 1 0 4 1 ∞ 4 
111 DDB1 50 0 19 5 ∞ 3.8 
112 MVP 30 0 19 5 ∞ 3.8 
113 AP2A1 1 0 19 5 ∞ 3.8 
114 XPOT 4 0 11 3 ∞ 3.66666
7 
115 RBM26 19 0 7 2 ∞ 3.5 
116 GANAB 50 0 13 4 ∞ 3.25 
117 FLNA 124 0 46 15 ∞ 3.06666
7 
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118 DYNC1H1 67 0 73 24 ∞ 3.04166
7 
119 SCAF8 40 0 3 1 ∞ 3 
120 FARSA 19 0 3 1 ∞ 3 
121 PSMD1 14 0 3 1 ∞ 3 
122 RETSAT 9 0 3 1 ∞ 3 
123 EPRS 43 0 18 6 ∞ 3 
124 TRAP1 11 0 9 3 ∞ 3 
125 SLC7A2 3 0 3 1 ∞ 3 
126 ATP2A2 15 0 18 6 ∞ 3 
127 TELO2 2 0 3 1 ∞ 3 
128 ERAP1 2 0 3 1 ∞ 3 
129 EIF3D 1 0 3 1 ∞ 3 
130 RBBP5 1 0 3 1 ∞ 3 
131 CEBPZ 1 0 6 2 ∞ 3 
132 EEF2 48 0 17 6 ∞ 2.83333
3 
133 IARS 12 0 11 4 ∞ 2.75 
134 EIF4G1 52 0 27 10 ∞ 2.7 
135 RANBP2 60 0 16 6 ∞ 2.66666
7 
136 TBC1D10B 21 0 5 2 ∞ 2.5 
137 MPHOSPH
10 
18 0 5 2 ∞ 2.5 
138 ACACA 242 0 75 30 ∞ 2.5 
139 EGFR 8 0 5 2 ∞ 2.5 
140 RBM27 7 0 5 2 ∞ 2.5 
141 NUP214 107 0 21 9 ∞ 2.33333
3 
142 PELP1 1 0 7 3 ∞ 2.33333
3 
143 GIGYF2 80 0 18 8 ∞ 2.25 
144 POLD1 35 0 11 5 ∞ 2.2 
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145 DARS 50 0 13 6 ∞ 2.16666
7 
146 XPO5 38 0 13 6 ∞ 2.16666
7 
147 CAD 115 0 41 20 ∞ 2.05 
148 MIA3 25 0 2 1 ∞ 2 
149 EIF3C 13 0 2 1 ∞ 2 
150 MAP4 24 0 4 2 ∞ 2 
151 APP 11 0 2 1 ∞ 2 
152 MED1 8 0 2 1 ∞ 2 
153 CDK12 21 0 6 3 ∞ 2 
154 SON 7 0 2 1 ∞ 2 
155 BAIAP2L1 7 0 2 1 ∞ 2 
156 KIAA1522 11 0 4 2 ∞ 2 
157 ITGA5 5 0 2 1 ∞ 2 
158 NUP107 4 0 2 1 ∞ 2 
159 UGGT1 4 0 2 1 ∞ 2 
160 SCYL2 4 0 2 1 ∞ 2 
161 NOL6 2 0 2 1 ∞ 2 
162 NUP155 3 0 4 2 ∞ 2 
163 PDXDC1 2 0 4 2 ∞ 2 
164 MCM4 2 0 4 2 ∞ 2 
165 PIGT 1 0 2 1 ∞ 2 
166 PKM 136 1 30 15 136 2 
167 PRRC2B 87 1 5 2 87 2.5 
168 MYH9 78 1 14 2 78 7 
169 ACLY 218 3 31 13 72.6666
7 
2.38461
5 
170 IPO7 70 1 25 11 70 2.27272
7 
171 GCN1 139 2 50 10 69.5 5 
172 SF3A1 61 1 6 3 61 2 
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173 NUP153 56 1 3 0 56 ∞ 
174 SRP54 54 1 12 5 54 2.4 
175 FASN 85 2 19 1 42.5 19 
176 PRRC2C 42 1 13 2 42 6.5 
177 PRRC2A 41 1 8 0 41 ∞ 
178 IPO9 31 1 18 1 31 18 
179 DYNC1LI1 31 1 7 1 31 7 
180 CKAP5 61 2 8 2 30.5 4 
181 SEC16A 30 1 5 2 30 2.5 
182 DNAJC7 27 1 2 0 27 ∞ 
183 ITGB4 27 1 6 3 27 2 
184 PBRM1 26 1 5 1 26 5 
185 NCAPG 25 1 8 4 25 2 
186 IQGAP1 97 4 27 7 24.25 3.85714
3 
187 CPD 22 1 2 1 22 2 
188 NUP54 43 2 2 0 21.5 ∞ 
189 UBR5 21 1 24 11 21 2.18181
8 
190 AP3D1 20 1 10 0 20 ∞ 
191 P4HA2 20 1 2 1 20 2 
192 EIF2B4 20 1 6 3 20 2 
193 EIF3A 19 1 13 1 19 13 
194 CLSPN 18 1 1 0 18 ∞ 
195 PSMD4 17 1 1 0 17 ∞ 
196 ATP6V1H 17 1 2 1 17 2 
197 GNL2 17 1 8 4 17 2 
198 CDK13 33 2 4 2 16.5 2 
199 ARHGEF2 16 1 8 3 16 2.66666
7 
200 MAP7D1 16 1 5 2 16 2.5 
201 HUWE1 16 1 7 3 16 2.33333
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3 
202 HSPH1 15 1 1 0 15 ∞ 
203 BAG6 14 1 9 3 14 3 
204 CHD8 28 2 11 4 14 2.75 
205 DYNC1LI2 14 1 4 2 14 2 
206 AP3B1 13 1 4 0 13 ∞ 
207 IPO5 51 4 20 7 12.75 2.85714
3 
208 ITGAV 25 2 2 0 12.5 ∞ 
209 MKI67 50 4 19 5 12.5 3.8 
210 BTAF1 12 1 1 0 12 ∞ 
211 UMPS 24 2 4 1 12 4 
212 NSUN5 11 1 3 0 11 ∞ 
213 SCAF4 11 1 1 0 11 ∞ 
214 GTF3C2 11 1 3 1 11 3 
215 HSP90AA1 74 7 23 9 10.5714
3 
2.55555
6 
216 ARFGEF2 20 2 1 0 10 ∞ 
217 VARS 10 1 12 5 10 2.4 
218 ECM29 19 2 13 4 9.5 3.25 
219 EP300 9 1 4 0 9 ∞ 
220 POLE 9 1 4 1 9 4 
221 LMO7 34 4 6 2 8.5 3 
222 KTN1 17 2 6 2 8.5 3 
223 CHTF8 8 1 1 0 8 ∞ 
224 TCERG1 8 1 7 2 8 3.5 
225 MYO1G 8 1 2 1 8 2 
226 HSP90AB1 82 11 26 13 7.45454
5 
2 
227 ATP7A 14 2 2 0 7 ∞ 
228 KIF11 13 2 1 0 6.5 ∞ 
229 MTCL1 6 1 1 0 6 ∞ 
157 
 
 
230 EMC1 6 1 1 0 6 ∞ 
231 THRAP3 5 1 2 0 5 ∞ 
232 NAP1L1 15 3 4 0 5 ∞ 
233 CEP350 5 1 1 0 5 ∞ 
234 NCAPG2 5 1 1 0 5 ∞ 
235 DIAPH3 5 1 1 0 5 ∞ 
236 UBQLN1 19 4 9 4 4.75 2.25 
237 ZCCHC6 9 2 1 0 4.5 ∞ 
238 KCMF1 9 2 3 1 4.5 3 
239 CLTC 13 3 4 2 4.33333
3 
2 
240 TRIM33 4 1 2 0 4 ∞ 
241 ERCC6 4 1 1 0 4 ∞ 
242 AP2M1 12 3 9 2 4 4.5 
243 FUBP1 4 1 3 1 4 3 
244 NUDCD3 19 5 2 0 3.8 ∞ 
245 ETF1 7 2 1 0 3.5 ∞ 
246 CCDC88B 7 2 2 1 3.5 2 
247 PLD3 6 2 5 0 3 ∞ 
248 RTF1 3 1 1 0 3 ∞ 
249 NCAPH 3 1 1 0 3 ∞ 
250 FANCD2 3 1 5 1 3 5 
251 PLA2G4A 6 2 5 2 3 2.5 
252 LTV1 3 1 5 2 3 2.5 
253 CCAR1 9 3 2 1 3 2 
254 DAB2 17 6 4 0 2.83333
3 
∞ 
255 ENO1 93 34 4 1 2.73529
4 
4 
256 ADPGK 8 3 1 0 2.66666
7 
∞ 
257 INTS1 5 2 1 0 2.5 ∞ 
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258 PRPF8 5 2 3 1 2.5 3 
259 KRT16 108 44 11 0 2.45454
5 
∞ 
260 UBR4 7 3 6 0 2.33333
3 
∞ 
261 PDS5A 7 3 6 1 2.33333
3 
6 
262 PRDX2 7 3 4 2 2.33333
3 
2 
263 HDLBP 2 1 6 1 2 6 
264 XPO7 2 1 8 2 2 4 
265 RIC8A 2 1 3 1 2 3 
266 LGALS3BP 2 1 6 3 2 2 
 
a 
    Proteins and spectral count data for two independent trials of EGFR-pathway dependent K-
BMAPS. 
b
 Proteins were ordered based on the ratio value of last column, with the higher ratios 
towards the top and infinity (zero peptide spectra in the negative control reaction ) as the higest 
ratio. 
c 
Spectral counts  for peptide  observed in the EGF reaction and the nagative  reaction for 
two indeendent trials were shown. 
d
 Shown is the ratio of the spectral counts observed for that 
protein in EGF reaction  devided by the spectral counts for that protein in the negative control 
reacti
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 Kinase-catalyzed phosphorylation plays an important role in cell physiology by 
regulating a myriad of cellular functions. Thus aberrant kinase activity is implicated in various 
diseases. Methods are needed to discover kinase substrates and map signaling pathways to 
explore biology and to help drug discovery. A few techniques are currently available to discover 
kinase substrate and map cell signaling. However, to augment kinase substrate discovery 
approaches, it is essential to develop alternative techniques. Pflum has recently discovered 
cosubstrate promiscuity of protein kinases with gamma-modified ATP analogs. Here, kinase-
catalyzed biotinylation with ATP-biotin was used to develop novel tools to discover kinase 
substrates and to explore kinase signaling cascades.  
 Initially, a characterization of the generality of kinase-catalyzed biotinylation was 
performed using 25 different protein kinases and substrates as a collaborative project. 
Experimental results concluded that all tested protein kinases were capable of transferring a 
biotin tag to protein substrates, confirming the generality of kinase-catalyzed biotinylation.  
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Next, kinase-catalyzed biotinylation was applied to develop a substrate-discovery 
method, entitled, K-BILDS (Kinase-catalyzed biotinylation with inactivated lysates for discovery 
of substrates) to identify substrates of an interested kinase.  Here, kinase inactivated cell lysates 
were used as the pool of cellular proteins to identify substrates of one particular kinase. As a 
proof-of-concept, K-BILDS was initially applied to PKA, which resulted in successful 
identification of ~200 candidate PKA substrates with a ~20% coverage of previously known hits. 
An interactome analysis and in vitro kinase assay was also performed to validate K-BILDS as a 
successful tool to discover substrates. 
Kinase-catalyzed biotinylation was further applied in to map a cell signaling network. 
Here, a screen entitled, K-BMAPS (kinase-catalyzed biotinylation to map signaling) was 
developed by initially applying to EGF-treated cell lysates to map EGFR pathway-related 
phosphoproteins. K-BMAPS with EGF-treated lysates successfully discovered many EGFR 
pathway-related phosphoproteins, confirming the ability of K-BMAPS to map a cell signaling 
network. Thorough analysis established that K-BMAPS detected late and continuous effects of a 
signaling network, validating the screen to monitor kinase signaling cascades. 
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